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Abstract 
The overall aim of the thesis was to assess the feasibility and utility of using 
blood collected on filter paper, dried blood spots (DBS), to improve patient 
management in remote settings. The use of DBS was evaluated for patient 
monitoring, quality assurance of point of care testing, and for surveillance to 
improve syndromic management. 
Systematic literature reviews, laboratory studies, and implementation of DBS 
based diagnostics were performed to answer these objectives. DBS is a feasi-
ble alternative to plasma in monitoring viral load in HIV patients on treatment. 
The type of filter paper, collection, storage and processing methods are criti-
cally important to obtain valid results for monitoring HIV. 
A DBS protocol was evaluated for syphilis serology, giving an adjusted sen-
sitivity and specificity of 97.7% and 99.4% compared to plasma. DBS was 
implemented as quality assurance for Point-of-care test (PaCT), which showed 
that health worker proficiency varied significantly between clinics, stressing 
the importance of quality assurance. 
Laboratory evaluations revealed the possibility of obtaining adequate sensi-
tivities to detect febrile illnesses; malaria, dengue, leptospira, B.bacilliform-
is, and chikungunya, but not for R. typhi and O.tsutsugamushi by DBS. When 
implemented in Peru, a local B.bacilliformis outbreak was identified which 
proved that DBS was more sensitive than the current surveillance method. 
The goal of this research was to determine whether DBS can improve patient 
management in remote settings. As new technologies are being developed 
rapidly, the use of simple and robust tools such as filter paper has continued 
to provide an affordable and reliable solution for clinical sample collection. 
While DBS is not the best sampling method, it is the simplicity and robustness 
that makes it useful in remote settings. This research showed that DBS can be 
used for monitoring HIV patient on antiretroviral therapy, the quality of syphi-
lis diagnosis, and determining the major causes of fever in children to improve 
recommendations for syndromic management. 
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I 
Introduction 
Chapter 1 
1 Introduction 
1.1 INFECTIOUS DISEASES 
Infectious diseases are a major cause of morbidity and mortality worldwide, 
primarily affecting children and young adults. The burden of treatable 
infectious diseases is substantial and is one of the main causes of mortality 
in developing countries (1). Human im,munodefiC:iency virus (HIV), malaria, 
respiratory and diarrhoeal infections are the main infectious diseases 
causing illness in developing countries (2). 
The burden of infectious diseases is commonly measured in number of 
deaths, but the World Health Organisation (WHO) and the World Bank have 
suggested to measure the impact by Disability Adjusted Life Years (DALYs). 
This measure combines years of life lost, as well as the decreased quality of 
life into one figure. Infectious disease account for a staggering -325 million 
DALYs per year, according to WHO (2). While HIV is a significant contributor 
to this number, other sexually transmitted infections (STI) such as syphilis, 
which is responsible for an estimated 520,000 adversely affected pregnan-. 
des and neonates per year, should not be ignored (3). 
Most of these deaths are preventable if the infections are identified early 
and appropriately treated.Correct identification of infectious causes of ill-
ness without appropriate tools is a considerable obstacle to effective clini-
cal management in developing countries. 
15 
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1.2 PATIENT MANAGEMENT 
Patient management refers to the clinical care given to patients, including 
diagnosis and treatment, management forthe chronically ill, and other clinical 
services offered to the population or on individual level. Clinical diagnose~ 
are based on examination of signs, symptoms, and laboratory tests. 
"DiagnOSis is the act or process of identifying or determining 
the nature and cause of a disease or injury through evaluation 
of patient history, examination, and review of laboratory data" 
(The American Heritage- Dictionary of the English Language, Fourth Edition) 
While diagnoses .in developed countries rely heavily on diagnostic tests, this 
is not the case in many developing countries. The lack of laboratory support 
prevents clinicians from making accurate diagnoses and evidence based 
clinical decisions. For example, febrile children. are presumptively treated 
for malaria in areas of high endemicity, although their febrile illnesses may 
be caused by bacteria or viruses (4). 
Appropriate diagnostics could substantially improve the diagnosis and man-
agement of infectious diseases in developing countries and with appropri-
ate prevention and therapy, reduce their burden. Diagnostic tests are used 
for various purposes such as patient management, epidemiological studies 
providing surveillance of disease prevalence, outbreak investigation, guid-
ing of clinical decision making, drug and vaccine research, and to monitor 
progress towards disease elimination. During infectious disease outbreaks, 
accurate detection of the pathogen causing the outbreak can enhance and 
accelerate the response (5-7). The clinical management of malaria infected 
children when better laboratory tests became available is an example (8, 9). 
Diagnostic tests are an essential component in control and prevention strat-
egies in both developing and developed countries. More specifically, the use 
of diagnostic assays has become a key aspect of country policy guidelines 
and national public health strategies to red~ce morbidity and mortality in 
developing countries. Diagnostic~ are particularly useful in national public 
health strategies for the detection of 'sexually transmitted infections (STls) 
16 
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as most of these infections are asymptomatic. Undetected infections can 
result in serious complications such as infertility (10-13). 
Diagnostics for patient monitoring has become increasingly valuable in, 
treating infectious diseases, such as HIV, in which the disease needs to ~e 
monitored to ensure drug regiments adherence and identify emergence of 
drug resistance (14). 
Diagnostics are essential for the eUmination of infectious agents and vac-
cine development. As efforts to eUminate malaria in certain settings showed, 
sensitive and early detection of malaria cases are essential to prevent fur-
ther spread of Plasmodium species (15). Sensitive and specific diagnostics 
are particularly needed for the detection of malaria infections in symptom-
atic and asymptomatic carriers as disease prevalence and parasite density 
decrease. (16). 
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1.3 DIAGNOSTICS IN DEVELOPING COUNTRIES 
Disparities in the quality and accessibility of healthcare for patients around 
the world are vast and given the opportunities diagnostics offer, healthcare 
can be improved globally by increasing accessibility to diagnostics. Urdea 
et al. estimated the potential impact that accessible diagnostics would have 
for various infectious diseases (17). More accessible syphilis diagnostic 
tests that are at least 86% sensitive and 72% specific could save ~ 138,000 
adjusted life years and avert ~148,000 stillbirths (17). A new diagnostic test 
for chlamydia and gonorrhoea with a sensitivity and specificity of at least 
85% and 90%, could save three million DALYs and prevent >161,000 HIV 
infections among female se}( workers. 
Although millions of DALYs potentially saved when accessibility is improved," 
the difficult trade-off between sensitivity and accessibility of diagnostics is 
also shown. While assays (with close to 100% sensitivity and specificity) 
are commercially available for STls, these assays are often not suitable to 
be used in rural health settings (18). By accepting a loss in performance but 
gaining an increase in accessibility, a cost-effective and most importantly, . 
large health impact could be obtained (19, 20). 
Access to accurate diagnostics is often limited due to a variety of factors 
related to the clinical samples and diagnostic assays used. As most assays 
are developed and validated for laboratory settings in developed countries, 
environmental control and mechanical equipment requirements could lim-
it their use in developing countries. For blood based screening tests, ve-
nous blood needs to be obtained by a trained phlebotomist, centrifuged 
and shipped cold to a laboratory. Additionally, costs, technical complexity, 
source of electricity, cold storage requirements of kit reagents, laboratory 
infrastructure requirements, and the necessity of trained and skilled labora-
tory technicians could be reasons why certain assays are not used or appli-
cable in developing countries (1). 
To aid the development of d,iagnostics suitable for developing countries, 
characteristics of the ideal diagnostic tests were established and summarised 
as "ASSURED" (1). ASSURED is an acronym for; affordable, sensitive, specific, 
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user-friendly, rapid, equipment free and delivered to those who need it (1). 
The development of diagnostic assays fulfilling the ASSURED criteria has 
almost been achieved for the detection of certain infectious diseases. Syph-
ilis point of care tests (POCT), fulfils some of the ASSURED criteria, as these 
are affordable (less than US S 1) and provide a result within 20 minutes, al-
lowiDg patients to be tested and treated on the same day. As POCTs are 
stable at room temperature and do not require a~ditiorial equipment, they 
are highly accessible. As the use of POCT expands rapidly across the world, 
POCTs for HIV and in some cases syphilis are incorporated in governmental 
infectious disease programmes and have become the backbone of national 
routine screening services in various developing countries (10). However, as 
testing is decentralised, ensuring the proficiency of health care workers in 
performing the testing becomes more problematic. DBS can potentially play" 
an important role in quality assurance of POC testing. 
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1.4 EVALUATION OF DIAGNOSTICS IN DEVELOPING COUNTRIES 
Commercially available assays that are sold in the United States (US) 
or Europe need to obtain approval to be marketed by regulatory bodies, 
such as the United States Food & Drug Administration (FDA). FDA approval 
'( 
can be obtained when the product completes stringent tests successfully. 
Besides the evaluation of the sensitivity and specificity of a laboratory 
assay; robustness, accuracy, stability o~ reagents,. safety control, labelling, 
and package materials are assessed. Laboratories performing diagnostic 
tests ought to assure the quality by participating in regular External Quality 
Assurance (EQA) programmes. 
Even though commercially available assays approved by FDA are thoroughly 
validated, verification and validation is still needed when these assays are" 
implemented in any laboratory around the world (21). There are various fac-
tors influencing test performance that should be taken into account when 
applying diagnostics. Environmental influences, such as temperature, can 
profoundly affect the quality of kits, and affects sample integrity. Adequate 
training and, for some tests, subjectivity of reading the results can influence 
the reproducibility and reliability of a test (4). Additionally, co-infections, 
suppressed immune systems, and differences in characteristics of the pop-
ulation or pathogen, including genetic variation, are all factors influencing 
diagnostic testing (22, 23). Potentially one of the main reasons why assay 
performance differs from the manufacturer's claims is poor sample quality. 
Regardless of which test is used, poor quality samples will not provide trust-
worthy results. The evaluation of diagnostics in developing countries should 
cover the complete process of shipping kit reagents, collecting samples and 
performing tests in a representative setting where the test would be used. 
The Nature Reviews Microbiology 2006 supplement contains guidelines to 
aid laboratory technicians in validating diagnostic assays (24). 
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1.5 POTENTIAL USES OF DRIED BLOOD SPOTS TO IMPROVE 
PATIENT MANAGEMENT 
As mentioned in section 1.1, accessible diagnostics could substantially 
improve the diagnosis and management of infectious diseases in developing 
countries. POCTs are helping to increase accessibility of diagnostic tests fn 
developing countries, but there is still a large unmet need for improvement 
(4). As diagnostic assays and sample collection ~ethods are both limiting 
the use of laboratory based assays in developing countries, alternatives 
need to be found. Since the development of new diagnostic tests takes five 
to ten years (25), other solution needs to be sought to impro\:,e accessibility 
and applicability of existing diagnostics in developing countries in the near 
future. 
To improve patient management, an alternative sampling method to venous 
blood (i.e. dried hlood spots) was assessed, which can be easily collected, 
stored and transported to centralised laboratories. The collection of whole 
blood on filter paper i.e. dried blood spots (DBS) has shown to be a valuable 
tool for the collection and transportation of whole blood in various develop-
ing countries (26). As noted in Section 1.2, diagnostics are used for a variety 
of aspects in infectious disease control and prevention strategies, and playa 
pivotal role in many patient management services. Giyen the variety of un-
met needs for improvement in patient management, three purposes of diag-
nostics in patient management were selected for this thesis. These purposes 
are; patient monitoring for HIV viral load, quality assurance for POCT, and 
surveillance of causes of fever. The uses of DBS to improve accessibility and 
quality for each of the selected diagnostic purposes were assessed for in-
fectious diseases that are a major public health concern. Additionally, these 
three distinctive public health concerns were chosen potentially to enable 
transferability of the work to other infectious disease disciplines and health 
concerns. A more detailed description of the severity of the health concerns 
are given in the introduction of each chapter. 
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1.5.1 HIV PATIENT MONITORING AND EARLY INFANT DIAGNOSIS 
When HIV paCTs were rolled out, HIV testing became accessible in remote 
African locations (27). With the focus of international organisations as WHO 
and UNAIDS on making HIV treatment accessible for all HIV positive patients, 
'f 
patient monitoring need to be accessible as well (14). Methods such as 
CD4 counting and viral load measurements are essential for the initiation 
and management of the rapidly increasing number of HIV positive patients 
on antiretroviral therapy. Access to these tests in developing countries is 
a concern (28). It is not expected that CD4 counting or HIV VL assays will 
become available for use in remote locations within the coming few years 
(29). With over 8 million patients on Antiretroviral Treatment (ART), HIV VL 
monitoring is becoming increasingly essential to ensure compliance with .. 
drug regimens and that patients are switched to an effective treatment when 
resistance develops. While efforts are made to develop a pac H IV VL assay, 
alternative solutions are needed for now and the near future. The WHO is 
reviewing DBS as an option to improve access to viral load monitoring and 
early infant diagnosis (EID) by collecting samples remotely and performing 
tests at reference laboratories. In order to do this, the difficulties related 
to collection and transportation of plasma tubes need to be solved for use 
in remote settings as phlebotomists and cold storage, particularly during 
transportation, are not available or feasible. The use of filter paper for the 
collection of whole blood, DBS, has several advantages over venous blood 
collection. DBS can be implemented as an easy and inexpensive means 
'of collecting and storing blood specimens under field conditions, while 
blood is collected by finger or heel prick (30-34). The reduction in materials 
required, biological waste produced and the fqct that no phlebotomists are 
required at clinic level, considerably decreases the costs and ease of sample 
collection compared to venipuncture (35). DBS could potentially increase 
the accessibility of HIV VL and EID testing to re~ote areas (36':'38). 
1.5.2 QUALITY OF POeT 
Due to the fact that the use of paCT in developing countries is expanding 
rapidly, the need for a continuous quali'ty assurance (QA) method becomes 
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urgent (14). With paCT, testing performed by healthcare workers (HCWs) 
takes place at bed sides or at remote health clinics. Monitoring the quality 
by QA is, therefore, not always feasible. The potential risks of offering paCT 
without QA could have significant consequences. Because of the lack of QA 
and opportunity to retest a percentage of patients on a regular basis, the 
uncertainty and unawareness of the performance of paCTs are worrisome. To 
achieve the maximum potential of paCTs, QA syste~s need to be developed 
(4). DBS samples have been suggested as a suitable QA method for ensuring 
the quality of HIV paCTs, but this has not been evaluated in practice (39). 
1.5.3 SYNDROMIC DIAGNOSES 
WHO treatment guidelines for children are documented in the Integrated .. 
Management of Childhood Illnesses (IMCI) guidelines. The syndromic 
management of childhood illnesses is stated in these guidelines, to aid 
policy makers and healthcare practitioners in resource constrained settings. 
The guidelines state that, in malaria endemic regions, children should be 
treated for malaria when diagnosis is not available by laboratory testing 
or paCT. When malaria paCT was incorporated in the IMCI treatment 
guidelines, overtreatment of malaria became apparent in various regions of 
the world. Recent results indicate that malaria prevalence is decreasing while 
treatment is increasing (8, 40). Various "non-malarial" febrile pathogens can 
cause severe illness and in those cases appropriate treatment to prevent 
health consequences is required. The frequent overtreatment of malaria in 
areas where fever can be caused by dengue, rickettsia, and other febrile 
illnesses, leads to the unnecessary use of anti-malarials which in turn leads 
to a reduction in overall health benefits (41). n 
Distinguishing between benign and serious causes of fever in young chil-
dren is a cause of concern for HCWs all over the world. The differentiation 
between viral infection and "occult bacteremia" (clinically significant pres-
ence of bacteria in the blood stream) is the main distinction that mostly 
relies on laboratory tests (42).The great range of possible causes and often 
the lack of laboratory tests, forces-HC~s in developing countries to start 
treatment without clear evidence. 
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The bacterial or viral causes of fever in children often show epidemic, en-
demic and seasonal characteristics that can vary from area to area. These 
characteristics make diagnosis without laboratory support complex. When 
the incidence and prevalence of the various fever associated pathogens in 
children are monitored, care could be improved. Fever associated pathogens 
such as malaria, dengue, rickettsias, leptospira, or chikungunya would re-
quire surveillance to determine the prevalence an~ incidence accurately in 
febrile children from rural areas. Surveillance method should include locally 
prevalent infectious diseases. To give an example, Bartonella bacilliformis, 
is a life threatening febrile infection and outbreaks occur in Peru (43, 44). As 
the symptoms are relatively comparable to other febrile infectious diseases, 
such as malaria or dengue, B.bacilliformis remains misdiagnosed, and prev-
alence data are not available. 
To improve the syndromic management of febrile children, a surveillance 
system would be a suitable option to empower governments and clinicians 
with prevalence data, to develop evidence based guidelines, and provide 
children with agequate treatment. 
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1.6 AIMS AND OBJECTIVES 
Hypothesis: 
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DBS can improve patient management in developing countries 
Objectives: 
1. To assess if patient management could be improved by using DBS 
samples. 
a. To conduct a systematic review of the published literature on 
the applicability of filter paper sampling in the diagnosis of 
infectious diseases. 
b. To conduct a systematic review of the applicability of DBS in 
HIV viral load patient monitoring and early HIV infant diagnosis. 
2. To assess if DBS can be used to assure the quality of point-of-care 
testing in developing countries. 
a. To evaluate syphilis POCT performance before implementing 
the quality assurance method. 
b. To evaluate DBS as an alternative sampling method· for 
obtaining quality control samples for syphilis. 
c. To implement central laboratory testing of DBS as a quality 
assurance method for HIV and syphilis POCT. 
3. To assess if DBS can be used for detecting causes of fever in children. 
a. To develop and implement a surveillance method based on 
DBS for identifying the infectious causes of fever in children, 
in a proof of concept study. 
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1.7 STUDY RATIONALE 
To address these objectives, the thesis requires a clear conceptual framework 
to harmonise and structure the research efforts of using DBS samples, 
potentially to improve clinical management in developing countries. 
Science is facts; just as houses are made of stones, so is 
science made of facts; but a pile' of stones is not a house 
and a collection of facts is not necessarily science. 
Henri Poincare (1854 - 1912) 
Although the use of DBS will be discussed in considerable detail, this thesis 
focuses on the possibility of improving clinical and laboratory based diag-
noses, and providing solutions to unmet needs in developing countries. 
A schematic overview of the objectives and methods is given in Figure 1.2. 
Figure 1.1: Schematic overview of the PhD thesis 
Hypothesis -
Objectives 
Method 
" -
Chapter ~ , 
,', 
Chapter 4, 5, 6 t: .. '~.'. :'.r •. I • Thesis 
To illustrate the objectives in Figure 1.2, objectives 1a and 1b are presented 
separately while grouped as one objective in the previous section (study 
rationale). 
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1.8 STRUCTURE OF THESIS 
The thesis consists of six chapters following the three objectives. Chapter 
2 describes the literature, to identify potential uses of DBS for diagnostics 
in developing countries. This chapter provides a complete overview of 
DBS utility for infectious diseases, specifically focused on the detection of 
infectious diseases by using nucleic acid or serology based assays. 
Chapters 3-6 comprises of four research papers, each with an introduction. 
In Chapter 3, the results of a systematic literature review are presented on 
the use of DBS for HIV viral load monitoring and HIV early infant diagnosis. 
Both Chapter two and three address objective 1 of the thesis. 
Objective 2 is covered by three research papers in Chapters 4-6. Chapter 4 .. 
depicts the evaluation of the performance and accessibility of two syphilis 
screening assays in Tanzania, and the trade-off between assay performance 
and accessibility is discussed in detail. Chapter 5· reports on the develop-
ment and validation of filter paper based Treponema pallidum antibody de-
tection. Chapter 6 describes the implementation of the method developed 
in Chapter 5 as a quality assurance method in Tanzania for syphilis and HIV 
POCT. 
Chapter 7 reports the assessment of DBS samples to improve clinical man- . 
agement potentially, through providing setting-specific information on the 
infectious causes of the syndrome of fever in children. Chapter 7 describes 
the proof-of-concept development of a surveillance method based on DBS 
for the causes of fever in children. The surveillance method was implement-
ed for the detection of Bartonella bacilliformis in Peru. 
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1.9 CONTRIBUTION OF THE CANDIDATE TO THE THESIS 
Chapter 2 contains two sections: the first section (overview of DBS methods) 
was independently designed and executed by the candidate, and the 
second (DBS systematic literature review) was undertaken by the candidate 
and Ivo Elliot. The systematic literature search was performed by the 
candidate in collaboration with Ivo Elliot and supervised by Paul Newton 
and the candidate's supervisors David Mabey and Rosanna Peeling. The first 
section will be used for the WHO technical brief on HIV VL on DBS, and the 
second section will be submitted to Lancet infectious diseases journal. The 
candidate will be first author, with an equal contribution note to Ivo Elliot 
as most of the work was done in duplicate, to make the literature review 
systematic. 
Chapter 3 was based on the assignment of WHO to perform a literature re-
view regarding the evaluation of HIV viral load methods. The literature re-
view will lead to a peer reviewed publication and technical brief. This was 
delegated by Rosanna Peeling to the candidate and Kimberly Sollis. The can-
didate initiated an additional literature review for HIV viral load measure-
ments on DBS samples. When WHO reviewed the additional DBS sections, a 
separate article and technical brief for DBS was requested. Only the DBS lit-
erature review is included i~ Chapter 3. The systematic literature review for· 
HIV VL and EID for DBS samples was performed by the candidate, Kimberly 
Sollis proof read earlier versions of the manuscript. The literature review 
was supervised by Rosanna Peeling. 
It is amazing what you can accomplish if 
you do not care who gets the credit 
Harry S Truman (1884 - 1972) 
The work conducted on Chapters 4, 5 and 6 was linked to a research project 
funded by the Bill and Melinda Gates Foundation for the implementation of 
syphilis POCT in seven countries. Chapter 4 was developed by the candidate 
and supervised by his supervisors. ~he laboratory tests were executed in 
collaboration with laboratory technicians at National Institute for Medical 
Research (NIMR) and the TAZAMA team in Tanzania. The TAZAMA team (Jim 
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Todd, Basia Zaba, and Mark Urassa) were willing to share their samples for 
this project and contributed to the project proposal by obtaining ethical ap-
proval and making it possible to implement this project into their on-going 
study. Chapter 5 was developed by the candidate in collaboration with the 
candidate's supervisors, and the laboratory tests were performed in collabo-' 
ration with NIMR laboratory technicians. Chapter 6 was designed in collabo-
ration with the candidate's supervisors and perform~d in collaboration with 
Julius Mngara who maintained contact with HCW during the study period 
and Thomas van der Vlis, who assisted in handling the samples in the labo-
ratory. 
Chapter 7 was based on a grant obtained by the candidate in collabora-
tion with his supervisors. The project was developed and conducted inde- .. 
pendently. Paul Newton, Dave Moore and Patricia Garcia collaborated by 
making it possible to use their samples or generously made it possible to 
use their research setting and network. David Mab"ey and Colin Sutherland 
provided feedback on the grant report, which resulted in this thesis chapter. 
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2 The use of DBS for infectious disease 
detection 
2.1 HISTORY 
The use of paper to store clinical samples for subsequent analysis has a 
long history. In Germany, during World War II, dysenteric faeces were dried 
on filter paper and Shigella subsequently i,dentified (.45). In 1950 Joe et al. 
in Leiden, The Netherlands received faeces dried onto filter paper by post 
from Indonesia and also successfully detected Shigella (46). Robert Guthrie 
is widely credited as being the first to use blood dried on filter paper (so-
called Guthrie cards) to diagnose phenylketonuria in neonates in 1963 
(47). However, in 1957 Wolff in Leiden had already noted the fruitlessness 
of performing serological analysis on blood sent from the tropics and was 
investigating the use of filter paper as a possible alternative(48). In 1963 
van Thiel collected blood samples on filter paper in West New Guinea and 
was able to detect antibodies to leptospirosis in Leiden, even after the 
filter paper was stored for a year in a sealed box at room temperature (49). 
Since then, filter 'paper has become a widely used method of storing and 
transporting diverse specimen types, from humans, animals, and plants, for 
analysis. From humans, almost all types of body fluids, from blood to saliva 
and faeces to breast milk, have been stored on filter paper. 
The collection of blood by filter paper has been applied in various research 
and clinical settings. Dried Blood Spots (DBS) have been applied to surveil-
lance (33, 50-55), diagnostics (56), screening (57), drug resistance screening 
(58-60), therapeutic drug monitoring (61), and as a quality control method in 
various research and clinical settings around the world (39, 62). 
When performing diagnostic or epidemiological 'surveys, particularly in re-
mote areas in resource-poor settings, the facilit1es for processing whole 
blood and maintaining frozen samples are frequently non-existent. Dried 
blood spots (DBS) provide an ideal and inexpensive means of potentially 
overcoming these difficulties. Samples such as finger-prick blood are easily 
and quickly collected onto filter pape-r an,~ shipped at room temperature, 
hence allowing the samples to be sent by post. The reduction· in required 
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materials, reduced biological waste production and minimal training of per-
sonnel at clinic level, decreases costs considerably in comparison to stand-
ard blood collection by venepuncture (35). Additionally, the small size of 
DBS -a little bit bigger than a credit card- allows easy storage and use after 
prolonged periods. DBS has shown to be particularly useful in increasing! 
uptake of testing services (63,' 64). 
Blood sample volumes on filter paper are inevitably small and rigorous assay 
validation must be performed to achieve suitable sensitivity and specificity. 
For certain pathogens and sample types long-term storage at ambient tem-
perature, particularly when exposed to high humidity, will reduce sensitivity. 
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2.2 RATIONALE 
The use of DBS in infectious disease detection has been reviewed in the 
context of epidemiological studies (65), HIV detection and monitoring (36, 
66-70), virology (26), cytomegalovirus (71, 72) and for drug assays (73). 
However, there are no recent clinically-orientated reviews of DBS for the 
diagnosis of infectious diseases. A review on the current use of filter paper, 
focusing on evaluation of DBS assays compared to a recognised gold standard 
for the diagnosis and or epidemiological study of infectious diseases for 
both nucleic acid amplification and serological assays, was performed. 
The aim of this literature review was to provide a complete overview of lit-
erature describing both technical details and uses of DBS samples for infec-
tious diseases. In thls review, the objectives were (1) to assess the general 
implications of using DBS instead of traditional sampling methods and (2) 
to assess the use of DBS for the diagnosis or surveillance of infectious dis-
eases. Objective 1 is addressed in section 2.3. For objective 2, discussed in 
section 2.7, the use of filter paper with samples other than whole blood is 
briefly reviewed as well. As filter paper samples are also used for veterinary 
health with little overlap with human health, a brief summary of this parallel 
work, particularly for livestock diseases with significant economic impact, 
was included in section 2.7. 
2.2.1 METHODS 
For section 2.3, the literature review and additional information was obtained 
from manufacturers and websites to provide a detailed description of 
available techniques. This is presented as a review -of DBS techniques and key 
considerations. Section 2.7 is solely based on a review of studies evaluating 
the performance of DBS for infectious disease detection. Standard guidance 
in performing the review as documented by the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) checklists was followed (74). 
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2.2.1.1 Inclusion criteria 
Inclusion criteria were defined using PICOS (Population, Interventions, 
Comparisons, Outcomes, Study Design) criteria (75). Studies evaluating 
the performance of DBS for the detection of infectious diseases against a 
valid reference sample were considered for inclusion. Both DBS and a valid 
reference sample had to be performed on the same commercially available 
assay, when applicable DBS. 
Included studies evaluated the use of DBS compared with a recognized gold 
standard reference sample (e.g. serum, plasma or whole blood) for qualita-
tive and or quantitative analysis of nucleic acids or serological (antibody/an-
tigen) testing to detect any human or animal pathogen. Where commercially 
available assays are routinely employed in diagnosis, in-house methods or 
outdated commercial assays were excluded. The following diseases had in-
house assays excluded after agreement between all reviewers: human im-
munodeficiency virus (HIV), hepatitis Band C, cytomegalovirus (CMV), mea-
sles and rubella. Excluded articles are listed in Annex 10.2.8. 
2.2.1.2 Information Sources 
Studies were identified by searching tre electronic databases MEDLINE and 
Embase. The search was performed on 13th December 2011. Additional 
relevant studies were identified by reviewing the references of the included 
studies. 
2.2.1.3 Search Strategy 
We used the following terms to search the electr?nic databases and made 
use related search tools when applicable: 
"dried blood" , "blood spot", "blood spots", "dried serum", "serum spot", 
"seru m spots" , "fi lter pa per", "fi lter cards" , "fi lterdisc", "fi lter discs", "fi l-
ter disk", "filter disks" ,"blotting paper", "Guthrie card", "Whatman paper", 
"Isocode stix" ,"FTA paper", "FTA card", "filter paper", "disease" and made 
use of corresponding Medical Subject Heading (MeSH) terms for the above 
keywords. 
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2.2.1.4 Study seLection 
Titles and abstracts were screened for relevance. Full text articles of 
potentially eligible studies were then obtained and assessed against 
inclusion criteria. Reasons for exclusion were recorded. The study selection 
process was performed in the first instance by PWS and IE. Where uncertainty 
about eligibility existed, studies were discussed and eligibility was decided 
by consensus. The study selection process is summarised in the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow 
diagram shown in Annex 10.2.2. 
2.2.1.5 Data extraction process 
A data extraction form was developed and tested prior to use in the review. 
Information was extracted and entered into a Microsoft Excel datasheet. 
Quantitative data extracted included: study site, filter paper type, sample 
and reference sample type, paper storage conditions and details of the assay 
test (manufacturer or in-house reference, punch size, elution volume and 
conditions, extraction kit and assay input volume). Descriptive data included 
any relevant additional outcomes. See full review protocol in Annex 10.2.1. 
Two reviewers independently extracted data from the included studies. 
Disagreements were resolved by consensus. 
During the selection process studies examining the practical aspects and 
implications of using DBS compared with non-filter paper samples (either 
in addition or separately to evaluating DBS) were identified. These articles 
include detailed studies, reviews and guidance on key areas including: filter 
paper types, DBS preparation, drying, transportation, biohazard risk, storage 
and stability, punch size, punch disinfection, and elution methods. 
A non-exhaustive selection of studies on the use of filter paper with samples 
other than whole blood and for animal pathogens were identified. Where 
available, sensitivity and specificity of assays performed on these samples 
were recorded in comparison to a gold standard reference sample. Addi-
tional practical information concerning the use of these sample types was 
also recorded where relevant. Lastly, a lirnited selection of studies on ani-
mal pathogens - both zoonotic and non-zoonotic - and particularly those 
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important in veterinary health were identified during the initial selection 
process and kept separately. General descriptive information on the use of 
filter paper in this field was extracted. 
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2.3 REVIEW OF METHODS AND KEY CONSIDERATIONS 
2.3.1 TYPES OF FILTER PAPER 
Filter paper compounds include cellulose, glass, quartz fibre filters, nylon, 
PVC, polyvinylidine and many other filter membranes. Cellulose filters J 
derived from cotton are most commonly used in infectious disease research. 
There are two types of cellulose filter paper; treated and non-treated filter 
paper of which the non-treated is more commonly used. There exist many 
versions of the 100% cellulose filter paper, varying by thickness and pore 
size among the many manufacturers that produce comparable cards. The 
100% cellulose filter paper is widely used in neonatal screening (76). For 
the collection of whole blood, the thickness is of considerable importance 
as the compactness 'and volume of blood on the filter paper can vary 
tremendously. For laboratory tests, a small section of blood containing paper 
is removed and used for further analysis. The type of paper will therefore 
influence the blood sample volume that is processed. The quality of paper 
e.g. the thickness and consistency of filter paper is essential to standardise 
and reduce variability within and between samples (76). 
The treated filter paper types often contain lysis buffers, impregnated on the 
filter paper membrane. This method lysis the cells and reduces contamination 
risks. It additionally -according to the manufacturer -leads to greater stability 
and inactivity of enzymes that are potentially harmful for nucleic acids. Most 
treated cards can only be used for nucleic acids and are not suitable for serol-
ogy or chemical analysis. Although many types of filter paper are used in in-
fectious disease detection, we selected four papers, 2 treated and 2 untreated 
filter papers. These two treated filter papers are regularly used for infectious 
disease detection and the 2 untreated filter papers are the only two approved 
by the FDA and have CE marking (Conformite Europeenne) for human whole 
blood sampling (filter paper grade 903 of Whatman ,and Ahlstrom grade 226 
of PerkinElmer). Every lot of these filter papers are checked by US Centre for 
Disease Control and Prevention (CDC) to ensure the correlation between spot 
size and whole blood volume varies minimally (77). The table below gives 
details of four filter paper types used fo(the"detection of infectious diseases 
(Table 2.1). Details were obtained from the manufacturers. 
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Table 2.1: Commonly used filter paper types, (manufacturers' details) 
Pa~er cards 903 FTA FTA Elute 226 
Manufacturing company Whatman part of GE Whatman part of GE Whatman part of GE Perkin Elmer 
Healthcare Healthcare Healthcare 
--- --._--
Material 100% cellulose Treated cellulose Treated cellulose 100% cellulose 
~~~--
Adjustable format Yes. Custom formats are Yes. Custom formats are Ye's. Custom formats Yes. Custom formats 
available as well as standard available as well as standard are available as well are available as well as 
standard catalogue items. 
This is an untreated 
matrix that is suitable for 
Number of spots 
Quantity of whole blood per 
spot 
Recommended drying time 
catalogue items. This is an catalogue items. This is 
untreated matrix that is a treated format that is 
suitable for antibody testing suitable for nucleic acid 
as well as nucleic acid testing. testing. 
Standard format has 5 circles, A few standard formats are 
12- 13mm diameter. Custom available, 1 - 4 circles, 1" in 
formats can have as many diameter. Custom formats 
circles as needed can have as many circles as 
needed 
75 - 80lJl per circle 100 - 125lJl per circle 
-- _.- - - - .... - -
3 hours 3 hours 
as standard catalogue 
items. This is a treated 
format that is suitable 
for nucleic acid testing. antigen testing as well as 
Standard format has 
4 circles, 12- 13mm. 
Custom formats can 
have as many circles as 
needed 
70 - 80lJl per circle 
3 hours 
nucleic acid testing. 
Standard format has 
5 circles, 12- 13mm 
diameter. Custom formats 
can have as many circles 
as needed 
. 75 - 80lJl per circle 
3 hours 
n 
.:J 
QJ 
v 
~ 
m 
-. 
N 
o 
OJ 
l/1 
r-+ 
m 
-. 
QJ 
r-t' 
C 
-. 
rD 
rD 
< 
(l) 
~ 
l.J-J 
\0 
Paper cards 
Stability 
Lot variability 
-
- --- ----
Pack quantity 
FOAl CE approved transport 
of blood for diagnostics 
Recomrpended storage time 
and conditions 
Suggestions and Comments 
(manufactur,er's) 
903 
Stability of> 3 months 
for viral RNA has been 
documented in reference 
papers 
Not documented for H IV 
testing 
100 cards per pack 
FTA FTA Elute 
Stability of > 3months DNA is stable at room 
for viral RNA has been temperature for more 
documented in reference than 10 years. 
papers. DNA is stable at room 
temperature for more than 
10 years. , 
Not documented for HIV Not documented for HIV 
testing 
----
testing 
100 cards per pack 100 cards per pack 
226 
Comparable performance 
to 903 filter paper. 
100 cards per pack 
Class 2 medical device and CE For research use only CE marked as a sample Class 2 medical device 
and CE marked as a 
sample collection device 
for blood 
marked as a sample collection 
device for blood 
For nucleic acids: Room temperature storage 
Short-term: +4°C for DNA, +4°C for RNA 
Long-term: -20°C 
903 has been used since the FTA offers the advantage of 
199((S, first with antibody pathogen inactivation, safer 
testing and later HIV-l and for handUng and shipping. 
viral load tests. 
collection device for 
blood 
Room temperature 
storage for DNA, +4°C 
for RNA 
FTA Elute offers the 
advantage of pathogen 
inactivation, safer for 
handUng and shipping. 
For nucleic acids: 
Short-term: +4°C 
Long-term: -20°C 
The thickness of 226 filter 
paper is very consistent 
and is therefore ideal for 
. quantitative analysis 
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2.3.2 COLLECTION OF FILTER PAPER SAMPLES 
Various protocols have been written for the collection of filter paper samples 
by finger prick. A basic outline is given below, obtained from Mei et al. (76). A 
detailed presentation and training session has been developed by the WHO 
which is useful for teaching purposes (78, 79). 
Table 2.2: Collection procedures for DBS samples 
• Clearly label card with appropriate sample number or name 
• Do not touch the filter paper circles before or after blood collection 
• Clean the puncture site with 70% isopropanol or 70% ethanol 
• Use sterile, disposable lancet 
• Keep the puncture site below the heart level 
• Wipe away the first drop of blood 
• Apply the second drop of blood to the surface of the filter paper circle by 
gently pressing the paper to puncture site or use sterile micropipette 
• If not completely covered, apply immediately a second drop of blood to 
the circle 
• Fill all the circles only on one side of the filter paper . 
• Dry the specimen at ambient temperature for 3-4 hours in horizontal 
position, out of direct sunlight and protected from insects or rodents 
• Avoid touching or smearing the blood spots 
Pack filter pape·r with desiccants and humidity indicator in a gas 
impermeable zip lock bag 
• Insert DBS bags into rip-resistant envelope 
• Include documentation and place in large envelope for transport 
Although sample collection procedures are relatively straightforward, 
adequate training is necessary to minimize potential sources of error. Proper 
placement of whole blood on the filter paper is critical as the uniform 
absorbing properties are diminished if blood is smeared onto the filter 
paper. To assure blood is uniformly absorbed, a droprshould be formed on the 
finger and contact between the finger and filter paper should be prevented. 
Applying multiple drops onto the same area will cause blood to layer which 
prevents a homogenous distribution of whole blood across the filter. More 
details for spotting and storing DBS samples can also be found on the website 
of the laboratory technologist committee (80). The importance of correct 
DBS preparation, storage, and manipulation conditions was highlighted by 
Bertagnolio et al., who showed that amplific~tion success rates for HIV drug 
resistance sequencing varied from 53 to 92% (66). 
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2.3.3 QUALITY CONTROL OF SAMPLES 
The quality and integrity of a clinical sample is essential for proper quality 
diagnostic testing, irrespective of which tests are applied. The quality 
of the filter paper samples upon arrival at the laboratory can vary due to 
environmental factors that in the end could influence test results. Effects 
such as humidity, contamination, mould, and overall state of the cards can 
be beneficial to register. Recording these effects is noteworthy because 
they may result in exclusion of those samples due to poor quality. Besides 
environmental influences that can affect the quality of DBS samples, incorrect 
sample collection is also a potential cause that needs to be ' recorded. 
Layered samples, small quantities of blood, serum rings, and supersaturated 
sampling influence the sample quality. A reference of incorrect DBS samples 
are given in Figure 2.1 (81). 
Figure 2.1: Examples of invalid DBS samples. Obtained from NYDSOH (81). 
Invalid Sarrples 
1. 1. Insufficient Quantity 
2. 2. Appears Scratched or abraded 
3. 3. Not dried prior to mailing 
4. 4. Supersaturated 
5. 5. IJluted, discolored, or contaminate< 
6. 6. Exhibits serum rings 
7. 7. Ootted or layered 
8. 8. No blood 
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With insufficient blood or poor sample integrity, a correct test result cannot 
be given. Diluted or discoloured DBS samples are indicators that the sample 
may not have been properly dried or became contaminated, causing the 
colour change. Clotted or layered cards raise the possibility that a sample 
contains blood of two persons spotted onto one card or that the sample was 
incorrectly collected. It is preferable to exclude these samples for further 
analysis. Serum rings can occur when alcoh~l used for cleaning the finger 
did not dry sufficiently before puncturing the finger. Serum rings can also 
occur due to clinical conditions such as anaemia that influence the amount 
of serum collected when obtaining a punch from the filter paper (see Chapter 
7). In this case, serum ring samples could contain insufficient blood for valid 
diagnostic tests. 
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2.3.4 SAFETY & SHIPMENT REQUIREMENTS 
As DBS contains dried blood, the samples should be processed as contagious 
material. The safety procedures and package requirements are fewer than 
would be the case with liquid whole blood. US CDC has shipping guidelines 
for DBS posted online (82). Although it is believed that bacteria and viruses 
have reduced activity when stored at DBS samples, Streptococci group A 
could be cultured after elution of DBS samples (83, 84). Standard safety 
measures and regulations should be in place for processing DBS samples in 
the laboratory. Permits may be required for international shipments but this 
depends on country regulations and particular circumstances. Acc'ording to 
the manufacturer, FTA and FTA elute inactivate highly pathogenic organisms. 
2.3.5 PUNCHING SAMPLES 
Manual or automated punch devices, such as handheld office punches or 
automated machines used for neonatal screening are suitable for removing a 
section from the filter paper (Table 2.3). Most automated punching platforms 
work with 96 well-plates which are ideal for serological assays such as ELISA, 
but are less suitable for nucleic acid detection as most extraction methods 
are not based on 96 well-plates. Manual punches such as office punches are 
an affordable option (±2 Euro), although it is necessary to attach a small tube 
to handheld office punches to guide the punched material to the correct well 
for further analysis (personal experience). 
Nucleic acid extraction protocols for DBS samples in 96 well-plate format 
exist, both as commercially available kits and in-house methods (Qiagen 96 
well-plate DNA minikit, Chelex, Roche MagnaPure robot). Unfortunately, for 
most extraction methods, the eluate needs to be separated from the filter 
paper before extraction. Most automated extraction robots are not suited for 
filter paper debris as these clots the pipette tips. 
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A recent development is that perforated filter paper cards are now commer-
cially available, allowing the spots to be removed with a pipette tip. These 
cards could remove the necessity to use punching machines, limiting the 
use of equipment and potential contamination risks. This currently exists for 
both Whatman 903 and 226 of PerkinElmer. 
To assure the punches contain the correct quantities of dried blood, it is 
recommended to punch with the back of the card facing forward in order to 
visually check that the filter paper is thoroughly saturated with whole blood. 
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Table 2.3: Punch methods (Manufacturer's specifications) 
Office · hole- Harris-unicore DBS Puncher (1296- Multi Puncher (1296- Auto Puncher 
Punch methods Scissor ~unch and multicore 071) 081) (1296-091) 
Manufacturer Whatman PartnerTech BSD Robotics BSD Robotics 
Method overview Manual Manual Manual Semi-automated DBS Semi-automated DBS Automated DBS 
punching punching punching 
Applicable DBS types All types All types All types Sheet and cassette Sheet and cassette Cassette 
throughput 30 punches per 40 punches per 40 punches per 1 plate/4 minutes NR NR 
hour hour hour 
-- - --- -
._._- - -,-
Replacement timet NR NR -10 punches' 400000 punches 400000 punches (appr.) 400000 punches 
punches (appr.) (appr.) 
Punch sizes Complete circle 3mm,6 mm 1.5 - 8.0 mm 3.2mm, 4.7mm and 3.2mm, and 6 mm 3.2mm and 6mm 
(diameter) (12mm) 6mm 
-
----- ".-- ~ ---- ------ --,- - --_ .. - ----
Maintenance costs None None none NR NR NR 
. " - ~,.~ 
-
Operational costs None None None NR NR NR 
Cleanin'g procedures Punch a clean Punch a clean Punch a clean Piston and chute Chute cleaning, wiping Chute cleaning, n 
:::J 
card twice or use card twice or use card twice or use cleaning, wiping parts parts vacuuming, wiping ClJ u 
1 % Virkon with 1% Virkon with 1% Virkon with r-+ (j) 
70% ethanol 70% ethanol 70% ethanol N 
, -
- - -- --
VaUdated fo'r PCR no no no NR NR NR 
end-point samples 0 
- -- - - - -. - --- - - - -
OJ 
Environmental none none none 15-3SoC 10-3SoC 18-30°C VI 
requirements 10-8S% RH Max 800/oRH @ 10-3 ~ °C 20-800/oRH r-+ (j) 
(temp/ humidity/ 110-120V/220-240V -> SO%RH @ 40°C 110-240V SO/60Hz n.i 
r-+ 
electricity etc) SO/60Hz 110-240V SO/60Hz 200VA c 
" '1) 
60VA 200W (j) .. - - ~ 
Costs 1-3 f 1-3 f 20 f 10080 f 31164 f 68730 f < 
~ NR= not reported 
(j) 
lJ1 ~ 
2.4 CONSIDERATIONS WHEN USING DBS SAMPLES 
There are some key considerations to be made when deciding to use DBS 
for the detection of infectious diseases. When implementing DBS sampling, 
healthcare workers need to be trained in how to collect, store and transport 
samples appropriately. Even though the methodology is easy, training is 
necessary to ensure correct sampling methods. Another key consideration 
is that implementing DBS in a laboratory could mean that a complete new 
sample flow has to be designed within that laboratory, and all necessary 
training and safety procedures need to be given to laboratory technicians. 
Besides these relatively minor limitations, the use of DBS also influences 
the laboratory testing procedures. When considering using DBS samples 
for infectious diseases detection, it is recommended to assess critically the 
concerns raised below. 
2.4.1 BLOOD VOLUME AND SPOT SIZE CORRELATIONS 
When spotting DBS with finger prick blood, it is not possible to know the 
exact volume of blood that is placed on the paper. As the quantity of whole 
blood or plasma is essential for developing and executing a reliable test, 
spot size is critical. A direct correlation between spot size and quantity of 
whole blood exists, provided the blood is absorbed on to the filter paper 
homogeneously (85, 86). The volume of blood absorbed correlates well 
with the density of the filter paper (86). The type and brand of filter paper 
influences the interaction between spot area and blood volume. (orran et 01. 
evaluated three different types of filter paper, often used for malaria research 
(3MM, no. 1 and glass fibre). A two-fold difference in quantity of whole 
blood was found, depending on the filter paper used (86). To investigate if 
whole blood on filter paper spreads homogeneously, filter paper fibres were 
evaluated. It appeared that the volumes differed by 1-2°10 for each different 
lot of Whatman 903 and PerkinElmer 226 filter paper when compared using 
a central or a peripheral punch (76). This <2°1o difference also shows that 
there is minimal difference betweer: filter paper lots (76). When comparing 
903 and 226 filter papers, no more than 4-5°10 difference was detected for 
analytes that are used for neonatal screening (77). Even though. blood is 
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homogenously spread on filter paper, applying more whole blood to each 
spot increases the amount of serum in a centre punch (76). Quantitative 
recoveries of analytes used for neonatal screening gave minimal differences 
by seven laboratories when using carefully created (spiked) blood samples, 
suggesting high consistency of recovery with DBS (77). 
2.4.2 WHOLE BLOOD COMPOUNDS AND EFECTS ON QUANTITY OF 
PLASMA 
Most infectious disease diagnostic assays are developed for plasma or se-
rum samples and require a large sample volume. For example, HIV viral load 
quantification can require 600 ~L of plasma while DBS typically contain so-
lDO ~l of whole blood. As the quantity of DBS sample is dramatically less, 
it is essential to ensure that DBS contains the right amount of whole blood. 
The quantity of serum in whole blood that was dried on filter paper is dif-
ficult to determine but essential for protocol develop~ent. Various factors 
such as blood haematocrit, blood volume per spot, and technical aspects 
of filter paper contribute to different extraction yields of plasma in a DBS 
sample (87). 
The relation between plasma and haematocrit levels is relatively straightfor-
ward for Ethylenediaminetetraacetic acid (EDTA) whole blood but is slightly 
more complicated for DBS samples. When haematocrit levels of blood spot-
ted on filter paper increase, the amount of serum per spot (6mm) decreases 
(76). ,Additionally, because of the higher viscosity, high hematocrit blood 
yields a smaller DBS area than blood with a lower hematocrit. On the other 
hand, high haematocrit levels significantly increase levels of certain amino 
acids in centre punches (88). With low haematocrit levels, levels of various 
amino acids were higher in peripheral than in central punches (88). 
If 100 ~l of whole blood with a haematocrit of 55% i~ spotted onto filter pa-
per (903 or 226 filter papers), a 3.2mm centre punch would contain between 
1.465 - 1.487 ~l of serum and a 3.2mm peripheral punch would contain 
1.445 - 1.459 ~l of serum (76). This estimate can be used to calculate the 
correct punch size to obtain the necessary serum input volume when devel-
.> 
oping a DBS protocol for diagnostic assays. 
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Whole blood collected by finger prick and venous blood differ from each 
other in composition (89). As capillary blood links arterial and venous blood 
flow, blood composition is different for each of these three phases. Capillary 
blood consists of different blood components from venous blood and when 
obtained by finger prick, the local trauma causes capillary blood to contain 
other body fluids (e.g. extra- and intracellular fluids) (89). When spotting 
whole blood on filter paper, the integrity of antibodies or.nucleic acids could 
be reduced by biochemical structural changes or oxidative damage by hae-
moglobin. Although changes over time of the dry state of haemoglobin did 
not cause oxidative damage to DNA in DBS samples (90). It has been noted 
that storage of DNA or RNA on DBS could cause difficulties for sequencing 
due to tearing of DNA a~d RNA structures when stored on filter paper (91). In 
most cases, the length of DNA or RNA is adequate for general PCR and basic 
sequencing purposes (92). 
2.4.3 CONSIDERATIONS WHEN USING DBS INSTEAD OF PLASMAl 
SERUM 
The composition of serum and DBS eluate differs due to the presence of 
red blood cells and other whole blood components that would otherwise 
be spun down and removed. Cells such as white or red blood cells could 
interfere with assays and potentially reduce sensitivity. Additionally, when 
drying whole blood on filter paper, cell structures can be ruptured and their 
content released onto filter paper which could interfere with assays. These 
effects can be seen when higher Optical Density (00) values are obtained 
for negative DBS samples that would be obtained with plasma samples. This 
could potentially lead to false-positives. The level of interference will vary 
by assay type and it may be necessary to perform additional steps to remove 
these interferences. For all PCR applications, this is not a problem because 
nucleic acids require isolation and purification from the sample. 
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Besides the influences mentioned above, DBS can also affect the detection 
of the infectious disease of interest. Depending on the pathogenic charac-
teristics, intracellular or extracellular pathogen loads could differ between 
whole blood and plasma. For example, when measuring HIV viral load with 
DBS samples, proviral DNA as well as intracellular HIV RNA are present, which 
influences drug resistance and viral load measurements compared to viral 
load measured in plasma samples (58, 93, 94)., 
To give another example, dengue can be detected in plasma samples by RT-
peR. To obtain the highest sensitivity, it is necessary to obtain the samples 
after onset of disease, as the viral load in dengue drops after five days of 
fever (95). When using DBS samples, it appears that viral particles persist 
longer in capillary blood than in venous blood and this positively influenced 
the sensitivity of DBS, even when plasma or serum became negative (5, 95, 
96). 
As DBS spots are rehydrated in the laboratory, filter paper fibres separate 
from the membrane and fibres could clot filter tips when handling sample 
materials. It is therefore necessary to remove the DBS when using automat-
ed platforms which is currently a limitation for automation. 
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2.5 CONSIDERATIONS FOR USING DBS SAMPLES FOR 
SEROLOGICAL ASSAYS 
Taking the previous sections into consideration, concerns, problems and 
potential limitations of using DBS for serological assays are included 
and discussed in this section in more detail. Serological antibody or 
antigen detection by Enzyme Immunosorbent Assay (EIA), Enzyme-linked 
immunosorbent assay (ELISA), or agglutination tests are the main focus 
of this section. These assays are widely available and commonly used for 
infectious disease diagnostics. In this chapter, the necessary punch size, 
elution buffer choices and input calculations will be presented. 
2.5.1 PUNCH SIZE CALCULATION 
In order to obtain a comparable sensitivity to plasma samples, ideally, 
the sample input volume of DBS should be equal to serum or plasma(97). 
It is therefore highly unlikely that a serological assay. that requires 50 or 
100 jJl of serum would be applicable for DBS samples. Many assays dilute 
plasma samples to about 1:200, and these assays should be more successful 
candidates for DBS samples. 
To assure correct DBS sample volumes are used for the assay, calculations 
can quickly determine the appr<?priate punch size and elution volume. All 
calculations below are based on the use of grade 903 of Whatman and filter 
paper 226 of Perkin Elmer. The standard printed filter paper cards of What-
man and PerkinElmer contains 5 spots, each of 12mm diameter circles. The 
calculations below are based on a fully covered spot with whole blood. 
A punch of 3.2 mm would give 3.42l of whole blood (76). The quantity of 
red blood cells varies per person (haematocrit level) and this influences the 
amount of plasma in whole blood. To develop a protocol for DBS samples, 
a standard haematocrit level of 55% could be used, but this should be ad-
justed to match the population. When haematocrit levels are 55% , a 3.2mm 
punch would contain 1.47jJl of serum. To translate this to a more commonly 
used punch size in infectious disease research, a centre punch of 6mm would 
roughly give 5.2 -5.7jJl of serum, based on- 80pl spotted whole blood sample. 
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2.5.2 PUNCH AND CONTAMINATION RISKS 
Implementation of DBS specimens in the laboratory requires efforts to 
prevent and identify risks of contamination. The process of punching DBS 
samples could lead to contamination. 
Contamination risk for serological assays is less of a concern than for nucleic 
acid testing. When reviewing the procedures at the nation~l neonatal screen-
ing laboratory in the Netherlands, the Rijks Instituut voor Volksgezondheid 
en Milieu (RIVM), punching devices (DBS punchers) were cleaned weekly 
(personal communication). To exclude contamination, cleaning with bleach 
and alcohol is sufficient to prevent cross contamination of antibodies. Re-
garding the automated punching machines, fluid based cleaning protocols 
are complicated by the limited access to the punch head for cleaning. Clean-
ing the punch device by punching through a clean DBS card twice .appears 
to be the fastest and easiest way to prevent cross- contamination (98), al-
though it would be recommendable to perform more stringent cleaning 
procedures. Based on the current methods available, the automated punch 
devices would be a more appropriate option for serological assays as this 
vastly increases speed and potentially limits human errors. 
2.5.3 SAMPLE ELUTION 
A DBS spot can contain 5.2 - 5.7~l of serum but, as it is in a dry state, it needs to 
be eluted before the serum can be tested. In determining the elution volume, 
the punch size and elution volume is directly correlated with sample input 
volume and concentration necessary for the diagnostic assay. It is essential 
to calculate the correct punch size, elution volume,~ sample concentration 
and sample input volume for valid serological tests. This calculation can be 
done by using the manufacturer's protocol. For example, if 10~l of serum is 
diluted in 1: 100 sample diluent according to the manufacturer's protocol, 
a 6mm punch could be diluted in 100~l of elution buffer to obtain a 1:20 
"plasma" concentration. By adding the DBS eluate in a 1:5 concentration with 
the sample diluent from the kit, it is possible to obtain a roughly comparable 
end concentration for plasma and DBS samples. 
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Once the sample elution volume has been calculated, determining the com-
ponents of the sample elution is a vital step. The elution buffer is vital for 
efficient antibody or antigen e)(traction and reducing non-specific interfer-
ence that results in background noise. The elution of antibody or antigen is 
done by using Phosphate Buffered Saline (PBS) or by specifically developed 
elution buffers (99-101). The addition of antimicrobial buffers and soap 
components such as Tween, , sodium azide, , ~erthiolat~, in fetal calf se-
rum or bovine serum albumin can be useful to minimise background noise, 
increase antibody recovery, and prevent microbial growth (101, 102). Dif-
ferent buffers and extraction protocols have been evaluated and most pro-
tocols showed good extraction performances with little differences between 
protocols (102,103). The elution of antibodies from a punch can be >95% 
for IgG, depending on the storage length and temperature conditions prior 
to elution (86). 
Based on the literature, an overnight elution at 4°( with PBS with 7.4pH and 
0.05% Tween20 is most regularly used for serological assays such as ELI-, 
SA, EIA and agglutination assays. In case of problematic elution efficiency 
or background noise, it would be worthwhile to experiment with different 
elution buffers. I<nuchel et al. investigated the use of a quencher, ,which re-
duced background noise dramatically (104, 105). 
Besides alterations to the elution procedure to suit the requirements of the 
serological assay, the assay procedures can also be adjusted. To improve 
results, it may be useful to use a stronger wash buffer and shorter or longer 
incubation periods if the 00 value is incorrect. In some cases, the cut-off is 
altered to match the 00 values of DBS samples (106t 
When eluting a DBS spot, the spot should be white after the elution period, 
indicating efficient elution. If the spot is red after elution, it may have inap-
propriately released antibodies and antigens and the results are therefore 
not trustworthy (86). To validate DBS samples, 00 values of matching plas-
ma and DBS samples can be compared to estimate t~e recovery of antibod-
ies (86). 
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2.5.4 STORAGE CONDITIONS OF DBS SAMPLES 
Correct storage of DBS samples is essential for valid test results. A DBS 
sample contains dried blood and the general consensus is to prevent 
humidity by using desiccants and ziplock bags. Humidity could lead to 
antibody and nucleic acid reduction due to protein activity (DNAse or RNAse 
proteins) or microbial contamination. Although the effects of humidity 
on nucleic acids and antibodies have not yet been proven in great detail, 
humidity could lead to growth of fungus. When a sample is contaminated 
with microbial growth, the sample cannot be used and should be removed 
to prevent further contamination of other samples (107). Patton et al. found 
that humidity was associated with a loss in sensitivity compared to samples 
stored with desiccants (23). It is recommendable to store samples dry by 
using desiccants and a re-sealable bag. 
Various studies have examined the time DBS sample could be stored. Mei et 
al. found that Toxoplasma IgM recovery of samples stored for two years at 
-20·C was 100% compared to DBS samples at baseline (85). Although only 
one sample was used, HIVantibodies could be detected on a 14 year old 
DBS sample stored at room temperature (108). 
Acceptable storage temperatures of DBS samples depend on the analyte of 
interest as antigen or antibody could have different storage requirements. 
Although it is preferable to freeze samples promptly after collection to min-
imize sample degradation, DBS allow flexibility for collection in field set-
tings. Based on the literature and in the context of sample collection in re-
mote settings, the rule of thumb would be for short term «4 weeks) storage, 
room temperature «30·C) would be acceptable, while storage for long term 
(>4 weeks) samples should be stored at 4·C but preferably at -20·C. Circum-
stances such as excessive heat and sunlight (UV) should be prevented at all 
times to prevent degradation of DNA and other whole blood components 
(76). Although DBS have been stored for over many years in unfavourable 
conditions and showed satisfactory results (108), it is highly recommended 
to follow these guidelines. 
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2.6 CONSIDERATIONS OF USING DBS SAMPLES FOR NUCLEIC 
ACID ASSAYS 
2.6.1 PUNCH SIZE CALCULATION 
A benefit of using DBS samples for nucleic acid detection is that the precise 
punch size is not necessarily relevant, unless it is for a quantitative assay 
such as HIV viral load. While for serological assays punch size and elution 
volumes are essential to be correctly related to the necessary plasma 
concentrations, this is not necessary for most nucleic acid amplification 
assays. Instead, most efforts are made to obtain the highest quantity of DNA 
or RNA from a DBS sample. For serological assays, most punch sizes are 3.2 or 
6mm diameter while for nucleic acid assays, 6 or 12mm are more commonly 
used. Punch size and the associated quantity of blood processed contribute 
to the sensitivity for low copy numbers of DNA or RNA detection (109). 
As PCR assays are becoming more sensitive, smaller sample quantities can 
be used. Because of this, DBS are a suitable sample type. The quantity of 
pathogen DNA or RNA should be high enough to be detectable by PCR when 
the small quantity of blood is eluted from the filter paper. Pathogens such 
as malaria or HIV that can reach up to a million copies of DNA or RNA per mL 
of blood are suitable targets for D~S, while pathogens such as Salmonella 
enteric serovar Typhi with 1 - 10 copies per mL of blood, are not. 
2.6.2 PUNCH AND CONTAMINATION RISKS 
When implementing DBS analysis in the laboratory, risks of contamination 
should be identified and prevented. The process of DBS handling could 
harbour contamination risks when punching samples. By automated 
processing of punching and extracting nucleic acids from DBS, many of these 
contamination risks could potentially be eliminated. A study investigated 
potential contamination risks of using manual handheld punchers (with 
three cleaning methods) and an automated punching method (Wallac 
a~topuncher) (110). Both manual and automated methods showed little to 
no contamination risk when analysing HIV DNA by.PCR (111, 112).ln fact, the 
manual method with no cleaning procedure at all showed no false positive 
results. The automated punching machine in this study made use of lasers to 
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cut the filter paper, and thus is theoretically contamination free. Surprisingly, 
the automated punching device caused minor false positive HIV DNA results 
due to cross-contamination (110). Although contamination risks seem low, 
potential cross-contamination is still possible and precautions need to be 
made. Because automated punching platforms are difficult to clean with 
liquids, it is advisable to use hand punches which can be cleaned easily by 
bleach or nucleic acid degrading liquids such as DNaway. One study found 
that viral DNA could be transferred between samples by a punch, at least 
13 times after a positive sample (113). The best method to clean a single 
hole punch was to use bleach, rinse in water and displace water by 1000/0 
ethanol (113). DBS samples are- commonly stored in individual zip lock bags 
with desiccants to prevent cross-contamination, when used for nucleic acid 
testing. Contamination can occur more rapidly with nucleic acids then with 
serology as the methodologies are more sensitive. 
2.6.3 ELUTION & EXTRACTION 
Various studies have reviewed the use of in-house developed protocols or 
adapted versions of commercially available extraction kits for nucleic acid 
isolation for DBS samples (109, 114, 115). Over the last few years, various 
manufacturers of extraction kits have developed alternative protocols to 
extract DNA or RNA from DBS with existing extraction methods and platforms 
(i.e. BioMerieux, Abbott, Roche, Qiagen). All methods are based on the elution 
of DBS by lysis buffer and the eluate is processed by an extraction method 
that resembles the standard procedures for whole blood or plasma . 
. 
The extraction efficiency of DNA from Whatman 903 filter paper has been 
evaluated. De Vries et ol. compared eight different extraction methods and 
showed that sensitivity for the detection of cytomegalovirus (CMV) detec-
tion varies considerably depending on the extraction method used (114). 
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The extraction methods developed by Barbi et al., Qiaamp DNA investigator 
kit (Qiagen, Hilden, Germany), BioRobot Universal system (Qiagen, Hilden, 
Germany) and MagNA Pure LC (Roche Basel, Switzerland) were the most 
sensitive methods. Another study evaluated the most sensitive method for 
CMV DNA detection, of which the phenol-chloroform extraction and QIAamp 
blood minikit had the highest sensitivity in detecting 200 copies CMV DNA/ 
mL DBS samples (109). Monleau et a1. compared NucliSens extraction plat-
form with Abbott preparation system for Whatman 903 filter paper DBS sam-
ples. The NucliSens extraction method provided HIV viral load results com-
parable to plasma samples, while Abbott platform gave minor but significant 
lower HIV viral loads (116). A study evaluating extraction methods with up to 
27 year-old archived samples obtained the best performance with QIAamp 
DNA kit (BioMerieux) and EZNA Forensic DNA reagent set (Omega Bio-Tek, 
Norcross, USA) for Real-Time PCR analysis (115). 
The extraction of DNA or RNA from FTA Elute and FTA is different to that from 
903 filter paper, due to filter paper characteristics. FTA Elute has an extrac-
tion protocol that only makes use of water by washing the lyses buffer away, 
and DNA is eluted from the filter paper by heating at 95°C and washing out 
by vortexing the sample 60 times. The FTA is in that respect the opposite, 
as DNA remains bound to the filter paper and a small punch of 1mm can be 
inserted into the PCR reaction. FTA and FTA ELute provide adequate DNA 
yields (117, 118). FTA and FTA Elute cannot successfully be used for RNA 
targets (personal communication with Whatman, GE). 
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2.6.4 STORAGE CONDITIONS OF DBS SAMPLES 
When reviewing storage condition of DBS for nucleic acid testing, there 
are mixed messages from the literature. For example, genomic DNA could 
be amplified and sequenced successfully after storage of DBS at 28 GC with 
73% humidity for 10 years (119) while others found a 10-fold reduction of 
HCV RNA after 4 weeks at room temperature (120). Solomone et oL. found 
HCV RNA positivity was preserved after 11 months of storage (121). For 
sequencing, long fragments are needed and success of sequencing seems 
to rely heavily on adequate storage and extraction methods (66). Mitchell 
et oL. found that DBS storage at 37GC and high humidity diminished HIV-1 
DNA load, compared to storage at -20 GC (122). Additionally, HIV RNA seems 
more stable than HCV RNA, as sensitivity dropped for HCV when not stored 
at -20 GC while for HIV it remained at comparable levels (123-125). Although 
Fiscus et oL. found a 5% HIV RNA copy number Loss per day when stored at 
room temperature for 28 days (126). The storage of FTA filter paper at room 
temperature containing HIV DNA was detected at similar rates as the initial 
test, four years ago (127). 
To summarise, the different findings of storage requirements are caused by 
technical and biological differences which complicates interpretation of re-
sults between studies. Differences in sensitivity after storage considerably 
varies due to technical differences in filter paper, humidity control, drying 
and spotting methods, and the extraction and detection methods applied. 
Biological differences also influence storage effects due to the viral or bac-
terialload of the samples, DNA or RNA, and pathogen type (virus, gram neg-
ative / positive bacteria). Standard protocols for long term storage would be 
helpful for the many assays and infectious diseases, but the available data 
at the moment is insufficient. As the literature alone does not provide one 
clear recommended general storage protocol for DBS that is suitable for de-
veloping countries, personal experience was used to develop the transport 
and storage protocol, given below. 
To provide a general guideline for storage recommendations, the recom-
mendations below are based on storage for RNA and DNA samples stored on 
Whatman 903 or Perkin Elmer 226 filter papers, stored with desiccants and 
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adequately dried (>4 hours) before being stored or transported. For nucleic 
acid testing, -200( to -800( is appropriate for long-term storage. Sample 
collection, temporary storage and shipment to the laboratory can usually be 
done at room temperature. Although it is preferable to freeze samples prompt-
ly after collection to minimize sample degradation, DBS allow flexibility for 
collection in field settings. Based on the literature assessed and other guide-
lines reviewed online, samples collected in the field can be stored at room 
temperature «30 0 () and should be sent to the laboratory within 4 weeks. At 
the laboratory, samples should be stored ideally at -200( when processed 
within 4 months. When samples have to be stored for longer, it is recom-
mendable to store samples at -80 0 ( when RNA, sequencing or related tests 
needs to be performed. (ircumstances such as excessive heat and sunlight 
(UV) should be prevented at all times to prevent degradation of nucleic acids 
and other whole blood compounds. WHO Guidelines for HIV drug resistance 
testing are available that closely relate to the one suggested in this thesis. 
It is highly recommended to follow the recommendations made in this the-
sis or the guidelines of the WHO HIVDR for DBS storage (78, 79, 128). When 
samples have been stored at -20°(, it is suggested to ship samples on dry ice 
to prevent unnecessary thawing and freezing cycles. When removing sam-
ples from the freezer, thorough equilibration to room temperature is need-
ed, as well as a replacement of desiccants with new ones (66). 
2.6.5 RECOMMENDATIONS 
Table 2.4 contains, based on the literature review and personal e}(perience, 
recommendations that can be used as a starting point for serological assays 
and NAAT assay testing. These recommendations are a general consensus on 
results obtained by the literature and should be adapted to specific assay 
requirements, pathogens or settings where it will be used. Regarding the 
storage recommendations, these are developed to allow some fle}<ibility in 
sample collection in remote settings. Ideally, samples are stored at -2 00( or 
even at -80 0 ( as soon as possible to prevent any loss of material but these 
recommendations provide, for most infectious diseases, an acceptable 
trade-off between loss of material and improved utility. 
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Table 2.4: Recommendations for DBS testing with serological or NAAT tests 
Recommendations Serology NAAT 
Type of tilter paper FDA approved tilter paper: FDA approved tilter paper: 
Whatman 903 or PerkinElmer Whatman 903 or PerkinElmer 
226 226 
Collection method CDC guideline for serological WHO guidelines for HIV drug 
Storage 
(time till testing 
takes place) 
Punching & 
cleaning 
Elution & 
extraction 
tests on DBS, available online resistance testing are the best 
(129) to use, available online (128) 
<4 weeks - Room Temperature <4 weeks - Rooom Temperature 
<4 months - +4°C <4 months - -200( 
>4 months - -200( or -BOO( >4 months - -BOO( 
Humidity controlled by 
desiccants 
Humidity controlled by 
desiccants 
Automated puncher Manual punch 
Cleaning: punch through clean (leaning: bleach, rinse in 
card 1x after each sample or water, displace by 1000/0 
thoroughly clean after each ethanol after each punch 
plate 
PBS with 0.05% tween20 
eluted overnight at +4°(, 
potentially elute with bovine 
calf serum if result requires 
improvement 
Elute with lyses buffer, at least 
1 hour, preferably extracted 
with automated platforms as 
BioMerieux Nuclisens. 
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2.7 REVIEW OF THE USE OF FILTER PAPER FOR INFECTIOUS 
DISEASES 
2.Z1 RESULTS 
Of the 4,011 articles retrieved (Annex 10.2.2), 3,524 were irrelevant to the 
study question, 92 did not evaluate filter paper and 98 were conference or 
meeting summaries and were excluded. Of 296 articles identified for further 
assessment the following were excluded ,- 60 that did not evaluate DBS, 7 
that used tests no longer commercially available, 34 using in-house assays, 
15 that did not use diagnostic assays, 31 were no suitable 'gold standard' 
comparator was used, 16 in non-peer-reviewed journals and 26 using non-
human pathogens or non-whole blood samples. Detailed assessment of the 
DBS techniques of the resulting 104 articles was performed. The same 296 
papers were also assessed for review of the practical aspects of filter paper 
use, for non-whole blood sampl-es and for veterinary health; 192 articles 
were examined for this purpose after 65 were excLuded as irrelevant to the 
study question, 23 that had no suitable 'gold standard' reference and 16 
that were not peer-reviewed. 
2.7.1.1 HIV 1 & 2 and HTLV 1 
Efforts to make HIV testing more accessible in rural areas in developing . 
countries, where >900/0 of new HIV infections occur, is critical for controlling 
the disease. DBS have the potential to provide a simple, robust and affordable 
option for collection of whole blood, screening, quality control of point 
of care tests, HIV viral load measurements and drug resistance testing in 
environments where traditional venous blood collection/transport cannot 
be performed (66, 130). Twenty-four studies e>(amined the use of DBS, for 
the detection of HIV, compared with serum or plasma; twelve evaluated 
serological assays and 12 nucleic acid amplification tests (NAATs) ( Annex 
10.2.3). 
60 
Chaptet' 2 - DBS literature review 
Table 2.5: Summary of studies evaluating serological and NAAT diagnosis of HIV, 
comparing DBS with whole blood (DNA) and serum/plasma (RNA). 
HIV-l No. of 
Assa~ t~~e detection studies Sensitivit~ % S~ecificit~ % References 
Serology Ab / Ag 7 100 98.7-100 (131-137) 
Serology Ag (p24) 5 84-98.8 98-100 (138-142) 
Serology Western blot 1 92 100 (137) 
NAAT DNA 6 · 97-100 99.6 -100 (130, 143-147) 
NAAT RNA 6 99.2-100 95.6-100 (143, 148-152) 
NAAT DNA E:t RNA 3 99.7-100 100 (144,147,153) 
Serological assays using DBS samples were evaluated in 13 diverse countries, 
thereby probably representing all HIV-l subtypes using third generation 
enzyme-linked immunosorbent assays (ELISA) that detect antibodies, 4th 
generation ELISA tests that detect antibodies and antigens, and specific 
antigen tests (p24). The p24 antigen tests are used as an alternative to NAATs 
to detect infection in infants. Only one study examined detection of HIV-2 
using DBS against sera, reporti!1g sensitivity and ,specificity of 87.5% and 
100%, respectively (131). 
DBS have been, evaluated for the detection of HIV-l with diverse NAATs in 
11 countries. Although HIV is an RNA virus, proviral HIV-l DNA detection is 
commonly used for infant diagnosis. Six studies evaluated the Roche Am-
plicor and Roche Cobas Taqman assays on DBS samples, giving sensitivities. 
and specificities between 97-100% and 99.6-100%, respectively. DBS HIV-
1 RNA and p24 antigen assays are increasingly used (154). 
Most HIV viral load assays use quantitative Reverse Transcriptase PCR that 
requires large quantities of plasma (100-600~l) to transcribe RNA into DNA 
before amplification. Besides extracellular HIV-~ RNA amplified from plasma 
samples, DBS contain whole blood and therefore intracellular HIV-l RNA and 
HIV-l proviral DNA. As a result, when HIV-l viral load assays are used with 
DBS, both HIV-l RNA and HIV-1DNA will be amplified, making it potentially 
more sensitive than HIV-l DNA assays. This has potential implications for ear-
ly detection of HIV but also for potential overestimation of viral load. 
Three studies evaluated the Roche and Abbott NAATs to detect HIV-l RNA 
and DNA in DBS against whole blood. 'fhe BioMerieux HIV-l RNA assays 
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cannot amplify HIV-l DNA. False positive results by quantitative NAATs is 
a concern when used for qualitative purposes, but these assays remain a 
promising alternative for infant diagnosis (130, iSO, 155). Indeed, the WHO 
recommends testing infants for HIV DNA, HIV RNA, or the ultrasensitive p24 . 
antigen on plasma or on DBS samples, given that the sensitivity and speci-
ficity are >98% (154). 
Two papers examined the possibility of detecting HTLV-l serologically or by 
in-house NAATs, but with relatively small sample sizes. Both showed good 
performance compared to plasma samples (156,157). 
2.7.1.2 HEPATITIS VIRUSES 
Seven studies evaluated the use of DBS for the diagnosis of hepatitis viruses .. 
(Annex 10.2.4). Three studies evaluated DBS Hepatitis C (HCV) serology 
against serum and plasma, finding high sensitivity and specificity >98% 
(103, 158, 159). Only two studies have examined the use of DBS samples 
for Hepatitis B (HBV) serology, yielding different performances for the three 
serological HBVassaytypes (160,161). The potential to include HCV and HBV 
in HIV serology-based epidemiological studies makes testing for multiple 
viruses from one sample possible, and a cost-effective way to expand 
surveillance services. For most serological assays, a cut-off determines 
the positive or negative outcome of a test and can be adjusted if aimed for 
screening, confirmation or for surveillance. Adjusting the cut-off specifically 
for DBS samples could improve sensitivity and/or specificity, depending on 
the required balance between them (162). 
The detection of HCV and Hepatitis E virus (HEV) by NAATs appear prom-
ising but more evaluations are needed before conclusions can be drawn. 
Tuaillon et of. found that HCV RNA is susceptible to degradation when sam-
ples are stored at ambient temperatures (+20°C),. while Solmone et of. found 
that 100% positivity was maintained when samples were stored at 'room' 
temperature over a period of 11 months (159, 163). More evaluation of the 
optimal storage DBS conditions for HCV NAAT is"required. Annex 10.2.4 sum-
marizes all included studies. 
62 
Chapter- 2 -- DBS literc3ture rr::\!i(~\'V 
2.7.1.3 FLAVIVIRUSES 
The WHO estimates that dengue affects> 50 million people each year, often 
in explosive outbreaks. Capture or sandwich ELiSAs are used to serologically 
diagnose acute dengue (lgM, IgG antibodies and NS1 antigen) and estimate 
seroprevalence. Four studies comparing dengue ELISA using DBS and serum 
reported high sensitivities (>86%) and specificities (>89%) (164-167) (Table 
2.6). One study reported poor correlation of DBS witt) serum results (166), but 
results were not analysed wlth the appropriate statistical technique (168). 
Antibody titres determined from DBS were more variable and lower than those 
from sera, suggesting a limited role in the diagnostic confirmation of acute 
dengue. All studies concluded that DBS IgG determination could be used 
successfully for seroprevalence studies. Storage conditions of one month at 
'room' temperature, appeared to have no detrimental impact on results (167). 
Dengue nucleic acid detection from DBS was also highly sensitive (>90.7%) 
in comparison to serum. The 100% specificity reported by Prado et al. may re-
flect the nature of the samples, which were prepared by spiking whole blood 
with dengue virus (165, 169). Consistent with the period of highest viraemia, 
sensitivity was highest on day one after onset of fever falling rapidly by day 
four. Matheus et al. found that dengue RNA could still be detected in dried 
capillary blood samples from a small number of patients 12 days following in-
fection, whereas corresponding venous samples were negative (165). Indeed, 
capillary viraemia may be more prolonged than venous (170), suggesting that 
it would be important, in evaluation of dengue NS1 assays and NAATs, that 
both DBS and blood samples are compared using capillary blood. Dengue 
RNA was found to be stable at 37°C for a year (169). It is important to note 
that the virus remains viable and confers an infective risk on untreated paper 
during the first 48 hours after spotting on to untreated paper (169). 
In a seroprevalence study of chikungunya virus, IgG was successfully de-
tected on filter paper with 97.9% sensitivity in comparison to serum (171). 
Though IgM was not fully evaluated on DBS, it appeared to give similar re-
sults to those from sera (171). 
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Table 2.6: Summary of studies evaluating DBS for Flavivirus diagnosis 
Number of 
Disease, assay type samples & filter 
& country Author paper type Test Sensitivity % Specificity % 
Dengu~~erology BaLmaseda et al. 169 sampLes In house ELISA IgM, 96 IgM 89 IgM 
(2008){164) Whatman No.3 IgG & IgA(171) 93 IgA 89 IgA 
Nicaragua( 164) 86 IgG 92 IgG 
French Guiana Matheus et al. 130 sampLes In house ELISA 89 94 
(2007)(165) Whatman paper IgM(173) 
" -Cuba Herrera et al. 189 sampLes In house uLtramicro 92.1 98.6 
(2006)(167) Whatman 2992 ELlSA(174) 
Vietnam Tran -et al. (2006) 781 sampLes Dengue Fever IgM NR NR 
(166) Whatman 903 & IgG ELISA (Focus 
Diagnostics, USA) 
Notes 
Detecting IgM or IgA is useful 
for acute dengue diagnosis. IgG 
is optimaL for dengue incidence 
surveiLLance. Danger of cross-
reactivity of IgG with other 
Flaviviruses( 164) 
IgM stabLe at room temperature 
for 1 month and at 4°( for> 2 
months. 
DBS correlated poorly with serum, 
particularLy for acute dengue 
infection. However, correLation 
inappropriate analysis( 168). 
Limited role in diagnostic 
confirmation of dengue cases. IgG 
useful for seroprevaLence studies. 
No effect of 1 month storage on 
results. 
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Number of 
Disease, assay type samples & filter 
& country Author paper type Test Sensitivity % Specificity % 
Dengue Matheus et al. 130 sampLes In house PCR(175) 90.7 82.9 
NAAT (2007)(165) Whatman paper 
French Guiana(165) 
Cuba 
:Chik~ngunya 
Serology 
La Reunion ' 
-~~~ 
Japanese 8 
encephalitis 
Serology 
Thailand 
Prado et al. 
(2005)(169) 
Grivard et al. 
(2007)( 171) 
Burke et al. 
(1985)(176) 
52 samples In house PCR(175) 93 
Nobuto paper 
144 sampLes IgG ELISA NationaL 97.9 
Whatman 903 Arbovirus Reference 
Laboratory, Lyon, 
France 
243 samples In house ELISA 72 
Nobuto paper In house Haem- 38 
agglutination during 
inhibition assay epidemic 
100 
100 
NR 
Notes 
Serotyping aLso performed. 
Sensitivity and specificity highest, 
during the 1st 4 days of infection, 
falling rapidLy thereafter. 
Samples prepared with blood 
spiked with dengue virus. Lower 
limit of detection for dengue 2 
than 3. RNA stable at 37°C for 
1 year. Risk of viral infectivity 
from paper for 48hrs at room 
temperature. 
SeroprevaLence study. 
IgM aLso detected with similar 
opticaL density threshoLds as 
sera, but no independent quality 
control performed. 
ELISA and haemagglutination 
inhibition tests were compared 
with serum. ELISA was more 
sensitive during epidemic 
periods. Newer, commercially 
availabLe assays are available but 
have so far not been evaluated on 
DBS. 
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2.7.1.4 OTHER VIRUSES 
Three studies evaluated measles antibody (lgM or IgG) detection using DBS 
samples. Uzicanin et al. demonstrated that the sensitivity of DBS samples, in 
comparison to serum, increased for IgM from 95.7% for samples collected 
from day 1-6, to 100% when samples were collected one week after the 
appearance of the rash(177). This illustrates for serological assays, the 
importance of the time of sample collection after the onset of the disease 
to obtain adequate sensitivities and that'this varies between pathogens. For 
measles antibody tests, DBS can be stored for up to 6 months at 4°C. However, 
beyond 6 months sensitivities fell, suggesting that long-term storage at 4°C 
affects measles antibody stability(178). 
We found only one study evaluating the use of DBS for Epstein-Barr virus ... 
(EBV) serology. Interestingly, this study compared venous and capillary 
blood spotted on two different filter paper types (Whatman 903 and No.3) 
for ELISA (EBNAl plus VCA-p18) and found a high~r sensitivity with 903 pa-
per (179). For the detection of CMV, a serological assay and a NAAT test were 
evaluated between plasma and DBS. The NAAT was 100% sensitive and spe-
cific while the serological assay had lower sensitivity and specificity, but 
both were >93% (106,180). Annex 10.2.5 summarizes all included studies. 
2.7.1.5 MALARIA 
For the detection and speciation of malaria, no commercially available 
DBS assays evalautions have been published in peer-reviewed journals. 
Two studies compared PCR on DBS against whole blood and found a lower 
sensitivity, particularly for samples with low parasitaemia (181, 182) (Table 
2.7). DBS PCR compared to microscopy, achieves comparable performance 
or, in some studies, is more sensitive (9). It appears that DBS is more specific 
than whole blood samples when used for PCR analysis using the less sensitive 
microscopy as the reference method (182, 183). 
The nested PCR assay developed by Snounou et aLin 1993(184) is commonly 
used as the reference method for malaria PCR. Based 'on the eight papers 
included in this review, malaria detection by P~R on DBS appears to be a 
suitable alternative to microscopy and are frequently used in surveillance 
studies(185). DBS are also commonly used for detection of malaria resist-
ance molecular markers (186). 
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Table 2.1: Summary of studies evaluating DBS for malaria 
Sample 
size & filter Un- Sensitivity Specificity Reference 
Countr~ Author ~a~er assa~ Pf Po Pv Pm known % % test Notes 
Thailand Long etal. 56 samples In-house ./ 94.6 NR Thin/thick 
(1995)(187) Whatman (188) bLood smear 
903 
MaLaysia Singh et al. 166 samples In-house ./ ./ 97.4 NR Thick blood 
(1996)(189) Whatman (184) smear 
3MM (adjusted) 
MaLaysia Singh et al. 129 sampLes In-house ./ ./ ./ ./ NR NR Limit of detection: 
(1999)(190) Whatman 6 parasites per lJL 
3MM 
----~----. -~---- -----
Singapbre Tham et al. 52 samples In-house ./ ./ 100 100 Thin/thick Limit of detection: 
(1999)(191) Whatman (192) bLood smear 4 parasites per lJl 
NO.1 n 
-:::s 
MaLaysia, MangoLd et 81 sampLes In-house ./ ./* ./ 94.1 (Pf) 100 (Pf) Thin/thick *1 out of 1 Po QJ -0 
.--t" 
Myanmar, al. (2005) . Isocode . 100 (Pv) 99.1 (Pv) bLood smear sampLes detected ' (l) 
Thailand (193) cards N 
--------"'----------""-.----~~-.-
ThaHand Boonma et al. 136 samples Multiplex ./ ./ ' 100 (Pf) 100 (Pf) 100 Consensus of Specificity of all 
(2007)(183) Whatman PCR(194) 92.7 (Pv) (Pv) 3 PCR assays 3 assays lower 0 OJ 
3MM (93.8-97%) when (J) 
Nested ./ ./ 100 (Pf) 99 (Pf) . compared to r-+ (l) 
PCR(195) 100 (Pv) 100(Pv) microscopy. OJ r-+ C 
--. 
(l) 
RT- ./ ./ 100 (pf) 100 100 (pf) 100 "' (l)
< 
0\ PCR(196) (pv) (pv) (l) 
-.....J ~ 
(J\ 
00 
Sample 
size & filter 
Country Author paper assay 
Saudi AL-Harthi et 118 sampLes In-house 
Arabia aL. (2008) Whatman (197) 
(181) 
ThaHand Yamamura 156 samples In-house 
Zimbabwe et al. (2009) FTA card 
(198) 
Iran Ataei et aL. 75 sampLes In-house 
(2011)(182) DNA (199) 
Banking 
Card 
Kenya Wangal et .al. 356 samples In-house 
(2011)(9) Whatman 
3MM 
Un- Sensitivity 
Pf Po Pv Pm known % 
./ 73 
./ 97.8 
./ ./ 97 
./ 100 
N~= Not reporting Pf= Plasmodium falciparum, Pv= P. vivax, Po= P. ovale, Pm= P. malaria 
Specificity Reference 
% test Notes 
NR Thin/thick SeveraL microscopy 
negatlve sampLes 
positive on DBS 
PCR. 
100 
100 
79 
bLood smear 
Thln/Thick Llmlt of detectlon: 
blood smear 10 coples/ reactlon 
Thin/thick WhoLe blood 
blood smear more sensitlve but 
Less spedfic than 
DBS compared to 
microscopy (100% 
sensitivity, 95.2% 
spedfidty) 
Thln/Thick Low speclficlty 
blood ~mear potentlally caused 
by lnsufficlent 
microscopy 
expertlse 
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2.7.1.6 NON-MALARIAL PARASITES 
Parasites account for many neglected tropical diseases afflicting hundreds of 
millions of people worldwide, predominantly in resource-poor regions with 
limited access to diagnostic facilities are affected by parasites (200). The use 
of filter paper to aid with diagnosis and understanding the epidemiology of 
these diseases is thus very attractive. The mapping of lymphatic filariasis and 
monitoring of elimination programs provide an ideal role for DBS. Three recent 
studies evaluated serological tests for the Og4C3 antigen to W bancrofti on 
DBS, compared to serum, giving sensitivities of >93% and specificities of 82-
100% (201-203) (Table 2.8). The earliest study performed, by Gyapong et al. 
in Ghana, reported a lower sensitivity (50%) (204), possibly due to difference 
in strain type (most other studies were performed in Asia) or technical factors 
that have since improved. The CELISA (w. bancrofti and Brugia spp.) and Brugia .. 
Rapid (Brugia spp.) tests performed on DBS eluate and compared with serum or 
plasma proved reasonably sensitive (71-980/0) (99, 205). Cross-reactivity with 
other common parasitic infections, including Onchocerciasis, Strongyloides, 
Ascaris and Dirofilaria species are important (99,205). Nucleic acid testing was 
evaluated for Brugian filariasis and Loa loa and appears sensitive, particularly 
for the latter at 96% (206-208). African and American trypanosomiases have 
both been successfully detected on DBS with high sensitivity and specificity 
by serology (209-212). A recent evaluation using a commercially available 
test for T. cruzi was, however, performed for relatively few patients (211).' 
Strict control of humidity by storing DBS in sealed plastic bags with silica gel 
immediately after drying may have been a key factor resulting in the higher 
sensitivity reported by Chappuis et al. compared to Truc et al. (209,210). 
PCR testing on DBS for visceral leishmaniasis (L. infantum) in immunocom-
promised patients before therapy was evaluated against bone marrow mi-
croscopy in a small series of patients, yielding a sensitivity of 75% (213). 
PCR on DBS was significantly more sensitive than microscopy and culture of 
peripheral blood. The authors suggest a possibl,e role for PCR 'as an initial 
screening test using DBS, potentially avoiding the more invasive bone mar-
row aspiration. Seroprevalence studies for echinococcosis, fascioliasis, and 
toxoplasmosis performed well on DBS. Detection of exposure to giardiasis 
suffered from lower specificity, possibly reflecting cross-reactivity or long-
. 
term persistence of antibodies (214, 215). 
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Table 2.8: Summary of studies evaluating DBS for parasites other than malaria. 
Number of 
Disease, samples & filter Sensitivity ·Specificity 
assa~ t~~e {t c6untr~ Author ~a~ert~~e Test % % Notes 
Lymphatic Filariasis: Santhanam 94 samples In-house EIA(217) 92 77 
Wucheraria bancrofti et al. (1989) Whatman 903 
(Wb) (216) 
Brugi€l malayi & 
timori (Bspp)Serology 
India(216) 
-- ---~------
Ghana Gyapong et 1808 samples Og4C3 ELISA (Wb) 50.3 96.4 
al. (1992) Og4C3 paper (Tropical Biotech) 
(204) 
-
Sri Lanka Itoh et al. 60 sampLes Og4C3 ELISA (Wb) 97 NR 
( 1998){201) Nobotu 1 (Tropical Biotech) 
I n 
India Hoti et al. 30 samples Og4C3 ELISA (Wb) 76.6-93.3 Time of the day at which samples ::r-100 ClJ 
"D (2002)(202) Whatman nO.3 (Tropical Biotech) are collected impacts sensitivity .-+ ro 
(Hoti et al.) -, N 
---
India, Egypt, Haiti Wattal et al. 188 samples Og4C3 ELISA (Wb) NR NR 
Kenya, Papua New (2007)(203) Whatman nO.3 (TropicaL Biotech) 0 
CP 
Guinea, Sri Lanka If) 
Egypt Well et al. 81 samples Fllariasis (Wb tt B.spp) 91 (Wb) NR Well et al. based on a panel of .-+ ro 
(2011)(99) CELISA (CeUabs) 98 (B. spp) known positives. -, TropBio paper NR OJ 
.-+ 
C 
Brugia Rapid (Malaysian Significant cross-reactivity with I 
-, 
Uganda Fischer et al. 66 samples 79 NR ro , 
(200S){20S) Whatman 3MM BioDiagnostics Research) other filarial infections{99, 205) ro < 
" 
L ro 
0 
---.-___ --"" _~. __ ~. __ L- __ ."-- _.__ "'."--___ -"" . ___ ., 
~ 
-.....J 
~ 
Number of 
Disease, samples & filter 
assay type & country Author paper type 
Lymphatic Filariasis I(Luber et aL. 36 sampLes 
Brugia malayi (2001)(206) Whatman 3MM 
NAAT 
I ndonesia(206) 
MaLaysia 
Loa loa 
NAAT 
Cameroon" 
HAT 
Serology 
(Card Agglutination 
Test) 
Sudan(209) 
CentraL African 
Republic 
Ivory Coast 
Rahmah et aL. 21sampLes 
(2010)(207) Whatman 3MM 
Fink et aL. 68 sampLes 
(2011)(208) NR 
Chappuis et 100 samples 
ale (2002) NR 
(209) 
. Truc et aL. 940 samples 
(2002)(210) Whatman No.4 
Test 
In-house 
PCR(218,219) 
In-house 
PCR(218,219) 
In-house 
PCR(208) 
Sensitivity Specificity 
% % Notes 
86 NR 
NR 
96 
NR 
NR No cross-reactivity with other 
fiLariaL species. Limit of detection 
1 microfiLaria per 20uL DBS. 
Micro-CAn (lTM Antwerp) 91 NR 
NR 89.4-95.5 95.5-96.6 Truc et aL. report rapid drop in 
sensitivity (67.8%) after 3 days 
. without strict humidity controL of 
paper. 
Ranges reported by Truc et aL. 
reflect testing at 2 different sites. 
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Number of 
Disease, samples & filter Sensitivity Specificity 
assa!l t!l~e & countr!l Author ~a~ert!l~e Test % % Notes 
Chagas disease Luquetti et al. 24 samples Chagas Stat-Pak (ICT) 100 100 Chagas Stat-Pak performed on 
Serology ~rf (2003)(211) NR (chembio Diagnostic ELISA 78.1 ELISA 99.7 small sample size (24). More 
Brazil(211) systems) sensitive and specific than large-
Zicker et al. scale evaluation with serum. 
Brazil (1990)(212) 6222 samples In-house ELISA, IF & IF 69.2 IF 99.4 
Whatman NO.1 HA(220, 221) HA 64.6 HA 99.6 
Echinococ~osis Coltorti et al. 479 samples In-house ELISA NR NR Coltorti reports sensitivity of 
Serology (1988)(222) Whatman NO.1 DBS similar to that of serum. 
Argentina(222) 
------ ---~ --- ------- .~-
China Bartholomot 2482 samples In-house ELISA 96 87 
et al. (2002) Whatman NO.1 
(223) n 
-. --- --'.--.--"-.~-.~-- -- -- ---~-\~ - - ---- :::Y ------ ---- ..... --------- OJ 
Uruguay Cohen et al. 1149 samples In-house ELISA ) NR NR D 
I ,...... ( 1998)(224) Whatman NO.1 ro 
"""""' 
t'V 
Visceral Leishmaniasis Campino et 24 samples In-house PCR 71-75 NR 15/20 positive for patients not 
NAAT al. (2000) Whatman NO.2 on treatment and 17/24 if those 0 
(213) on treatment included. Useful as OJ IJ) 
Portugal 
--~-.-- ~ .... - "" 
____ ..=i-- __ 
an initial screening tool. r-T 
Fascioliasis Strauss et al. 68 samples In-house ELlS'A NR NR Samples stored for 10 years at ro 
OJ 
Serology (1999)(225) Whatman NO.1 4°C were successfully detected. r-T c 
Bolivia ~ 
ro 
< 
-......J 11) 
N ~ 
Number of 
Disease, samples &- filter Sensitivity Specificity 
assa~ t~~e & countr~ Author ~a~ert~~e Test % % Notes 
Giardiasis Guimaraes 133 samples In-house IF 82 70 Guimaraes high rate of false 
Serology (lgG) Q; et al. (2002) Whatman NO.1 positives with ELISA. 
BrazH(214) (214) 
'-r-- ---~. Saudl Arabla Al-Tukhl et al. 147 samples In-house ELISA 72796 39-98 Al-Tukhl et al. results ranges 
(1993 )(215) Whatman No.4 depended on ELISA Opt1cal 
Denslty readlng and final eluate 
dHutlon. 
Cysticercosis Peralta et al. 151 samples Qual1code Cyst1cercosis 80 NR Good agreement between serum 
Serology (2001)(226) Whatman No.4 ELISA kit and DBS. May be useful initial 
(Immunet1cs inc.) screening test. 
BrazH(226) All forms or neurocyst1cercosis 
stored for 1 week before n 
freezing. Ranges due to samples :::J OJ 
processed at 2 sites using 2 -0 ,-+ 
(() 
methods. ~ 
--"- .---~-"--- N 
Mex1cO Fleury et al 305 samples In-house ELlSA(228, 229) 39-66 87-96 
(2001)(227) Whatman No. 311 0 
OJ 
l/) 
Toxoplasmosis Parker et al. 273 samples Eiken Toxoreagent Latex 98.8 100 
,--
r-+ 
I ({) 
Serology (latex ( 1992}(230) Whatman 903 Agglutination I , OJ 
agglutination) I r-+ c 
I 
, 
UI«230) ({) 
---------------...--------
~--.-
----
__ ~~_____ _ _____ _" __ "~_"J , 
USA Stevens etal. 1098 samples In-house ELISA 96 94 ({) < 
"-J (1992)(231) Whatman 903 ({) 
LN ~ 
2.7.1.7 BACTERIA 
There have been suprisingly few studies evaluating the use of filter paper to 
diagnose or determine the seroprevalence of bacterial pathogens compared 
with viruses and parasites (Table 2.9). 
The success of using DBS to screen. for leprosy appears to be dependent 
on the bacillary burden, with multi bacillary patients more readily identified 
(232-234). The commercially available Serodia Leprae particle agglutination 
test (Fujirebio, Japan) using DBS had 97.5% ~oncordance with serum for 
patients of any bacillary burden type (235). Interestingly, the sensitivity of 
capillary DBS taken from the earlobe was slightly but significantly higher 
when compared to venous DBS and serum, possibly reflecting the higher 
density of organisms in this tissue (232). 
Brucella antibodies were eluted from filter paper with difficulty and correla-
tion coefficients with serum were modest, suggesting only a possible role in 
screening for cases(236). However, correlation coefficients are not valid sta-
tistical tests for comparison of diagnostic methods (bland ref~rence). Other 
bacterial pathogens performed well on DBS and could be stored successful-
ly for sufficient periods of time to allow transport to a laboratory for analysis 
(237-239) . 
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Table 2.9: Summary of studies evaluating DBS with serological assays for bacteria 
Number of 
Disease, assay . samples & filter 
type & country. Author paper type Test Sensitivity % Specificity % 
Leprosy :-autUn et al. {1997} 200 samples In-house NR NR 
Serology {232} NR ELlSA{240} 
Nepal{232} 
French 
Polynesia 
Chanteau et al. 
(1989)(233) 
Dhandayuthapani 
168 samples 
Whatman NO.1 
94 samples 
et al. {1989}{234} Whatman No.3 
In-house ELISA 
In-house ELISA 
Multibacillary 96 Multibacillary 96 
Paucibacillary 29 Paucibacillary 96 
NR NR 
India Sekar et al. (1992) 81 samples MLPA (Fujirebio, 67.7 (MLPA) 98.7 (MLPA) 
Orientid 
tsutsugamushi 
and Rickettsia 
typhi (Scrub & 
Murine typhus) 
Serology 
Laos{237} 
France 
(235) Whatman NO.3 
Phetsouvanh et al. 53 scrub samples 
(2009)(237} 
Fenollar et al. 
(1999)(238) 
53 murine samples 
Whatman 903 
94 samples 
Fischer Scientific 
paper(238) 
Japan) 
In-house ELISA 
In-house ELISA 
In-house 
ELlSA(241) 
76.9 (ELISA) 83.4 (ELISA) 
NR NR 
951gM 881gM 
90lgG 100lgG 
911gM 100lgM 
821gG 100lgG 
100 100 
Notes 
Earlobe capillary blood 
more sensitive than serum 
or fingerprick blood.{232} 
Lower antibody titres 
with DBS. Storage at room 
temperature for 1 month 
did not affect antibody 
titres.{237,238} 
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Disease, assay samples· & filter 
type & country. Author paper type __ Test Sensitivity % Specificity % 
Leptospirosis Desvars et aL. 52 samples MAT -Microscopic 100 100 
iSeroLogy (MAT): _ -, 2011)(242) Whatman 903 Agglutination 
La Reunion Test 
Syphilis " Coates et al. (1998) 1037 samples Serodia TPPA 98.3 100 
Serology (243) Whatman 903 (Fujirebio) 
Tanzania 
Endemic syphilis Backhouse et aL. 
(Yaws) Serology (1992)(239) 
Papua New Guinea 
BruceLLa Takkouche et al. 
Serology (1995)(236) 
Spain 
70 samples 
Whatman 903 
160 samples 
Whatman 2992 
TPHA - Serodia 96.5 
TP kit (Fujirebio) 
Brucella ELISA N R 
(Virotech System 
Diagnostika) 
100 
NR 
Notes 
DBS samples showed 
lower antibody titres 
compared with serum. 
Results unaffected by up 
to 2 months storage. 
Pearson correlation 
coeffic1ent: r = 0.8 for IgM 
and IgG. Time consuming 
extraction method. n 
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2.7.1.8 Use of fiLter paper for sampLes other than whoLe bLood 
Filter paper has been used to store almost any clinical specimen for 
subsequent analysis. Whole blood is the most practical sa~ple to collect 
on paper, however many reference assays use other samples types (e.g. 
serum or plasma) and some diseases are preferably diagnosed using other 
specimen types. Here we provide an overview of these specimen types. For 
full details see Annex 10.2.6. 
Evaluation of dried serum spots to detect Hepatitis A antibodies showed a 
sensitivity and specificity of 100% compared to liquid serum (244) and HIV 
ELISA a sensitivity of 83% (245). NAATs perform very well with Hepatitis A 
(92.3% and 100%) and HCV (100% and 100%) sensitivity and specificity 
respectively (244, 246). Both hepatitis viruses showed a 10-fold fall in viral 
load after storage for 4 weeks on filter paper at room temperature (244, 
246). 
Three studies used dried plasma and one, dried breast milk, compared to liq-
uid plasma for HIV quantitative PCR (247-249). HIV RNA on filter paper was 
stable' at room temperature for> 1 year. Buffy coat may be used as a substrate 
to detect HIV proviral DNA. When dried buffy coat spots were compared with 
liquid samples, there was 100% concordance between results (250). 
Although bone marrow is a difficult sample type to obtain, it is the most sen-
sitive substrate for diagnosis of visceral leishmaniasis. In one small study, 
34 out of 35 patients with diagnosis based on clinical presentation, was 
detected by NAAT on dried bone marrow spots. This was more sensitive than 
microscopy (251). 
Cutaneous and mucocutaneous samples may be scraped, aspirated or di-
rectly impressed onto filter paper-to diagnose leishmaniasis and, using slit 
skin smears, leprosy. The sensitivity cutaneous impressed filter paper for 
leishmaniasls ranged from 92.3-100% and specificity 100% compared to 
PCR on tissue samples (252, 253) and parasite speciation was possible. M. 
-
leprae was detected by peR from dried slit skin smear spots (60%) in pa-
tients with known leprosy as frequently as the standard technique of skin 
slit smear storage in 70% ethanol (58%) (254). 
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Sputum and saliva have been more widely examined. HIV PCR on saliva had a 
low sensitivity when tested on viraemic patients with known HIV (255). Only 
67% of serologically positive measles patients were positive by PCR on dried 
saliva spots, which was inferior to whole saliva and throat swab (256). De-
tection of malaria DNA in dried saliva (and dried urine) spots were less sen-
sitive than blood microscopy (257). Dried induced sputum spots and dried 
bronchoalveolar lavage fluid spots to identify Pneumocystis carin;; by PCR was 
reported with sensitivity of 67% and 90-91% , respectively compared to mi-
croscopic examination of these samples (258). 
Dried cervical fluid spots were evaluated for Human Papilloma Virus by PCR. 
Concordance of 94-100% was reported in two of three studies compared 
with PCR directly on smear or cytobrush samples (259-261). 
Cerebrospinal fluid (CSF) in children with meningitis was dried onto filter pa-
per (dried CSF spots) and assayed by PCR for Streptococcus pneumoniae and 
Haemophilus injluenzae with a sensitivity of 92% and 70% and specificity 
of 99% and 100% , respectively, compared with direct CSF PCR (262). The 
detection of neurocysticercosis IgM antibodies was less successful, ranging 
from 52-63% , in comparison to CSF, depending on the type of filter paper 
used to store CSF (227). 
Both stool and urine have been stored on paper. Vibrio choleraethe organism 
could be cultured from dried stool spots after 14 days if humid conditions 
were maintained (263) and was equivalent to standard transport medium. 
Viral enteric pathogens including Norovirus, Rotavirus and Adenovirus sero-
types 40 and 41 were detected by NAAT from dried stool spots. There was 
good concordance with EIA performed directly on stool (264-266). Pre-treat-
ing the paper with SDS/EDTA inactivated the virus, allowing safe handling of 
the paper. CMV is readily detected in urine in viraemic patients. Dried urine 
spots were reported to have 90% concordance with PCR on DNA extracted 
."" 
directly from urin.e(267). 
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2.7.1.9 Use of fiLter paper in veterinary heaLth 
Filter paper has been widely used in veterinary health, both in livestock 
and wildlife diseases as a specimen substrate. Several zoqnotic diseases 
discussed above, including echinococcosis, brucella and trypanosomiasis 
(268) are also important causes of mortality in animals. However, non-
zoonotic diseases are responsible for about half of livestock losses worldwide 
(268). Poultry, swine and cattle suffer the greatest burden of disease, with 
viruses and parasites the major causes of these often-fatal infections. 
Severe commercial losses occur in livestock industry and global surveillance 
and diagnosis is necessary to collect information on ecology and install ear-
ly warning systems to detect highly pathogenic strains such as Avian Influ-
enza virus (AIV). The difficulties of traditional sample collection methods, 
discussed above for humans, are equally applicable in the veterinary setting. 
Filter paper has played a key role in circumventing many of these challenges 
for veterinary medicine. Smith et al. discuss the problems likely to be faced 
with the use of (FTA) filter paper with veterinary samples (269). 
Porcine reproductive and respiratory syndrome viruses (154), Newcastle 
disease, AIV and Theileria species (270,271) have been successfully identi-
fied from blood DBS. Samples other than blood are perhaps more frequently 
encountered in animal, than human, disease diagnosis. Examples include 
cloacal swabs adsorbed onto paper to detect AIV (272), bursal fluid to iden-
tify infectious bursal disease virus of poultry (273), tongue epithelial sam-
ples from cattle for foot and mouth disease virus (274) and canid brain tis-
sue to identify rabies (275). These methods are also applicable to wildlife 
as demonstrated by Curry et al. who identified Brucella antibodies in dried 
caribou blood with high sensitivity and specificity (276). Leishmaniasis is an 
important zoonosis with reservoirs in canids. However serological studies 
amongst dogs using filter paper compared with serum have given relatively 
poor sensiti~ity of 22.2% or an agreement of 68.8 % (k = 0.234) (277,278) 
FTA paper carries the advantage of inactivating highly pathogenic organisms 
to allow safe transportation with reported complete inactivation of highly 
pathogenic AIV one hour after following adsorption onto FTA paper (279). 
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Human and animal health are inextricably linked but there has been very 
little, if any, collaboration between scientists and health workers interest-
ed in human and non-human health and filter paper diagnostics. More 'One 
Health' collaboration on these techniques would benefit both fields. 
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2.8 DISCUSSION 
Over the last 50 years, filter paper has gained an increasingly important role 
as a substrate for diagnosis, epidemiology and surveillance of infectious 
diseases. Recently, this role has gone beyond diagnosis to include detection 
of markers of resistance, detailed genetic or serological analysis and the 
monitoring of therapeutic interventions including drug levels, vaccine-
induced responses and viral loads. 
Almost any clinical sample may be stored on. filter paper for subsequent 
analysis, though finger-prick blood is the most convenient and widely used. 
Viruses, particularly HIV, have been most frequently targeted with filter pa-
per diagnostics. Serological tests perform very well with seven studies re-
porting sensitivity and specificity close to 100%. NAAT performance is more 
variable due to the greater instability of nucleic acids, but mostly reached 
similar accuracy. Infant diagnosis using both RNA. and DNA are feasible, 
however RNA tests tend to suffer with reduced specificity. Hepatitis viruses, 
many of the Herpes virus family, measles, and rubella also perform well with 
serological tests with sensitivities and specificities of >90%. NAATs appear 
promising, though more evaluations are needed particularly for HCV and 
HEV. Dengue serology performed on DBS is clearly suitable for seroprev-
alence studies, though this is less clear for the diagnosis of acute primary 
and acute secondary infections. A recent surveillance study suggests that 
including dengue NSl detection with anti-dengue IgM may increase sensi-
tivity (280). Dengue serotyping is epidemiologically important and can also 
successfully be performed using DBS (165,280). 
DBS also playa key role in the diagnosis of parasitic infections. Detection 
of malaria by PCR using in-house ~ethods is generally superior to the gold 
standard of microscopy. Most studies report sensitivities of >94% and spe-
cificities 0(?99% (182, 183, 196, 198). Due to the geographical distribu-
tion of filariasis and its prevalence in remote settings, filter paper has been 
extensively used to diagnose patients,' determine epidemiology and moni-
~ 
tor response to eradication programs. Using commercially available assays 
sensitivities of >90% may be achieved (99, 201). Specificity is more varia-
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ble due to problems associated with cross-reaction with other related para-
sites (99, 205). Leishmanisasis, giardiasis and cysticercosis have proved less 
promising in the few studies that have evaluated DBS compared to a recog-
nized gold standard (213,214,227). 
The detection of bacteria has less often been investigated using filter pa-
per. Serological tests for leptospirosis, treponema infections and rickettsia 
have yielded excellent results (238, 242, 243), whilst others, such as lep-
rosy, have been less successful (235). The selection of pathogens that may 
perform well on filter paper is dependent on several important factors. The 
presence and quantity of serological markers and nucleic acids in the blood 
at the time of sample collection, their stability on filter paper and the devel-
opment of sensitive and specific assays adapted to perform on filter paper. 
There are several key advantages of using filter paper over the tradition-
al specimens of whole blood or serum. Many of the pathogens discussed 
above are most common in remote and resource-poor settings with limited 
access to advanced diagnostic facilities. Filter paper obviates the need for 
a cold chain to preserve specimens in transport to a central laboratory, thus 
enormously increasing accessibility of these tests worldwide. Filter paper 
is generally cheap (although some of the treated papers, such as FTA, are 
very expensive), requires only a small sample volume (which may be more 
acceptable to the patient), less of a burden for the health system and needs 
minimal technical expertise to perform. This is likely to make sample collec-
tion more acceptable to the patient and increase testing uptake (281). Filter 
paper is easily and safely delivered using almost any existing transportation 
network available. Recent advances in chemically pre-treated cards have 
provided increased safety in handling and transporting samples (279). Per-
for'ated cards allow simpler and quicker preparation of samples for the elu-
tion step, limiting the need for punching tools and reducing cross-contam-
ination risk~~ Samples are stored and transported at ambient temperatures 
and can usually be stored for prolonged periods if sufficient precautions 
against humidity are taken. Filter paper has been used with multiplex sero-
logical and NAATs to diagnose combinations of Hepatitis B, C and HIV (282, 
283). This will increase the diagnostic potential of a single dried blood spot. 
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There are, of course, important difficulties and limitations to be encountered 
when using filter papers. It was apparent when conducting the literature 
search and review that a great variety of terminology has been employed 
when discussing filter paper. Studies evaluating the same pathogen often 
use different methodologies encompassing almost every stage of the pro-
cess from filter paper selection to final assay procedures, making comparison 
vexed. Some studies have used DBS without a justification that the method 
is accurate against a reference standard. Many filter paper varieties have 
been used (products are not always clearly labelled with the paper weight 
in g/m2) and sample volumes will vary, so care is advised when moving be-
tween paper types. A consensus document on terminology and methodol-
ogy would be invaluable for advancing the field of filter paper diagnostics. 
The importance of standardized sample collection, storage and processing of 
filter paper and justification of the accuracy of the methodology in compar-
ison to conventional techniques cannot be overstated. High temperatures 
and humidity over prolonged periods severely reduce test sensitivity par-
ticularly for NAATs, though this seems to vary between pathogens (137,138, 
141, 159, 169). Inevitably the sample size of DBS - the volume of blood per 
spot - will be less than that of a whole blood sample collected by venipunc-
ture. DBS containing whole blood may also influence NAATs or serological 
assays due to the presence of inhibitors. These can, however, be overcome 
. by developing DBS specific protocols (284, 285). Although some guidelines 
exist, there is an urgent need for more robust, standardized protocols for 
sampling, storage, processing and evaluating filter paper techniques. Many 
studies reported in this review were not prospective, real life evaluation 
such studies would provide a stronger evidence base to support recommen-
dations. Additionally, most studies used pipettes to spot venous blood onto 
filter paper which gives a greater"consistency in blood volume than direct 
application of blood to paper, that is unlikely to be achieved with field sam-
..:; 
ples. A number of studies did not report sensitivity and specificity and sev-
eral inappropriately u~ed correlation coefficients rather than Bland-Altman 
plots (168). The standards·for the reporting of diagnostic accuracy studies 
(STARD) guidelines are an important starting point for reporting filter paper 
evaluation (286). The inclusion of additional items to improve accuracy and 
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completeness of filter paper studies (Annex 10.2.7), could greatly improve 
consistency and clinical utility of the results. In brief, these could include 
the use of standardized terminology for DBS, sample collection, storage and 
processing details, key information regarding the reference standard and the 
use of appropriate statistical tests (e.g. Bland Altman plots versus correlation 
coefficients). 
The review has important limitations. First, in attempting to summarize stud-
ies where DBS were evaluated in comparison to a gold standard to diagnose 
infectious diseases, we did not include related subjects such as drug resis-
tance and viral load. Second, we excluded in-house assays for those diseas-
es with well-recognized commercially available assays though these are list-
ed in annex 10.2.8. Third, we did not do a detailed assessment of veterinary 
use of filter paper, as this subject would require an independent literature 
review in its own right. This highlights the need for more collaboration be-
tween scientists in human and animal health. Fourth, we were only able to 
review studies published in English. 
This is the first attempt to summarize the entire' subject of filter paper diag-
nostics in infectious diseases. We highlight the many advantages filter paper 
offers over traditional samples and discuss the limitations and difficulties as-
sociated with using this method of storing and processing clinical samples. 
Consensus should be reached regarding the methodology and terminology 
employed to better advance this important diagnostic tool. Filter paper has 
been shown to be a valuable asset in increasing accessibility of infectious 
disease diagnostics. In some cases, the sensitivity and specificity is slightly 
lower than the reference sample, however it is the potential of filter paper 
to make affordable, robust, sensitive, and specific diagnostics available to 
remote settings that raises its profile in international health . 
. .,) 
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C'lapter 2 - DBS literature revie IV 
2.8.1 ADVANTAGES AND DISADVANTAGES OF DBS 
As practically every aspect of DBS has been described and evaluated in this 
chapter, Table 2.10 summarises the main advantages and disadvantages of 
DBS compared to venous blood collection by venipuncture. 
Table 2.10: Advantages and disadvantages of DBS compared to venous blood 
collected by venipuncture 
Advantages of DBS 
Improves access to diagnostics 
Lower costs 
Ease of collection 
Transportation - no cold chain needed 
Small quantity of blood collected 
Better participation in studies 
Less biological wast~ produced 
Small size - less storage space required 
Minor patient discomfort 
2.8.2 RECOMMENDATIONS 
Disadvantages of DBS 
Small volume of blood affects sensitivity 
Contamination risks affects specificity 
Extraction of DNA/RNA is more 
complicated 
Adjustments required to protocols/ 
assays 
The STARD initiative was launched in 2003 to develop guidelines"forimproving 
the accuracy and completeness of reporting studies of diagnostic accuracy 
(286). During the literature review, we encountered a lack of accuracy and 
incompleteness in reporting findings, even sensitivity and specificity were 
not always reported. Based on the key issues encountered when reviewing 
the literature of DBS evaluations, the STARD checklist was amended to cover 
the specific details that should be reported when evaluating DBS samples. 
The key issues were combined with the additional points to the STARD 
checklist in Table 2.11. The complete STARD checklist, with the amendments 
highlighted, can be found in Annex 10.2.7. 
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Table 2.11: Summary of key concerns in reporting DBS studies and added STARD 
checklist points 
Concerns in reporting DBS 
studies 
Inconsistency in terminology 
Unclear or not reporting 
filter paper sample collection 
method, 
Unclear reporting of reference 
method and sample. 
Unclear or not reporting 
storage and time between 
collecting and analysing 
samples. 
Unclear or not reporting 
punch method and cleaning 
procedure. 
STARD checklist adjustments for DBS 
evaluations 
Make use of terminology: i.e. Dried Blood Spots, 
Dried Urine Spots, Dried Fluid Spots, Dried 
"Samples" Spots 
Sample 1:ollection: State which filter paper was 
used, which and how fluids were obtained and 
spotted onto filter paper, and the drying period 
before storage 
Report the index sample and its collection, 
storage, and transportation details. Provide 
detailed rationale for discordances in methods 
between index and reference test. 
Sample processing: state the time and storage 
conditions (humidity control and temperature) 
at the field, during transportation, and at the 
laboratory, preferably in a tabled manner. 
Report punching method with reference to source 
or manufacturer, and cleaning procedure, if used. 
Unclear or not reporting how For quantitative or numerical test results, indlcate 
quantitative data was obtained the calculation methods and rationale of the 
from filter paper samples. index and reference standard 
Unclear or not reporting For quantitative test outcomes, report the mean 
the biologlcal variability of and range of results for index and reference test 
samples and mean difference 
between index and reference 
sample 
Unclear or not reporting 
of diagnostic accuracy of 
quantitative test outcomes. 
For quantitative test outcomes, Estimates of 
diagnostic accuracy and measures of statistlcal 
uncertainty (e.g. 95% confidence intervals) by 
quantitative grouped ranges (e.g. 1,000-5,000 
copies/mL). 
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SysteInatic revie'Y of DBS in HIV viral 
load patient Inonitoring and early HIV 
infant diagnosis 
Chapter 3 
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3 Systematic review of DBS in HIV viral load 
patient monitoring and early HIV infant 
diagnosis 
3.1 INTRODUCTION TO PUBLICATION 
Access to antiretroviral therapy (ART) has increased over the last few years, 
with over eight million people receiving ART in middle and low income 
countries, in 2011 (287). CD4 cell counts aid clinicians when to initiate 
therapy and HIV VL aid to decide when therapy is failing. Access to these 
tests remains limited due to high costs, necessary laboratory infrastructure, 
and technical complexities in developing countries (66). When these tests 
are not available, treatment failure is based on clinical or immunological 
criteria, leading to undesirable late identification and accumulation of 
resistance mutations (288). Additionally, these tests may be used to detect 
acute HIV-l infection or infant diagnosis. 
To monitor treatment efficacy and to guide clinical decision making for 
switching treatment therapy in developing countries, there is an urgent 
need to evaluate simplified methods that can improve accessibility of pa-
tient monitoring assays (36,289). Additionally, access to HIV VL testing and 
EID is limited to the population living in close proximity to the laboratory 
because of the need for venous blood samples. To answer this need, this 
Chapter assessed the use of DBS for HIV VL and EID and potentially to im-
prove accessibility to these tests in remote settings. 
,.; 
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3.2 RESEARCH PAPER 
Systematic review of the use of dried blood spots in HIV 
viral load patient monitoring and early infant d.iagnosis 
PieterW. Smitl, I<imberly A. Sollisl, Rosanna W. Peelingl, HIV Monitoring 
Technologies Working Group (David. Barnett, Ben Cheng, Suzanne Crowe, 
Susan Fiscus, Rebecca Gelman, Alan Landay, Thomas Spira, Wendy Stevens) 
1 London School of Hygiene & Tropical Medicine, London, UI< 
Status: Not yet submitted 
Contributions: PWS initiated this study to review the use of DBS for HIV 
VL, as part of the study request made by the WHO to perform a systematic 
literature review for HIV VL assays performed with plasma samples. PWS 
and I<S performed the systematic literature search and extracted data. PWS 
wrote the first drafts of the manuscript and I<S provided comments and 
feedback. RWP provided guidance during the whole process an.9 contributed 
significantly to the writing of the manuscript. HIV Monitoring Technologies 
Working Group has not read this or an earlier version of the manuscript yet. 
The candidate The supervisor 
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Abstract 
The importance of adequate HIV viral load monitoring and early infant 
diagnosis in remote settings is rising, given that access to ~nd the use of 
treatment is rapidly increasing. Dried Blood Spots (DBS) have been considered 
as valid alternative to increase access to these tests in remote settings. We 
therefore provide an overview of the methods and identify gaps that need 
to be sorted before DBS can be widely used as the preferred sample choice 
in remote settings. Thirteen HIV viral load articles and six HIV early infant 
diagnosis papers were included. Although some challenges surrounding 
the pre-extraction and analytical stages need to be resolved, DBS can be 
used as an alternative to plasma for HIV viral load quantitation based on the 
suggested threshold of 5000 c/ml as cut-off for treatment failure. Although 
limited data is available for infant diagnosis, DBS seems a very sensitive and 
specific sampling strategy to make diagnosis more accessible. 
Introduction 
According to the latest WHO figures, in 2011 34 million people were living 
with HIV worldwide. Young women aged 15-24 are most vulnerable to 
become H IV positive, as infection rates are twice as high as men of the same 
age. This puts children at risk as well, and in 2009, 370.000 children were 
born HIV positive (290). 
Over eight million HIV infected individuals have been placed on antiretrovi-
ral therapy (ART) and will require on-going monitoring to ensure treatment 
continues to be efficacious (287). HIV VL testing is an important tool for 
monitoring treatment, detecting treatment failure and preventing misclas-
sification of treatment responses and inappropriate switching of treatment 
regimens (291). 
In many resource-limited countries, it is a challenge to diagnose HIV infected 
..:> 
infants because antibody diagnostic assays cannot be used. As HIV positive 
mothers pass IgG antibodies on to the, infant while in the womb, antibody 
tests can only accurately be used when the child reaches at least 18 months 
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of age but by this time, infants may be lost to follow-up and their infections 
remain un-diagnosed untl they present clinically at a health care facility. 
Early infant diagnosis (EID) relies on the detection of HIV nucleic acids to 
confirm HIV positivity of the infant. 
Assays to detect H IV nucleic acids are more technically advanced and costly 
than simple antibody tests and as a result, EID and VL testing are not readily 
available in primary healthcare facilities. Although used for different diag-
nostic purposes, the problems in access to EID and HIV VL testing in low in-
come countries are the same. Both tests are often not performed because of 
the costs, and requirement for expensive laboratory equipment and trained 
technicians (292,293). Additionally, access to HIV VL testing and EID is lim-
ited to the population living in close proximity to the laboratory because of 
the need for venous blood samples. 
Alternative sampling methods have been reviewed as a way to increase 
access to these tests in remote areas (38, 66, 294, 295). The use of filter 
paper for the collection of whole blood, Dried Blood Spots (DBS), has sev-
eral advantages over traditional methods of sample collection. DBS can be 
implemented as an easy and inexpensive means of collecting and storing 
blood specimens under field conditions (30-34). The reduction in materi-
als required, and biological waste produced, as well as the ability to collect 
sample by heel or finger prick without phlebotomy, considerably decreas-
es costs for sample collection, compared to venipuncture (35). DBS also in-
creases accessibility of HIV VL and EID testing in remote areas (36, 37). 
The process of DBS collection begins with a finger prick and spotting whole 
blood directly onto filter paper which is then left to dry at room tempera-
ture. Once dried, DBS can be stored with desiccant and shipped to central 
laboratories for HIV VL testing. The effects of using an alternative sampling 
method for HIV VL and EIA assays should be well understood as this poten-
~ 
tially influences the sensitivity and accuracy (296). 
Since both tests are p-erformed on comparable laboratory equipment that 
detects nucleic acids, we performed a literature review to assess the feasi-
bility of using DBS samples for HIV VL and EID tests. Although literature re-
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views have been published before that reviewed the feasibility of using DBS 
for HIV VL (36,55,297), this literature review provides an updated technical 
analysis of commercially available platforms and the use of DBS samples for 
HIV VL and EID. This review was initiated to critically assess the differences 
between DBS and plasma HIV VL measurements on commercially available 
HIV VL assays. Additionally, no literature review has been published yet that 
reviewed HIV EID with DBS samples. 
Material & methods 
We performed a systematic review of studies evaluating the use of DBS 
for HIV viral load quantification and for EID. The search protocol is given in 
Annex 10.3.1. 
Eligibility criteria 
Eligibility criteria were defined using PICOS (Population, Interventions, 
Comparisons, Outcomes, Study Design). Studies evaluating DBS and plasma 
samples for H IV viral load measures with commercially available technologies 
at the time of the review (April 2012) were considered for inclusion. 
PIcas HIV VL DBS 
Participants: HIV positive persons from any geographical location. 
Intervention (Diagnostic Assay): Any commercial technology available for the quantification of plas-
ma HIV-1 viral load at the time of the search with Dried Blood Spot samples. 
Comparators (Reference Standard): Plasma samples 
Outcomes: Evaluations or comparisons of the accuracy and/or reproducibility of the index sample 
type. 
Study Design: Evaluative studies using an acceptable reference technology or comparative studies. 
Other: Scientific articles published in peer reviewed journals, in English, from 1990 to present. 
PIcas EID DBS 
Participants: infants from any geographical location. 
Intervention (Diagnostic Assay): Any commercial technology available for the detection of HIV-1 DNA 
or RNA at the time of the search with Dried Blood Spot samples. 
Comparators (Reference Standard): whole blood, plasma, or serum samples 
... 
Outcomes: Evaluations or comparisons of the accuracy and/or reproducibility of the index sample 
type. 
Study Design: Evaluative studies using an acceptable reference technology or comparative studies. 
Other: Scientific articles published in peer reviewed journals, in English, from 1990 to present. 
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Information Sources 
Studies were identified by searching the electronic databases MEDLINE and 
Embase, and by inviting experts from the advisory group (HIV,.working group) 
to identify studies relevant to the review. The search was developed by PWS, 
I<S and RWp, conducted by PWS and I<S. 
Search Strategy 
The following search terms were used for HIV VL search: dried or dry, blood, 
spot, DBS, filter paper, Guthrie card, 903 paper, HIV, human immunodeficiency 
virus and human immune deficiency virus. The initial search for evaluations 
of DBS for HIV VL quantitation was conducted 15 February 2010, and 
updated 18 January 2012. For the search of publications evaluating DBS 
for EID, the following search terms were used; dried or dry, blood, spot, DBS, 
filter paper, Guthrie card, 903 paper, HIV, human immunodeficiency virus 
and human immune deficiency virus, DNA, RNA, infant, neonatal, neonate, 
early infant diagnosis, EI D. This search was conducted 2 April 2012. 
Study selection 
Titles and .abstracts were screened for relevance. The full text of eligible 
articles were reviewed and assessed against inclusion criteria. The inclusion 
criteria were: 
• Evaluation or comparison of performance of commercially available 
viral load quantification assays or EID assays 
• Evaluation of dried blood spots with valid reference sample using the 
same viral load or EID technology 
• Any HIV-l subgroup recognition 
• Quan~itation of plasma and dried blood spots for viral load and 
detection of RNA and/or DNA for EID 
For HIV VL, 473 articles were retrieved, 459 were excluded, and 13 articles 
were included. For EID, 225 articles were retrieved, 220 were excluded and 
4 articles were included (Annex 10.3.1). 
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Results 
Early infant diagnosis 
Five studies evaluated the performance of early infant diagnosis (EID) assays 
with DBS against whole blood or plasma samples as reference method using 
the same EID assay (144, 145,298-300). Four studies used Whatman 903 
filter paper (144, 298-300) and one 'study used Whatman NO.1 filter paper 
(145). Out of the five studies, Amplicor 1.5 assay (n=4) and Cobas Taqman 
were evaluated. More details can be found in Appendix 3. The samples used 
for the evaluations were of infants younger than 18 months (144,145,298), 
6 weeks old (299), and of children between 6 .weeks and 6 years (300). The 
sensitivity and specificity of the va rious assays are given in Table 3.1. 
Table 3.1: Sensitivity and specificity of HIV early infant diagnosis 
VL Sample 
Author Assa~ Threshold size Sensitivit~* S~ecificit~* 
Anitha et aL. (298) Amplicor 1.5 NA 64 . 100 100 
Lofgren et al. COSAS Taqman >1.000 176 100 99 
(144) >10.000 176 100 100 
Nsojo ,et aL. (145) Amplicor 1.5 NA 325. 100 99.6 
Sherman et al. AmpUcor 1.5 NA 2880 100 " 99.6 
(299) 
Stevens et aL. Amplicor 1.5 NA 800 100 99 
(300) 
Stevens et al. COSAS Taqman NA 800 100 100 
(300) 
"<sensitivity and specificity of DBS calculated compared to whole blood or plasma 
HIVVL 
Thirteen studies evaluated the performance of quantitative HIV VL assays 
with DBS samples against plasma (38,123,289,296,301-309). All studies 
used Whatman filter paper 903 (protein saver card, GE healthcare, USA) (38, 
123, 289, 296, 302-306, 308). Among the thirteen studies, the following 
platforms were used; Abbott RealTime HIV-1 assay performed on the M2000 
platform (N -5), BioMerieux NucliSens easyQ v1.1 (N=l) and v1.2 (N=3), 
Roche COBAS Taqman HIV-1 viral load (N=2), Roche Amplicor Monitor vl.S 
(N=2), Versant HIV-1 I<PCR~ (N=l) (Table 1). DBS VL results were compared 
to plasma results on the same platform (38, 123, 289, 296, 302-306, 308). 
Ikomey et al. conducted plasma and DBS samples in one run, while all 
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remaining evaluations used two runs to quantitate HIV VL using DBS and 
plasma samples (302). 
DBS preparation 
DBS samples were prepared with either EDTA-blood obtained from a 
venipuncture (38, 289, 296, 301-3'06, 308) or heel prick blood (123). 
Sample storage conditions varied from -20oe (301), -70oe (123) to ambient 
temperatures (38, 305, 306, 308). Samples in eight studies were humidity 
controlled with desiccants (38, 123, 289, 301, 306, 308) but six studies did 
not specify if desiccants were used (296, 302-304). Plasma samples were 
stored at -80oe (38, 305, 306, 308), -70oe (123, 303), -20oe (296, 302) or 
not specified (304,308). All studies included samples with a plasma HIV VL 
range starting from 2 or 3 logio copies up to 7 logio copies/mL. More study 
details can be found in ·Annex 10.3.3. 
Extraction methods 
The NucliSens extraction platforms were used by 6 studies. Andreotti et 
al. (289) began the extraction of DBS samples with the Roche automated 
viral isolation platform but continued to use the NucliSens isolation due 
to incorrect isolation of RNA specimens. The M2000 sample preparation 
platform (M2000Sp) was used by 6 studies in combination with the M2000 
detection platform. 
Sample volume and haematocrit 
The HIV VL measurements obtained by DBS samples, which roughly contain 
50 - 100 ~l of whole blood, were compared to plasma samples in thirteen 
studies. Plasma input volumes for the reference VL testing were 100 ~l 
(303), 500 ~l (289), 600 ~l (305) or unspecified (38, 123, 296, 301, 302, 
304, 306, 3~8). Because of this sample input difference, it is theoretically 
impossible that DBS and plasma samples give comparable viral load results. 
Marconi et al. found a mear difference between DBS and plasma VL of 1.94 
± 0.06 log10 copies/mL and provided this as a correction factor for DBS 
VL calculations (304). An Abbott RealTime HIV-l assay protocol for DBS 
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samples is now avaHable, incorporating this correction factor. Haematocrit 
values can be used in the viral load corrections by estimating the amount 
of plasma in a 50~l whole blood sample. One study found that haematocrit 
correction reduced the difference of DBS and plasma viral load from -0.43 
log10, to -0.127 log10. (123). An alternative is to reduce the reference 
sample volume for a better VL correlation of DBS and plasma (303). 4 out of 
13 studies reported that DBS VL were corrected for haematocrit or that DBS 
were corrected for the smaller sample input volume (123, 289,304,307). 
Bias 
The mean difference, bias, between DBS and plasma VL measurements 
ranged from -0.77 (HIV VL underestimation) (296) to 0.65 log10lmL (HIV VL 
overestimation) (301) across all studies (Figure 3.1). For the Abbott RealTime 
HIV-l assay, 51.9% up to 100% of the DBS HIV VL results were within 0.5 log 
difference of plasma samples (38,296,301,304,305,309). The percentage 
of samples within 0.5 log for the Roche COBAS Taqman HIV-l viral load and 
Versant HIV-l kPCR where 78.4% (289) and 82.7% (306), respectively. The 
BioMerieux NucliSens easyQ vl.l was evaluated by two studies for which 
64% (296) and 94% (303) of the results were within 0.5 log. The greatest 
variance between DBS and plasma was found in studies using the Abbott 
RealTime HIV-l assay (Figure 3.1). 
Table 3.2: SensHivity and specificity given per VL threshold used 
VL Sample Sensitivity Specificity 
Author Assa~ Threshold size %~'r %* 
Lofgren et aL (144) RealTime 1000 176 100 99 
10000 176 100 100 
400 137 99 87 
5000 137 100 97 
Pirillo et aL (306) kPCR 37 98 88.2 69.2 
5000 98 85.1 96.1 
Rottinghaus taL NucliSens 1000 173 77.8 98.1 
(307) v.l ~ l 
,'( sensitivity and specificity-Of DBS calculated compared to whole blood or plasma 
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Figure 3.1: Blas per HIV vlralload range, glven for each assay. 
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Detection limit and sensitivity 
The lower detection limit (95% detection rate) of DBS samples with the 
Abbott RealTime HIV-1 assay was determined by two different studies to 
be 550 and 800 c/mL (301, 308). Andreotti found a low sensitivity when 
plasma viral load samples were below 3 log HIV RNA c/mL with the Roche 
COBAS Taqman HIV-1 viral load assay-(200/0 detection rate) (289). Evaluating 
DBS with the Versant HIV-1 kPCR machine showed that 21 samples were not 
detected with plasma VL below 3942 c/mL, which is high compared to the 
lower detection limit found with the Abbott Realtime assay (289,306). 
The WHO has proposed a clinical threshold of5,000 c/mL to indicate treat-
ment failure (310). The sensitivity at this threshold varied from 85.1% to 
100% in two studies (38, 306). The specificity at 5,000 c/mL was deter-
mined in three studies and ranged from 96.1 % to 97% (38, 306). The sensi-
tivities of DBS for samples with specific plasma viral load ranges are shown 
in Figure 3.2. 
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Figure 3.2: Sensltlvlty per vlralload range of DBS compared to matchlng plasma samples 
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Quality assessment 
Each of the thirteen HIV viral load articles and 5 EID articles included in the 
review were assessed for quality by two independent reviewers. Twenty four 
criteria, based on the STARD guidelines, were used to assess the quality of 
publications (Figure 3.3). All 18 studies described sample storage conditions, 
discussed the clinical relevance and were easily identified as evaluation 
studies. 8 out of 18 studies described the population sampled and again 
only 8 studies described the distribution or range of HIV VL of the sampled 
population. 
Figure 3.3: Number of publications matching a selection (18 out of 24) quality 
criteria. 
Discusses clinica l relevance 
Distribution/ range of VL of population 
Use appropriate statistical methods 
Reports descriptive statistics 
Explains index test 
Explains reference test 
Reports training of technicians 
"' Report anticoagulant 
e5i Describes sample preparation 
.~ b Description of sample storage 
~ Desription of sample acquisition 
ni Describes population/ country of origin a Describe study design 
State study aims 
State research question 
Easily identifiable ~~~~~~e~~~~~~~~~ 
Causes of variability in VL 
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Publlcatfons 
All assays discussed in this literature review are sensitive enough to · be 
used for DBS samples as the lower detection limit of each of these assays, 
according to the manufacturer, are below 100c/mL. The most important 
differences between the assays are input volume and the extraction method 
both of which contribute to differences in mean bias and variability. The 
method of punching Qut the filter paper spot, the punch size, elution buffer 
used as well as the sample volume after e)<traction that was used for VL 
measurement, alter HIV VL results. In the analytical stage, haematocrit 
correction, quantity of blood and quantity of plasma processed, viral load 
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calculation method applied, cell associated RNA as well as HIV proviral DNA 
can alter viral load measurements in some assays. When these critical phases 
in processing DBS are addressed and resolved, it will become possible to 
reduce result variances, develop uniform protocols which allow a more 
detailed comparison between sample collection methodologies. 
Discussion 
DBS samples have been used for many years in the detection of various 
infectious diseases, throughout the world (311-313). DBS samples have 
been used for diagnosis of HIV by antibody and antigen detection and 
have shown to be a very useful diagnostic tool to increase accessibility of 
diagnostic tests. In addition to the practical benefits of using DBS samples, 
costs of sample collection and shipment are low compared to plasma 
samples (131). Although DBS samples seem very useful for EID and HIV VL 
measurements, there are still some concerns with r~spect to the assays and 
protocols reviewed in this literature review. 
Early infant diagnosis 
In contrast to HIV RNA assays, the presence of proviral HIV DNA or cell 
associated HIV RNA increases the sensitivity of EID assays. DBS samples are 
regularly used for EID and generally accepted as a sensitive method when 
venous blood cannot be collected (314-317). This is somewhat surprising 
given that only five published studies met the inclusion criteria of this 
review for evaluation of DBS for EID. Although all studies showed good 
sensitivity, the specificity was slightly less than with liquid blood samples 
(99-1000/0). Clinically, this means that 1 in every hundred patients will be 
false positively diagnosed. Furthermore, only two of the 6 commercially 
available HIV platforms were evaluated. It is recommended that assays are 
thoroughly evaluated and the protocol validated before diagnosing patients 
.~ 
using DBS sampl~s. 
Nucleic acid detection assays used for EID and HIV VL are often performed 
on the same or comparable platforms. While manufacturers provide sepa-
rate kits for EID and VL, there is increasing interest to use HIV VL assays for 
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EID as well. HIV VL assays can detect HIV RNA and by using whole blood 
samples, DNA may also be detected which could increase sensitivity for EID. 
Additionally, using one platform and one kit for both purposes would poten-
tially simplify testing procedures in the laboratory. Although more evalua-
tions are needed, the use of HIV VL assays for EID with DBS samples could 
potentially decrease costs, improve. EID accessibility and simplify testing 
procedures (148, 318). 
HIV viral load 
5000 clmL threshold 
Twelve out of thirteen studies suggested that HIV-l VL quantification from 
DBS is feasible (38, 123, 289, 296, 301-306, 308). The sensitivity of DBS 
samples at a threshold of 5,000 c/mL, the suggested clinical threshold 
indicating treatment failure, varied from 85.1 % to 100% in two studies. The 
specificity at 5,000 c/mL ranged from 96.1 to 97% .(38,306). Clinically, this 
means that 4 out of 100 HIV patients will switch treatment unnecessarily and 
15 out of 100 will remain on the same treatment despite having elevated 
HIV VL levels. The difference between DBS and plasma samples could be the 
result of biological and assay variation, which could cause false treatment 
failure results. 
The lower limit of detection in HIV VL quantitation assays when using DBS 
is 550-1000 c/mL, whereas with plasma, it may be as low as 200c/ml or 
even 20c/ml. One of the reasons DBS is not, and may never be, as sensitive 
as plasma in detecting low HIV VL, is that a complete DBS circle contains up 
to 50IJl of whole blood which is approximately 20-251Jl of plasma. The HIV 
quantitative assays are developed and validated for large plasma sample 
volumes (between 100 and lmL),and calculate VL based on the expected 
plasma sample input volume. When a HIV VL platform has no specific DBS 
protocol, it is necessary to alter the HIV VL result measurement which was 
calculated by the software for plasma samples, and adjust it for the smaller 
volume of a DBS samp-les ~o obtain a final HIV VL result that would match a 
plasma sample. 
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Correcting HIV VL values 
The DBS VL can be recalculated to HIV c/mL by applying the difference 
between plasma and DBS samplevolume. To makethe calculation, haematocrit 
values can be obtained to adjust DBS viral load results by calculating the 
amount of plasma in a DBS sample (123). Pirillo et al. made use of carefully 
designed reference standards for calculating DBS VL levels but unfortunately 
did not give details about the calculation. These calculations are important 
to compare DBS VL results between authors and to understand the effects 
of these adjustments on over- or under-quantification of HIV VL results. It is 
recommended to contact the HIV VL assay manufacturer for a DBS protocol. 
If no protocol is available, it is highly recommended that they are developed 
in close collaboration with the manufacturer so that the protocols are 
distributed to all laboratories using the same platform. 
HIV DNA 
When correlating plasma and DBS samples HIV VL measurements, it is 
important to remember that DBS contains HIV infected cells that are not 
present in plasma. While DBS samples may never have the same limit of 
detection as plasma to detect HIV-1 RNA, the contribution of HIV proviral DNA 
and intracellular virus particles can lead to an overestimation of viral loads or 
positive DBS results when viraemia is undetectable in ART treated patients' 
plasma samples (305). Monleau et al. treated DBS samples with DNase and 
found that DNA contributes largely to the HIV viral load measurements in 
DBS samples (319). The BioMerieux NucliSens easyQ platform is based on 
isothermal RNA amplification so HIV DNA is not detected. It can be expected 
that the levels of proviral DNA and intracellular virions in a sample will differ 
between patients, and within a single patient due to biological variation. 
This would imply that a standard correction would be inaccurate and a more 
detailed procedure would be necessary. The potential confounding of DNA 
.~ 
in low VL m'easurements needs to be researched further and correlated to 
clinical conditions of _HIV positive patients. As DBS adds more variability 
(-0.77 to 0.65 loglolmL), it is essential to critically review the laboratory 
procedures for DBS and minimize variability of each sample process step. 
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Because of the difference in sample volume and the presence of HIV DNA as 
well as cellular HIV RNA in DBS samples, the quantitation of HIV is complex. 
In our opinion, a carefully designed and executed reference curve for DBS 
samples needs to be made for each assay and population. It is therefore 
recommendable to contact the manufacturer and discuss a DBS protocol 
that includes these variables. When manufacturers provide a DBS protocol, 
DBS testing can become standardised and easier to be used for laboratories 
starting to use DBS for HIV VL. 
Conclusion 
The results shown in this study are comparable with previously published 
reviews (55, 297). The review published in 2009 included in-house HIV 
VL assays while in this study, we focused on commercially available assays 
and assessed the quality of the papers. Although not all points on the 
STARD checklist are equally important, distribution,of HIV VL or population 
description, are important. 
When, challenges surrounding the pre-extraction and analytic;al stages are 
resolved, DBS can be used as an alternative to plasma for HIV VL quantita-
tion based on the suggested threshold of 5,000 c/ml. 
HIV VL in infants is high with interquantile ranges of 0.5 million to almost 
5 million copies/ ml at 6 weeks of age (320) in the absence of prophylac-
tic antiretrovirals, suggesting that DBS are a suitable sample (321). As more 
mothers and infants receive antiretrovirals to prevent mother to child trans-
mission of HIV, lower HIV RNA levels in infected babies will be observed. 
Assays for HIV VL and EID detect nucleic acids and are performed on similar 
laboratory equipment and HIV VL assays have been evaluated for early in-
fant diagnosis. Using the same platform and consumables for two diagnostic 
tests, the economies of scope would have advantages for clinical settings. If 
~ 
HIV VL and E.ID testing was performed on a single platform, standardisation 
and a robust consens~s for sampling, s,toring, and processing DBS samples 
would be essential to allow successful implementation of DBS samples. 
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Chapter 4 
4 The trade-off between accuracy, costs and 
accessibility of syphilis screening assays 
4.1 INTRODUCTION TO PUBLICATION 
Chapters 4, 5 and 6 address objective 2 of the thesis, which is to evaluate 
the use of DBS to assure the quality of paCT in remote settings. 
The WHO and Centre for Disease Control and Prevention (CDC) advocate 
the implementation of paCT with a quality assurance method in place (322). 
HIV and syphilis paCTs are currently used at antenatal care clinics (ANC) in 
Tanzania without rigorous QA methods in place. 
The paCTs currently used in Tanzania have already been evaluated in vari-
ous African countries (10, 22, 323-325). The study performed by Lyamuya 
et aL. evaluated five HIV paCTs in Tanzania, and all were highly sensitive and 
specific (99.4 -1000/0) (324). The thesis did not reassess the performance of 
HIV paCTs but extended on the research performed by others. 
Because of the limited number of studies evaluating syphilis paCT, we per-
formed an evaluation comparing paCT to a laboratory based screening as-
say, using Treponema palLidum Particle Agglutination (TPPA) as reference 
method. Initially, the evaluation performed in this chapter comprised of 
four laboratory assays, to assess the most sensitive method. The four as-
says were; the TPPA, Treponema palLidum Haemagglutination Assay (TPHA), 
Enzyme Immuno Assay (EIA), and paCT. The initial idea was to compare the 
4 methods, but the focus of the paper changed to discuss accessibility, costs 
and performance of the paCT and EIA. A version of the manuscript describ-
ing the evaluation of the four methods is described in Annex 10.4. 
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Abstract 
The availability of rapid and sensitive methods to diagnose syphilis 
facilitates screening of pregnant women, which is one of the most cost-
effective health interventions available. We have evaluated two screening 
methods in Tanzania: an enzyme immunoassay (EIA), and a point-of-care test 
(POCT). We evaluated the performance of each test against the Treponema 
pallidum particle agglutination test (TPPA) as reference method, kit costs, 
and the accessibility of testing in a rural district of Tanzania. The POCT 
was performed in the clinic on whole blood, while the other assays were 
performed on plasma in the laboratory. Samples were also tested by the 
rapid plasma reagin (RPR) test. 
With TPPA as reference assay, the sensitivity and specificity of EIA were 
95.3% and 97.8% , and of the POCT were 59.6% and 99.4% respectively. 
The sensitivity of the POCT and EIA for active syphilis cases (TPPA positive 
and RPR titre ~1/8) were 82% and 100% respectively. Only 15% of antena-
tal clinic attenders in this district attended a health facility with a laboratory 
capable of performing the EIA. 
Although it is less sensitive than EIA, its greater accessibility, and the fact 
that treatment can be given on the same day, means that the use of POCT 
would result in a higher proportion of women with syphilis receiving treat-
ment than with the EIA in this district of Tanzania. 
Introduction 
The prevalence of syphilis is high among pregnant women attending 
antenatal clinics in sub-Saharan Africa (326). Syphilis in pregnancy can 
have devastating effects on the developing foetus and is a major cause of 
stillbirths and neonatal deaths in Africa (327). Screening and treatment of 
pregnant women with a single dose of benzathine penicillin before the third 
,~ 
trimester could p~event up to 305,000 stillbirths per year (3, 328). 
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Latent syphilis can only be diagnosed serologically. Laboratory based as-
says such as the Treponema pallidum particle agglutination assay (TPPA) and 
rapid plasma reagin (RPR) test are widely used. As the agglutination is inter-
preted by a technician, the test result is subjective. Enzyme immunoassays 
(EIA) are now recommended for syphilis screening in Europe (329). They are 
easy to use, provide objective results, and are well adapted to high through-
put laboratories; but they are more expensive than the other assays, require 
equipment (a plate washer and a plate reader), and require cold storage of 
consumables, which is a limiting factor for some settings (330, 331). 
These laboratory based assays are not available in rural health facilities in 
Africa. POCTs are easy to perform, require only a drop of blood collected by 
finger prick, and do not require refrigeration; they could enable same day 
testing and treatment for syphilis at any health facility but are less sensitive 
than laboratory based assays (332). 
Selecting a screening assay, particularly in an African country, should not be 
solely based on the performance of the assay. Besides the performance of 
a test; cost, necessary equipment, cold chain requirements, and complexity 
of executing tests should be taken into consideration. Selecting a screening 
assay is therefore often a trade-off between the performance of the assays, 
cost, and accessibility for patients to be screened. Comparative evaluations 
that include these three aspects for syphilis screening have not been pub-
lished previously (333). This study evaluates two screening assays, a POCT 
and an EIA, to review the trade-off between performance, cost, and acces-
sibility of syphilis screening assays in an African district. 
Methods 
Samples and Field Procedures 
The I<isesa open cohort is a well-established ongoing community-based 
~ 
study in Northern Tanzania (334). The cohort study uses regular demographic 
surveillance with serotogical surveys, providing data on HIV incidence and 
prevalence (335). Subjects' that accepted voluntary counselling and testing 
(VCT) were tested for HIV and syphilis using POCT. All subjects with a positive 
syphilis result were given free medical treatment according to Tanzanian 
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government guidelines, and all those positive for HIV were referred to the 
Tanzanian care and treatment centre. The study was approved by the ethical 
review committee of the National Institute for Medical Research (NIMR) in 
Tanzania and the ethical committee of the London School of Hygiene and 
Tropical Medicine. 
Whole blood was collected by venepuncture into heparinised tubes from 
consenting subjects, and transported to the NIMR laboratory in Mwanza. 
Within 24 hours the blood was centrifuged and stored at -200 e. Samples 
were collected from April 2010 until September 2010 and were tested until 
March 2011. Samples were bar-coded to ensure anonymous testing. Double 
data entry was used to enter the results. Results were entered automati-
cally (EIA) or manually into the Laboratory Information Management System 
(LlMS). 
Point-oj-care test 
The SO bioline syphilis 3.0 poe tests (Standard Diagnostics, Kyong gi-do, 
Korea) were performed by trained clinicians, with whole b~ood samples 
collected by finger prick. A timer was used to ensure that the test was read 
after exactly 15 minutes. The manufacturer's instructions were followed. 
TPPA 
A total of 2099 plasma aliquots were allowed to come to room temperature 
and tested by TPPA (Fujirebio, Tokyo, Japan) according to manufacturer's 
instructions. TPPA results were read by two trained and experienced 
technicians. The reading of the TPPA occurred while masked to results of other 
tests. Discordant results between the two technicians were discussed and 
one outcome was agreed by consensus. Results were deemed indeterminate 
for biologically reactive samples or when a conclusive outcome could not be 
obtained du~e to difficulty in interpretation or lack of technician's agreement. 
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Enzyme Immuno Assay 
The Syphilis Enzyme Immuno Assay (EIA) (Lab21 healthcare, I<entford, UI<) 
became available at the midpoint of the study and was ,performed on 
1041 samples (49.6%). It was performed according to the manufacturer's 
instructions and read by Optical Density (00) 450/620nm using an 
automated reader (DTX 800, Beckman Coulter, USA) which calculated the 
cut-off according to the instruction manual. 
RPR 
Quantitative RPR (BD Macro-vue RPR, Becldon Dickinson, Sparks MD, USA) 
was performed on all samples according to the manufacturer's instructions. 
Since adverse pregnancy outcomes due to syphilis are seen in women with 
RPR titres of ~ 1:8 (327), an active syphilis infection was defined for the 
purpose of this study as TPPA positive and RPR titre ~1/8 (19). 
Sensitivities, specificities, positive predictive values and negative predictive 
values were calculated according to standard methods. The agreement be-
tween various methods was tabulated. Microsoft Excel (Microsoft Corp., USA) 
and the statistical package Stata 11 (Stata corp Lp,Texas, USA) were used to 
analyse the results. 
Access to screening 
We visited all 51 health facilities in one district of Mwanza Region (Geita 
District), to ask how many women attend each antenatal clinic per month 
(336). 
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Results 
Point- oj- care test 
The POCT was evaluated with a set of 2099 samples. Of these, 359 (17.1 %) 
samples were positive by TPPA and 225 (10.7%) by POCT. With TPPA as 
reference, the POCT had 11 false positive and 145 false negative results, 
giving a sensitivity of 59.60% (95% CI: 54.5-64.6%) and specificity of 
99.40% (95% CI: 98.9-99.7%) (Table 4.1). There was a 92.6% agreement 
between POCT and TPPA. The positive and negative predictive values were 
95.1 % and 92.3% , respectively. 
Table 4.1: The TPPA and POCT performances are given with RPR results divided 
into titres lower «1/8) or higher than 1/8 (~1/8). 
TPPA POCT RPR Samples 
<1/8 ~1/8 Neg 
+ + 71 41 102 214 
+ 21 9 115 145 
+ 3 0 8 11 
44 9 1676 1729 
Total 139 59 1901 2099 
+= positive, - = negative, Neg=negative 
Of the 145 false negatives by POCT, 115 (79%) were RPR negative and 31 
were RPR positive. Fifty out of 2099 samples tested by POCT had active 
syphilis (positive TPPA and RPR titre ~ 1/8), of which 41 were detected by 
POCT, giving a sensitivity of 82% (95 % CI: 69.2% -90.2 0/0) and specificity of 
100%. 
EfA 
The EIA was evaluated with 1041 samples that were used to evaluate the 
POCT as it became available in the second half of the study. Of these, 18.1 cVo 
of samples were positive by TPPA and 19.1% by EIA. 
With TPPA as reference, the EIA had 20 false positive and 9 false negative 
results, giving a sensitivity of 95.2% (95% CI: 91.1-97.460/0) and specificity 
of 97.7% (95% CI: 96.4-98.5%) (Table 4.2). There was a 97.3% agreement 
between TPPA and EIA. The' positive predictive and negative predictive val-
ues were 90.6% and 98.9% , respectively. The EIA showed a sensitivity and 
specificity of 100% to detect active syphilis cases (Table 4.2). 
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Table 4.2: The TPPA and EIA performances are given with RPR results divided into 
titres lower «1/8) or higher than 1/8 (~1/8). 
TPPA EIA RPR Samples 
<1/8 ~1/8 Neg 
+ + 53 26 100 179 
+ 0 0 9 9 
+ 3 0 17 20 
30 4 799 . 833 
Total 86 30 925 1041 
+= positive, - = negative, Neg=negative 
All 29 samples for which a discordant result was obtained by the two 
laboratory methods were retested. On retestin"g, 8 out of 9 TPPA positive 
samples became negative and one became indeterminate, and 6 out of 20 
TPPA negative samples became positive. Only four EIA positive samples 
changed outcome when retested (4 initially positive samples became 
negative out of 29 discordant results). 
Comparison of EtA and POCT 
Figure 4.1 shows the distribution of 214 positive out of 1041 samples 
identifIed by one or more of the screening assays. 
Figure 4.1: Distribution of positive samples among the three assays. 
TPPA 
9 
66 0 
113 
EIA 1 POCT 
19 6 
The numbe r.s represent positive samples detected by three assays (number 
is given in 3 circles), or by two assays (overlapped by two circles) or by one 
assay (given as number below the assay name). 214 positives detected by 
any of the three methods out of 1041 samples. 
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Costs of consumables 
The kit cost (excluding labour) in Tanzania of one EIA reaction is $0.42- $0.93 
and of one TPPA reaction is $0.46. The costs vary depending on the size of 
the purchased kits. This simple calculation does not include the number of 
negative and positive controls needed per run, which is higher for the EIA. 
The cost of the POCT was $ 1.10 per test in Tanzania. 
Accessibility 
Geita District has one district hospital, 8 health centres, which tend to be in 
larger villages, and 41 rural dispensaries. The EIA could only be performed 
at the district hospital, since health centres and dispensaries do not have 
centrifuges for plasma separation, cold storage capabilities, plate washers 
or readers. On average, 517 pregnant women attend the district hospital 
ANC for the first tii'ne per month, whereas 2849 attend a health centre or 
dispensary. If the prevalence of active syphilis is 2.3%, as found in this 
study, 77 pregnant women with active syphilis would be expected to attend 
an ANC in Geita District each month. Twelve of these would be attending the 
district hospital, and 65 would be attending health centres or~ dispensaries. 
With a sensitivity of 82%, the POCT would detect 63 of these, and enable 
them to be offered immediate treatment, whereas without the POCT only 12 
of 77 pregnant women with syphilis (15%) would be identified. 
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Discussion 
To our knowledge, this is the first study comparing POCT and EIA performed 
in an African setting. Additionally, this is the first study that ,includes costs, 
accessibility and diagnostic performances of syphilis screening assays into 
one evaluation. 
It is important to note that this study was performed in Tanzania on Tanza-
nian samples, which potentially influences the results. African samples can 
contain high immunoglobulin levels due to other infections which poten-
tially cause false positive test results (337, 338). 
Although tests were performed and stored according to the manufacturer's 
recommendations, potential environmental effects by transporting and us-
ing the kits under tropical conditions could not be completely ruled out. 
Performing tests in an African country relies more heavily on the robustness 
of the tests than in developed countries. This could potentially influence the 
test resu lts. 
The reproducibility of the EIA evaluated in this study was g90d, with few 
samples giving discordant results on re-testing. Thesamples that were dis-
cordant had very low ODs, just above the cut-off. Therefore, EIA seems to be 
a more stable and reliable test compared to TPPA. 
Adverse pregnancy outcomes due to syphilis are seen in women with RPR 
titres of ~ 1:8 (327). In this study, the EIA had a higher sensitivity for the de-
tection of these cases than the POCT (1000/0 versus 820/0), but a major limit-
ing factor is that the EIA can only be performed when sufficient laboratory 
infrastructure is available. Most importantly, in Mwanza region, the POCT 
would enable more pregnant women with syphilis to be identified due to its 
greater accessibility, since pregnant women can be screened not only at the 
hospital but also at health centres and dispensaries. The RPR test is easier 
to perform than the EIA and requires less equipment, but requires access to 
a laboratory with' elec!ricity. It has bee,n used to screen pregnant women in 
many developing countries, but the test results are difficult to interpret and 
results obtained in rural health facilities have not been encouraging (339). 
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In some countries blood is taken from pregnant women at rural health facili-
ties and sent to a central laboratory to be tested for syphilis, but under these 
circumstances women with syphilis will only be treated if they return for 
their results (340). A study in Kenya found that less than 10% of pregnant 
women with syphilis received appropriate treatment when serological tests 
were performed ~t a central laboratory (341). When same day testing and 
treatment were made available in these clinics, more than 90% of infected 
women were treated (339). 
A test which gives a result in 15 minutes, allowing patients to be tested and 
treated on the same day, may result in more cases being treated than a more 
sensitive laboratory test which requires patients to return for treatment at 
a later date The great advantage of the new paCTs for syphilis is that they 
do not require laboratory equipment or electricity, and can make same day 
testing and treatment for syphilis available at any health facility (336,342). 
Based on the performance, costs and accessibility of both tests, the paCT is 
the best option for this and potentially many other settings in developing 
countries. 
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5 The evaluation of DBS as QA sample for 
syphilis POCT 
5.1 INTRODUCTION TO PUBLICATION 
The literature review identified a limited number of publications describing 
the use of DBS samples for syphilis serology (Chapter 2) (343, 344). 
Even though the procedure of using DBS samples has been described, 
the serological tests that were used are not commercially available any 
more. Additionally, test procedures were not rigorously developed, which 
suggested that a new evaluation would be necessary. 
In order to use DBS samples as QA method for HIV and syphilis POCT, it is es-
sential to establish the exact sensitivity and specificity of DBS compared to 
the gold standard sample, serum or plasma. This will allow a better interpre-
tation of the concordance between POCT and DBS sample based test. And, 
as noted in chapter 1, evaluating an assay in the country where it will be 
used is essential to take biological and environmental factors into account. 
This paper evaluates the use of three different syphilis serological assays, 
TPPA, TPHA and EIA with DBS samples, to identify the best performing assay 
for use with DBS compared to matching plasma samples. This paper also 
identifies one assay that is providing excellent results while the other two 
appear not to be suitable for DBS samples. Moreover, it also shows the im-
portance of laboratory technicians being trained to obtain high sensitivities, 
particularly for assays that are subjective in result interpretation, as for hae-
magglutination assays as TPPA and TPHA. 
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Abstract 
Background 
Syphilis causes up to 305,000 stillbirths and neonatal deaths annually. These 
could be prevented if all pregnant women were screened, and those with 
syphilis treated with a single dose of penicillin before 28 weeks gestation. 
In recent years, rapid point-of-care' tests have allowed greater access to 
syphilis screening, especially in rural or remote areas, but the lack of quality 
assurance of rapid testing has been a concern. We determined the feasibility 
of using dried blood spots as specimens for quality assurance of syphilis 
serological assays. 
Methods 
We developed DBS extraction protocols for use with Treponema pallidum 
particle agglutination assay (TPPA), Treponema pallidum haemagglutination 
assay (TPHA) and an enzyme immunoassay (EIA) and compared the results 
with those using matching plasma samples from the same patient. 
Results 
Since DBS samples showed poor performance with TPHA and EIA, only the 
DBS TPPA was used in the final evaluation. After retesting the discordant 
samples, DBS TPPA showed an adjusted sensitivity of 97.7% and a specificity 
of 99.4% compared to TPPA using plasma samples as a reference. 
Conclusion 
Based on the results, DBS samples can be recommended for use with TPPA 
for quality assurance of point-of-care syphilis testing. 
Bacl<ground 
. .,'). 
Syphilis causes up to 305,000 stillbirths and neonatal deaths annually (3). 
These could be preve~ted if all pregnant women were screened and treated 
with a single dose of benzathine penicillin before 28 weeks gestation (328). 
Syphilis testing occurs most commonly by laboratory based assays such as 
Treponema pallidum haemagglutination assay (TPHA), Treponema pallidum 
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particle agglutination assay (TPPA), rapid plasma reagin (RPR), or enzyme 
Immunoassay (EIA). These tests need to be used with serum or plasma 
samples and require a centrifuge, shaker, and refrigeration for the reagents. 
They are therefore less suitable than point-of-care tests (POCT) for use in 
rural or remote locations. POCT screening tests for syphilis that are sensitive 
and specific in detecting treponemal antibodies are now available (332). 
The main advantages of POCTs are that they are easy to use, can be stored 
at room temperature, and can be used with whole blood, collected with a 
finger prick. The Global Report on Preterm Birth and Stillbirth and modelling 
studies have identified syphilis POCTs testing and treatment as an urgent 
priority for reducing perinatal morbidity and mortality (345-347). Many 
countries have therefore started to scale up the use of POCTs in prenatal 
screening programmes for syphilis, but the lack of suitable methods for 
quality assurance (QA) is a serious concern. 
Most QA methods have been developed to monitor the quality of tests per-
formed in the laboratory, and are not designed for monitoring POCT usage 
by healthcare workers at remote locations (10). Dried Blood Spots (DBS) 
have been suggested to be a suitable QA methodology for HIV POCTs (39). 
DBS samples have been used in prevalence studies for syphilis serology, but 
without prior validation of the methodology (12,13,348). DBS samples have 
been evaluated with TPPA (344), TPHA (343), and an in-house EIA which is 
not commercially available (56). The TPHA used in the study by Backhouse 
et al. is no longer commercially available. The fourteen year old TPPA proto-
col used by Coates et al. did not include a control for biologically reactive 
samples, and the final testing concentration of DBS eluate was more diluted 
than with plasma, potentially leading to reduced sensitivity for samples with 
low antibody titres (344). The aim of this study was to determine whether 
DBS can be recommended for use as samples for QA of syphilis serological 
assays. Our objectives were to develop and validate DBS protocols for use 
~ 
with commercially available syphilis diagnostic assays, and to determine 
" 
their performance in syphilis serological assays using plasma samples as a 
reference. 
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Methods 
Research setting 
The I<isesa open cohort is a well-established ongoing community-based 
study in northern Tanzania that conducts regular demographic surveillance 
on HIV prevalence and incidence (334). Subjects that opted for voluntary 
counselling and testing (VCT) were offered HIV and syphilis POCT (SO Bioline, 
USA) performed by trained and experienced technicians. If the VCT partici-
pant was treponemal antibody positive by POCT, free medical treatment was 
provided according to the Tanzanian governmeht recommendations, and all 
those positive for HIV were referred to Tanzanian care- and treatment cen-
tres. The study was approved by the Medical Research Coordinating Commit-
tee of the National Institute for Medical Research in Tanzania (NIMR) and the 
ethical committee of the London School of Hygiene and Tropical Medicine. 
Procedures 
For the community based HIV study, OBS samples (Proteinsaver 903 filter 
paper, Whatman, GE healthcare, USA) were collected by finger prick, air 
dried at room temperature for at least 3 hours and stored wlth desiccants 
in individual ziplock bags at -200C. After subjects donated a OBS sample, 
they were invited to opt in for VCT. Whole blood samples were collected 
from consenting subjects that opted in for YCT by trained clinicians and 
transported to the NIMR laboratory in Mwanza. Samples were bar-coded in 
the field to ensure anonymous testing. Within 24 hours, the blood samples 
were centrifuged and plasma was stored in 3 aliquots (lmL each) at -200C. 
From all subjects participating in the serosurvey who opted for VCT, 1,645 
samples were randomly selected for this study. 
All syphilis serology assays were performed according to manufacturer's di-
rections. The positive and negative controls supplied with the kits were used 
with every r"Jn. The technicians were blinded to other test results and TPHA 
and TPPA results'were read by two trained laboratory technicians. All tests 
were performed in at the NIMR laborato'ry, which participates in the WHO ex-
ternal QA programs for TPPA and Rapid plasma Reagin (RPR) tests. An active 
syphilis case is defined as RPR positive, confirmed by a treponemal test. The 
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results were entered using the laboratory information management system. 
The protocol development and evaluation was divided into two phases. 
In the first phase, we determined the feasibility of using DBS with TPHA, 
TPPA and EIA using 464 samples. During DBS protocol development, care 
was taken to ensure an equivalent DBS sample input was used, compared to 
plasma. In the second phase, the serological tests that work best with DBS 
were selected and validated with 1,181 samples. Plasma samples were used 
as the reference standard. The RPR test was performed on plasma samples 
that gave discrepant results between DBS and plasma samples to determine 
if any active syphilis cases might have been missed. Samples were prospec-
tively collected from July through September 2010 and were tested until 
March 2011. During phase 1, the preliminary evaluation of different syphilis 
serological methods with DBS samples, TPPA, TPHA and EIA were all per-
formed from the same DBS eluate as only one DBS spot was available. As a 
reference method, TPPA, TPHA and EIA were performed on matching plas-
ma samples in parallel. To ensure blinded reading in the laboratory, plasma 
samples were tested before DBS samples. Additionally, the three tests on 
DBS were performed separately from each other, to maintain blindness to 
other test results. 
A total of 1,645 plasma aliquots were brought to room temperature and 
25~l were used to test for treponemal antibodies by TPPA (Fujirebio, Tokyo, 
Japan), according to manufacturer's protocols, by laboratory technicians 
who routinely perform TPPA on plasma samples. 
For DBS TPPA testing, the protocol was adjusted as follows. A 6mm disk was 
manually punched and eluted in 100~l Phosphate buffered Saline (PBS) with 
0.05% Tween80 in a clean 96 flat wells plate, shaken for 2 minutes and elut-
ed overnigh~t at 4°(. Upon the next day, th~ plate was shaken 2 minutes and 
brought to room temperature. 25~l sample dilution buffer was added to the 
first column of a clean 96 .U-shaped plate, 25~l DBS eluate was added and 
mixed thoroughly. 25~l of the mixture was transferred to a second column 
and 25~l sensitized particles were added to column one, 25~l unsensitized 
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particles to column two. Plates were covered and incubated for at least two 
hours at room temperature on a vibration free surface, before result inter-
pretation. Discordant results between the two technicians were recorded 
as indeterminate. This protocol allows TPPA and HIV serological tests to be 
performed from one DBS spot. 
Plasma aliquots were brought to room temperature and 25 jJl were used 
to test for treponemal antibodies by TPHA (Lab21 syphilis TPHA, Lab21 
healthcare, Kentford, UK). TPHA plasma tests were performed according to 
manufacturer's protocols by trained laboratory technicians. 
For DBS TPHA testing, the following protocol was developed; 25 jJl of DBS 
eluate (obtained as described above) was added to 25jJl sample diluent, 
mixed and divided over two wells (25jJl each). 75jJl test or control cells were 
added and incubated for 1 hour. For both TPHA and TPPA protocols, the fi-
nal DBS sample elution volume was kept comparable with plasma sample 
volume. Discordant results between the two technicians were recorded as 
indeterminate. 
Plasma aliquots were brought to room temperature and 50 jJl were used 
to test for treponemal antibodies by Enzyme Immuno Assay (EIA) (Lab21 
Syphilis Total Antibody EIA, Lab21 healthcare, Kentford, UK). EIA plasma tests 
were performed according to manufacturer's protocols by trained laboratory 
technicians. 
A DBS EIA protocol was developed in collaboration with the developer of 
the assay. 40jJl DBS eluate was added and incubated for two hours at 37°(. 
Plates were~ washed five times using an automated washer, 50jJl conjugate 
was added, shaken and incubated for 30 minutes at 37°(, washed five times, 
50jJl substrate was added and incubated for 30 minutes at room tempera-
ture while kept in the dark.~50 jJl stop solution was added and the wells were 
read as Optical Density (OD) 450/620nm using an automated reader (DTX 
124 
800, Beckman Coulter, USA) with cut-off limits calculated according to the 
instruction manuaL The results were then entered directly into the labora-
tory information management system. 
Quantitative RPR (BD Macro-vue RPR, Becldon Dickinson, Sparks MD, USA) 
was performed according to manufacturer's protocols using plasma samples 
by trained laboratory technicians. 
Data analysis 
The sensitivity, specificity, positive predictive value and negative predictive 
value were calculated according to standard methods. The agreement 
between various methods was tabulated. Microsoft Excel (Microsoft, USA) 
and the statistical software Stata 11 (StataCorp LP, Texas, USA) were used 
for analysis of the results. Newcombe-Wilson score methods were used to 
provide confidence intervals for sensitivity and specificity. 
Results 
Phase 1: Preliminary evaluation of different syphilis serological methods 
wjth DBS samples 
During the first phase of the project, protocols for DBS samples were 
developed for TPPA, (DBS TPPA) TPHA (DBS TPHA) and EIA (DBS EIA). 464 
DBS samples were tested with TPPA, TPHA, and EIA. Table 5.1 shows the 
sensitivity and specificity of all three syphilis serology tests using DBS 
samples compared to plasma samples. The DBS EIA was discontinued before 
the end of phase 1 because of the many false positive results (specificity 
50.4%). The TPHA was also excluded from further testing because of low 
sensitivity (50.6%). 
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Table 5.1: Preliminary evaluation: The performance of three syphilis serological 
assays using Dried Blood Spots compared to plasma. 
Positive Negative 
Plasma as reference samples samples Sensitivity Specificity 
(using the same assay) detected detected (95% (I)~'t (95% (I) 
DBS TPPAt (n=463) 82/96 363/368 85.42% 98.91% 
(77.0 - 91.1 %) (97.2-99.6% ) 
DBS EIA (n=282) 53/56 114/226 94.60% 50.40% 
(85.4-9 8.2 % ) (44.0-57.0%) 
DBS TPHA* (n=445) 46/91 353/354 50.60% 99.20% 
(40.5-60.6% ) (98.4-100% ) 
n= samples 
,', 95% confidence interval, t 1 TPPA DBS indeterminate excludedJ 19 TPHA indeterminate 
results excluded 
To improve sensitivity of DBS TPPA, technicians were trained to use a 
lower cut-off for interpretation of the DBS TPPA test results, based on the 
agglutination patterns seen in phase 1. Reading was adjusted by altering 
the agglutination positive and negative thresholds applied for DBS samples 
because of the higher background compared to plasma samples. 
Phase 2: Evaluation of DBS samples in comparison to matching plasma 
samples. 
For the final evaluation of DBS TPPA, 1,181 matching DBS and plasma samples 
were tested, of which 179 plasma samples tested positive for treponemal 
antibodies, resulting in a 15.2% syphilis seroprevalence (Table 5.2) 
Table 5.2: Correlation between detection of Treponema paUidum antibodies by 
plasma TPPA and DBS TPPA 
(n=1147) TPPA plasma Total 
Positive Negative 
DBS TPPA Positive 169 10 179 
Negative 8 960 968 
Total 177 970 1147": 
Sensitivity of DBS against plasma 95.5% (95% (/ : 91.3 -97.7%) 
Specificity of DBS against plasma 99.0% (95% (/: 98.1-99.4%) 
-:: excluding 34 it .determinate results. 
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Of these 177 plasma positive samples, 66 were RPR positive (Table 5.3). Ex-
cluding 34 indeterminate results, DBS TPPA showed a sensitivity of 95.5% 
(95% (I: 91.3 -97.7%) and a specificity of 99.0% (95% (I: 98.1-99.4%) 
compared to TPPA plasma as a reference method. 
Table 5.3: RPR titres of TPPA DBS positiye samples 
RPR titre N=179 
negative 113 
1/1 13 
1/2 19 
1/4 13 
1/8 7 
1/16 4 
1/32 6 
1/64 1 
>1/128 · 3 
The optimisation resulted in a 10.1% increase in sensitivity. An overall 
agreement of 98.7% between the two readers was found. No non-specific 
reactivity (positive with unsensitized particles) with DBS samples was 
dete~ted. Of the 34 indeterminate results for DBS TPPA, 30 (88.3%) were 
,. 
negative and 4 (11.7%) were positive for TPPA using plasma samples. 
Unfortunately it was not possible to retest the 10 false positive DBS samples 
since insufficient sample eluate was available by the time plasma and DBS 
results were compared. The eight samples that were false negative were 
likely either borderline samples or due to incorrect DBS TPPA test reading. 
The eight false negative matching plasma samples were retested with 
quantitative TPPA and quantitative RPR, as shown in Table 5.4. 
Table 5.4: RPR results on the 8 Plasma samples with false negative DBS TPPA 
results. 
Sample 
BBI99P 
BBI792 
BBI6GG 
BBI5YI 
BBI8Ze 
BBI6LP 
BBI61<6 
BBI6NZ 
N= negative 
DBS 
N 
N 
N 
N 
N 
N 
N 
N 
• Quantitative TPPA 
t Quantitative RPR 
, 
TPPA" RPRt 
N N 
N N 
N N 
N N 
1/80 N 
1/160 N 
1/320 I N 
>1/640 1/64 
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Four plasma samples were negative when retested with TPPA, suggesting 
a borderline sample or false positive reading when initially tested. Taking 
these four false positive plasma TPPA samples into consideration DBS TPPA 
sensitivity and specificity increased to 97.7% and 99.4% .respectively. 
Discussion 
We developed and validated protocols for the use of DBS samples as 
specimens for QA of syphilis serological assays. Unfortunately, we were 
not able to obtain acceptable performance for the use of DBS samples 
with the Syphilis Total Antibody EIA and Lab21 Syphilis TPHA. The EIA false 
positive results were primarily caused by a high background, possibly due to 
substances eluted from the filter paper and whole blood that adhered non-
specifically to the wells. DBS samples tested with TPPA gave a sensitivity of 
97.7% and specificity of 99.4% compared to plasma samples. 
Of the eight samples that were false negative by DBS TPPA, four were nega-
tive when retested with quantitative TPPA on plasma samples and four were 
false negatives, of which two had relatively high TPPA titre,? (1/320 and 
1/640). We tested all plasma samples using the RPR assay to determine if 
any of the false negative samples were from women with active syphilis, 
defined as being RPR and TPPA positive. Since only one false negative DBS 
sample was positive for RPR, DBS samples showed excellent sensitivity and 
specificity when used with TPPA and are potentially useful as samples for 
the diagnosis of syphilis and for QA. 
Because TPPA is an agglutination assay, experience in reading results is 
essential and therefore training is necessary. 34 DBS samples (3%) were 
marked as indeterminate due to difficulty in interpreting the results or be-
cause of discordant reading by two technicians. Appropriate procedures for 
indeterminate samples have not been evaluated but retesting DBS eluates 
.l> 
in duplicate seemed suitable to establish a final reading (data not shown). 
DBS samples can pote!ltially be used fC?r quantitation with TPPA, although it 
would require evaluation against titers obtained with plasma samples. Be-
cause of the subjectivity, it is recommended that TPPA should be read by 
two readers. 
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DBS TPPA has been used as a surveillance tool in a few studies (13, 344, 
348) that used a protocol developed by Coates et al. (344). The DBS TPPA 
protocol developed in this study is an improvement to the protocol devel-
oped by Coates et al. as we adjusted the elution so that the sample input 
into the TPPA assays from DBS and plasma are comparable. We also included 
unsensitized particles in the proced.ure for control of biologically reactive 
samples. 
Conclusions 
As prenatal screening for syphilis using POCTs become widely implemented, 
a QA method appropriate for use with blood collected by a finger prick must 
be developed to assure the proficiency of POC testing in rural or remote areas. 
The aim of this study was to determine whether DBS can be recommended 
for use as samples for QA of syphilis serological assays. Based on the high 
sensitivity and specificity of DBS TPPA compared toplasma TPPA, DBS can be 
recommended for use with TPPA, but not with TPHA or EIA, as a confirmatory 
assay for syphilis or as samples for QA of POCTs. Our study also showed the 
importance of training laboratory technicians in performing arId reading the 
DBS TPPA, even when they are already trained in plasma TPPA. We obtained 
a 10.10/0 increase in sensitivity when technicians were more experienced in 
interpreting DBS TPPA agglutinations. 
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Chapter 6 
6 The implementation of DBS as QA method 
6.1 INTRODUCTION TO PUBLICATION 
This Chapter extends on Chapter 4; the evaluation of syphilis POCT in 
comparison to a laboratory based screening assay (EIA) in Tanzania, and 
on Chapter 5; the development and'evaluation of a laboratory protocol for 
syphilis serology on DBS samples. While this thesis assessed the performance 
of POCT and DBS for the detection of syphilis antibodies, it did not assess the 
performance of HIV POCT or HIV serology with DBS. The use of DBS samples 
for HIV serology has been evaluated in great detail and showed to be very 
sensitive (Chapter 2) (39, 52, 295, 349-352). 
In this chapter, the use of DBS as QA sample is implemented to review the 
implementation process over a period of nine months, in ten ANC clinics in 
Tanzania. Additionally, the performance of the QA method to detect under-
performing clinics is compared to syphilis proficiency panels, to review the 
performance in greater detail. The POCT testing performance of each clinic 
was obtained and compared to review potential differences in quality of 
testing. 
By performing this study and making the protocols developed for this study 
available online, the method could potentially be used and scaled up as QA 
method for POCT at regional or even country level. 
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Abstract 
Background 
Quality assurance (QA) programmes, which are routinely used in laboratories, 
have not been widely implemented for point-of- care tests (POCTs). A study 
was performed in ten health centres in Tanzania, to implement the use of 
dried blood spots (DBS) as a QA method for HIV and syphilis (POCTs). 
Method 
DBS samples were collected for retesting at a reference laboratory and the 
results compared to the POCT results obtained at the clinic. In total, 2341 
DBS samples were collected from 10 rural health facilities over a period of 
nine months, of which 92.5% were correctly collected and spotted. 
Results 
The QA method was easily implemented by healthcare workers under 
routine conditions in Northern Tanzania. For HIV, 967 out of 972 samples 
(99.5%) were concordant between DBS and POCT results. Fqr syphilis, the 
concordance of positive syphilis tests varied between clinics, ranging from 
38% - 89% with a mean of 64% (median 70%). The concordance of negative 
samples between syphilis POCT and laboratory based test using DBS varied 
from 93% to 99% , with a mean of 97%. 
Conclusion 
Overall, the quality of testing varied significantly at clinics and QA results can 
be used to identify clinics where healthcare workers require remedial training, 
suggesting the necessity for stringent quality assurance programmes for POC 
testing. As Tanzania embarks on scaling up HIV and syphilis testing, DBS can 
be a useful and robust tool to monitor the quality of testing performed by 
healthcare workers and trigger corrective action to ensure accuracy of test 
results. 
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Bacl<ground 
Point-of-care diagnostic tests (PaCTs) are increasingly used in both 
developing and developed countries (353). They allow sa,me day testing 
and treatment at remote locations where no laboratory support is available. 
Quality control measures, which are routinely used in laboratories, have not 
been widely implemented for paCTs". The World Health Organization and US 
Centre for Disease Control and Prevention advocates the implementation of 
paCT with a quality assurance method in place (322). 
In Tanzania, the Ministry of Health currently recommends the use of paCTs 
to screen pregnant women for HIV and syphilis, but a quality assurance (QA) 
method has not been implemented (336). Dried blood spots (DBS) have 
been suggested as a potential method for QA for HIV paCT (39), but this has 
not been implemented under routine testing services. 
In this study, we implemented DBS as a QA method for both HIV and syphi-
lis paCT in Tanzania. The study aims were; (1) to evaluate the feasibility 
of using DBS as a continuous QA method for end users in a rural setting of 
a developing country; (2) To review the performance of the various clinics 
involved in syphilis and HIV testing; (3) to compare this QA method with ex-
ternal QA using proficiency panels, and (4) to make the project's protocols 
available online. 
Methods 
Setting 
As part of a larger study that implemented syphilis paCT in seven developing 
countries, the Geita District in Northern Tanzania was chosen for this study 
(336). Ten out of 51 ANC clinics that participated in the main study were 
selected based on location, type of clinic, and willingness to participate. The 
study was c",onducted in ten primary health clinics that offered antenatal care 
(ANC) and HIV voluntary counselling and testing (VCT) services. To represent 
the various types of T.anzanian clinics providing ANC and VCT services, the 
district referral hospital, 'four health centres and five dispensaries were 
included in this study. The classification of clinic type is primarily based on 
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the number of personnel and which services are offered to the patients. The 
study population were pregnant women and their partners. The study was 
conducted over a period of nine months, from January till September 2011. 
Routine services offered 
The QA method was incorporated "in the national routine ANC and VCT 
services given at ANC clinics in Tanzania. Patients accepting HIV and syphilis 
testing were tested on-site using the SD Bioline syphilis 3.0 (Standard 
Diagnostics, Kyong gi-do, Korea) on whole blo"od obtained by finger-prick. 
The national HIV POCT testing algorithm consisted of SD Bioline HIV 3.0 
(Standard Diagnostics, Kyong gi-do, Korea), Determine HIV- 1/ HIV-2 (Abbott 
Laboratories, Wiesbaden-Delkenheim, Germany) with Unigold (Trinity 
Biotech, Dublin, Ireland) as the tie-breaker test. All tests used whole blood 
obtained by finger prick and were performed according to the manufacturer's 
recommendations. Free medical treatment was provi,ded to all patients testing 
positive for syphilis. H IV positive patients were referred to Tanzanian care-
and treatment centres. All services were performed according to Tanzanian 
guidelines. 
Implementation of QA method in routine practise 
The patients were requested to donate blood for quality control purposes 
and asked to provide oral consent by the health care worker (HCW). Ethical 
approval was obtained from ethical committees at the London School of 
Hygiene and Tropical Medicine and at the National Institute of Medical 
Research, NIMR, Tanzania. If consent was given by the patient, whole blood 
was obtained by finger prick according to standard protocols (322). Whole 
blood was applied to the POCT and the DBS was spotted afterwards. The 
HCW was instructed to not perform an additional finger-prick when the DBS 
could not be completely filled, to minimize discomfort for the patient. Only 
.,..') 
the POCT outcome, date of testing, patient number and the clinic name were 
recorded on the study- form. 
135 
At the start of the study, HCW that performed HIV and syphilis testing re-
ceived a one- day centralised training for the collection of DBS samples. 
During the training, HCW learned about the method and received hands-on 
training of spotting blood onto filter paper, labelling DBS samples, drying, 
and storing DBS samples. After the training, HCW were given filter papers 
(Protein Savercard 903, Whatman, GE healthcare, Wisconsin, USA), desic-
cant bags (indicating desiccants, Brownell ltd, UK), a dry rack (GE healthcare, 
Wisconsin, USA) and ziplock bags (Minigrip, Netherlands) to store the DBS 
samples. Syphilis paCT kits (SO Bioline syphilis 3.0,Standard Diagnostics, 
Kyong gi-do, Korea) were purchased and transported to the hospital, from 
where the kits were distributed to the clinics. To minimise the workload, 
DBS samples were stored up to 10- 15 cards per ziplock bag with desiccants 
at the clinic. Risk of cross contamination for serological testing was limited 
due to the tucked cover of the DBS cards protecting the blood spots. 
To minimise the workload of the busy HCW, identification stickers were 
used. One sticker was placed on the DBS and the other on a registration form 
where the matching paCT results could be encircled. Laboratory technicians 
were masked to the paCT results and the ANC registration for~ms containing 
the paCT results were entered into Epi-info v. 3.5.3 database (Centre for 
Disease Control and Prevention, Atlanta, USA). Interviews were conducted 
to obtain feedback of the HCW in June 2011. All HCW found the method 
easy and relatively quick to use. According to the HCW, the QA process time 
including spotting, labelling and recording result varied from 2-6 minutes. 
As most HCW provided counselling during the waiting time before the paCT 
results could be read, the DBS QA method did not cause any delay as this 
was done during the 15 minute waiting time. 
To review the feasibility of the QA methodology for large scale application, 
laboratory time was monitored. The time estimates in Table 6.1 are based on 
an experier-ced laboratory technician and do not take preparation of materi-
als (e.g. reconstitution of buffers) into consideration. 
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Table 6.1: Sample processed and data entered per hour per one techn1cian, 
divided per activity. 
Samples processed Data entry Samples entered 
Activity per hour required? per hour 
Register quality of DBS 200 yes 225 
Punch and prepare 180 no 
masterplates 
Murex HIV test 135 automated 
TPPA syphilis test 500 yes 200 
Vironostika HIV test 190 automated 
Clinic record form entry NA yes 140 
Average 241 188 
Shipment and laboratory methodology 
The ANC registration forms and DBS samples were collected in March, 
June and October. Samples were counted and checked for humidity 
(changed desiccants if required) before shipment at ambient temperature 
to the laboratory. On average, the time between . sampling and arrival at 
the laboratory where testing took place was 95 days (minimum= 62 days, 
maximum= 142 days). The DBS samples were transported at ambient 
temperature to the Leiden Cytology and Pathology Laboratory, Leiden, The 
Netherlands where the samples were tested. Upon arrival at the laboratory, 
the quality of DBS samples were reviewed and recorded according to the 
online protocol (354). The DBS quality data was entered into epi-info. The 
DBS were placed with new desiccants in a ziplock bag and stored at 4°C until 
tested. To allow fast interpretation of the results, an excel file was developed 
that imports Epi-info data. The Excel file automatically presents data from 
each clinic graphically which could aid supervisors to adequately identify 
and provide detailed feedback to clinics requiring supervision when the .QA 
method is implemented. All documents are freely available online (354). 
Syphilis testing 
Treponema pallidum Particle Agglutination assay (TPPA, Serodia,Tokio, Japan) 
was performed as des.cribed previously (Smit et al submitted). Briefly, 6mm 
spots were punched with a DBS puncher (PerkinElmer, Greenville, SC, USA) 
in a 96 flat well plate. 100~l Phosphate buffer Saline (PBS) with 0.05% 
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tween20 was added, shaken for 2 minutes and eluted overnight at 4°C. DBS 
eluates were shaken for 2 min and 25/Jl was transferred to a clean 96 U well 
plate. 25/Jl specimen diluent was added, mixed thoroughly and 25/Jl was 
transferred to a second column. 25/Jl sensitized or unsensitized particles 
were added and agglutination was read after 2 hours incubation. Results 
were read independently by two technicians. 
HIV testing 
An Enzyme Immunoassay (EIA,) Vironostika HIV EIA (BioMerieux, France), was 
used to review the HIV POCT results. The EIA was performed as described by 
the Center for Disease Control and Prevention (CDC) (Vironostika protocol) 
(355). 
Proficiency panel results 
For quality assurance purposes, various measures were taken at clinic leveL 
With every new syphilis POCT lot, a known positive and negative was tested at 
the clinic. Additionally, syphilis proficiency panels were made and regularly 
brought to clinics to assess the HCW performance. The syphilis proficiency 
panels consisted of four dried tubes samples (DTS) as described previously 
(356). Briefly, DTS samples were made in the laboratory by drying aliquots 
of known positive and negative sera in small tubes and panels were sent to 
the clinics. The proficiency panels were sent to the clinics from July 2010 till 
January 2011 every month. The proficiency panels consisted of four dried 
tube specimens with known serostatus and changing number of positive 
and negative samples. At the clinic, HCWs reconstituted the DTS with PBS-
tween20 buffer and the reconstituted serum was used to test with syphilis 
POCT. Results were recorded and sent back to the laboratory. 
Statistical analysis 
Double data entry into Epi-info 3.5.3 (CDC, Atlanta, USA) was applied and 
data was analysed in -Stat912 (Stata Corp, Texas, USA). Data was analysed 
using McNemar ChP to assess agreement of results from different tests. POCT 
results were categorised into 4 groups and coded 1-4; true positive, true 
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negative, false positive, and false negative, to compare the false negative 
and false positive results separately to the correctly concordant results. 
Multinomial logistic regression was used to obtain relative risk ratios (RR) 
and adjusted for clinic, month, quality of DBS samples, and HIV test result 
to obtain adjusted relative risk ratios (ARR). Likelihood ratio tests (LRT) and 
95% confidence intervals (95% CI) were used to assess the significance of 
the association. 
Results 
DBS as QA method 
To evaluate the implementation of the QA method across the ten antenatal 
care clinics (ANC), the quality of DBS samples was reviewed. In total, 
2,341 samples were collected. Of these samples, 140 samples (6.07%) 
were excluded due to invalid syphilis POCT or TPPA test result (e.g. TPPA 
indeterminate or no POCT result) (124 samples), missing forms (10 samples), 
or the DBS sample was unusable (6 samples), either because of fungal 
growth or because it did not contain enough blood to obtain at least one 
6mm punch. Of the remaining 2,201 cards, containing 11,005~spots, 10,179 
(92.5%) were correctly spotted. Of the 7.5% incorrect spots, 356 spots 
(3.2 0/0) were empty. 
The quality of testing at Tanzanian clinics 
HIV and syphilis tests are routinely performed as part of the ANC services 
provided to pregnant women visiting these clinics. Due to a prolonged stock-
out of HIV POCT during the study period, many women (55.8%) were not 
screened for HIV while still receiving a syphilis test (Table 6.2). 
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Table 6.2: Samples collected per clinic and proficiency panel results per clinic. 
POCT ~erformed ~er clinic Proficienc!l ~anel results 
Number of Number of last 3 overall 
Clinic Clinic t!l~e HIV tests s!l~hilis tests months'f( (7months) 
1 District referral 272 422 100°A> 86°A> 
hospital 
2 Dispensary 13 109 100% 89% 
3 Dispensary 45 71 100°A> 86°A> 
4 Dispensary 72 172 100% 88% 
5 Dispensary 15 113 100°A> 90°A> 
6 Dispensary 24 150 100% 93% 
7 Health Centre 84 337 100% 79°A> 
8 Health Centre 257 258 100% 92% 
9 Health Centre 25 283 100% 64% 
10 Health Centre 165 286 100% 95% 
Total 972 2201 100% 86% 
"' last 3 months of proficiency panel results (November - January 2011) 
Out of the 2201 samples included in this study, 972 (44.2%) had recorded 
HIV test results. In total, 43 patients (4.4%) were identified as positive by SO 
Bioline HIV paCT of which 30 were retested by Determine HIV paCT as part 
of the national testing algorithm. All Determine tests confirmed HIV positiv-
ity. It is unclear whether the 13 positives not confirmed by a second paCT 
(Determine) were identified as H IV positive or negative and they were there-
fore excluded from further analysis. Of the 30 positive samples, 28 (93%) 
were positive by DBS tests, 1 was negative and 1 sample could not be tested 
due to insufficient material for confirmatory testing. 929 (99.7%) samples 
were HIV paCT negative of which 3 (0.3%) were positive by DBS tests. 
Out of 2201 DBS samples collected, 130 (5.9%) were positive by syphilis 
paCT and 202 (9.2%) were positive by DBS TPPA. In total, 2012 samples 
were negative by syphilis paCT and 1999 were negative for DBS TPPA. The 
concordance of positive syphilis tests varied between clinics, ranging from 
. 
38% - 89% with an average of 64% (median 70%) (Figure 6.1). The con-
cordance of negative samples between both methods varied from 93% to 
99% , with an average of 97% (Figure 6.1 and Figure 6.2). Two clinics (clinic 
2 and 7) performed significantly different from the other clinics in the con-
cordance of syphilis results (P< 0.05); cli nic 2 performed significantly better 
and clinic 7 significantly worse than the other clinics (Figure 6.1). Compared 
to the district referral hospital, patients visiting clinic 2 had a Relative Risk 
of 3.7 for a false positive result (AOR=3.7, p <0.05). 
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Figure 6.1: Percentage of positive concordance of syphilis POCT per clinic 
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Figure 6.2: Percentage of negative concordance of syphilis POCT per clinic 
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No remedial training for POCT testing or DBS collection was given during 
the study period. To evaluate the performance of the clinics over time, 
January and August, the months when the largest number of samples was 
collected, were compared. There was no statistically significant difference in 
concordance of POCT and laboratory tests (ARR=0.55 7, P >0.05) between the 
two months. This finding suggests that the clinics did not perform differently 
at the beginning or at the end of the study. The quality of DBS cards had no 
effect on the proportion of discordant POCT and DBS TPPA results (likelihood 
chP ratio = 0.346, P= 0.556). 
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Figure 6.3: Syphilis POCT results evaluated against DBS as reference method 
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The table provides the number of syphilis POCTs performed for each clin ic. The 4 categories; 
positive, false positive, negative, false negative POCT results were based on DBS TPPA 
results. In the figure, percentages are based on the total number of samples collected per 
clinic. 
Hops = Hospital, Disp= Dispensary, HC= Health centre. Pos = positive, Neg= Negative 
Proficiency panel results 
To evaluate the performance of the QA method to detect underperforming 
clinics, we compared our results with those obtained using syphilis 
proficiency panels. All clinics scored 100% during November till January 
2011 . The proficiency results are given in Table 6.2. During the 7 months 
when proficiency panels were performed, clinic 9 scored the poorest with 
an average of 64% correct, while obtaining good performance in our QA. 
Clinic 7 scored 79% correct in the proficiency panels while having a poor 
performance by our QA. The proficiency panel results did not correlate well 
with the results found by our QA method. 
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Discussion 
In this study, DBS proved useful as a QA method for syphilis and HIV POCT 
to monitor the quality of testing performed by HCW as part of routine ANC 
services in Tanzania. The QA method was easily implemented by HCW 
under routine conditions. Although 92.5% of the samples collected by the 
clinics were of good quality, humidity remained a concern. Humidity control 
is essential to preserve antibody and "antigens stored on DBS samples and 
to prevent growth of mould. Storage of desiccants at the clinics for several 
months proved difficult as they became humid, especially during the 
rainy season. More suitable containers with an airtight lid should be used. 
Additionally, long term storage (e.g. more than 4 weeks) at clinics should 
be prevented as this potentially could lead to loss of samples or increase 
risks of unfavourable storage conditions that could lead to degradation of 
antibodies or antigen (23). 
This study showed the possibility to seamlessly integrate HIV and syphilis 
POCT quality assurance, making it possible to have o'ne QA method for pre-
venting mother-to-child transmission of HIV services. 
The DBS method has advantages over proficiency panels as this method 
gives insight into the quality of testing during routine patient services. Pro-
ficiency panel samples are tested by HCW with the knowledge that they 
are being monitored and only contain four samples. As only one proficiency 
panel is sent out to every clinic, only one HCW is evaluated while with DBS 
QA, all HCWs are included in the QA procedure. These reasons could poten-
tially affect the proficiency panel result and could cause misinterpretation 
of the actual testing quality during routine patient services. 
The overall performance of the 10 clinics for syphilis POCT was lower than 
the manufacturer's claim, although .in agreement with earlier evaluations in 
Tanzania that found a sensitivity of 59.6% when using whole blood, com-
pared to TPP.\ using plasma (332) (chapter 5). The low POCT performance 
should be interpreted with caution as differentiation cannot be made be-
tween discordant test resul~, and incorrect interpretation or recording of the 
results by HCW. Worker turnover may be one of the reasons for low perfor-
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mance as the replacement worker may not have been properly trained. The 
strength of this study is that the QA method can be evaluated continuously 
under routine clinical conditions. Because of this, the sample quality can be 
influenced by, for example, environmental influences during incorrect stor-
age at the clinic or inter and national transportation of the kits. Based on our 
results, the quality of testing varied significantly between the ten clinics, 
even though all clinics used the same" syphilis POeT lots. The hospital and 
dispensaries performed better than the health centres when using DBS as 
reference method. These QA results can be used to identify clinics where 
remedial training in the performance of syphilis POeTs is required. 
Unfortunately, it was not feasible to monitor the costs of this QA method. 
Although the process time in the laboratory was relatively quick, this QA 
method can be more costly than, for example, the use of proficiency panels. 
By combining this QA for multiple infectious diseases as we did for HIV and 
syphilis, the economies of scope would limit the QA costs compared to set-
ting up two independent QA methods. 
To use this QA method in practice, the number of samples that should be 
collected per clinic depends on the setting. The poeT performance (e.g. sen-
sitivity and specificity), incidence and prevalence of the infectious disease, 
robustness of the test outcome, staff turnover, as well as past QA results 
need to be taken into account in determining the number of samples that 
are required to obtain good insight in quality of POeT at the clinics (357). 
Conclusion 
To the authors' knowledge, this is the first paper describing the 
implementation of DBS samples as QA method for HIV and syphilis POeT. The 
key findings of our work suggest the necessity for stringent quality control 
of POeT as the quality of testing varied significantly between clinics. On 
average, the concordance of positive samples was low. The DBS QA method 
,'" 
potentially provid,es a better solution to assure the quality of POeT testing, 
in comparison to proficiency panels in Africa. The QA method evaluated in 
this study could be easily ro'ued out in developing countries to improve and 
assure the quality of POeT testing. 
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Chapter 7 
7 Development of a surveillance method for 
the causes of fever in children 
As Chapters 4,5 and 6 answered objective 2, this Chapter aims to provide an 
answer to objective 3. The potential use of DBS to improve syndromic man-
agement by surveillance of infectious diseases is assessed in the context of 
febrile children. 
7.1 INTRODUCTION 
Fever is one of the most common presenting symptoms in children. Fever 
in children can be classified into three broad categories, although overlap 
does exist. The first group is acute fever with an obvious focus, such as: 
respiratory infections, childhood exanthems, septic arthritis, meningitis, 
hepatitis, encephalitis, and enteric infections. The second, more complex, 
category is acute fever with nonspecific localizing signs. The last category is 
chronic fever with no clear pathogenic cause or diagnosis, despite adequate 
investigation. 
Distinguishing between benign and serious causes of fever in young chil-
dren is worrisome for health care workers all over the world. The differentia-
tion between viral infection and "occult bacteremia" (clinically significant 
presence of bacteria in the blood stream) is the most important distinction 
that mostly relies on laboratory tests. The great range of possible causes and 
frequent lack of laboratory tests forces health care workers in developing 
countries to start treatment without a clear clinico-pathological foundation. 
This project focuses on acute fever without localised signs since this is a 
problem affecting small children under ten years of age and very heavily 
depends on laboratory diagnostics to determine the causative agent. 
To analyse the causes of fever out~ide urban areas where it is not possible 
to collect and analyse blood samples, different approaches are needed that 
do not demarld traditional whole blood collection and analysis. 
The need for an easily_ collected sample method in combination with the 
ability to detect life threate'ning pathogens could provide the essential in-
formation to determine the prevalence, and seasonal characteristi~,s of the 
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specific causes of fever and associated deaths. This method could provide 
information for evidence based policy and treatment guidelines. 
To develop a surveillance method close to the given characteristics described 
above, the aim was to investigate the diagnostic accuracy of DBS for the col-
lection of whole blood. Real-Time PCR was selected as detection method 
because it is fast, allows detection of. multiple targets in one reaction (e.g. 
multiplex), is sensitive, specific, and can be performed on any Real-Time PCR 
machine with minimal adjustments. To obtain the highest sensitivity, priority 
was given to validate monoplex PCRs at this stage of the proof-of-concept 
study, before combining PCR assays into one reaction. By performing as-
says independently, every assay can be optimised individually to obtain the 
highest sensitivity. Multiplex PCR assays are complex to develop as primers 
and probes could have different optimal temperature requirements, binding 
between primers and probes could occur, affecting the performance of the 
PCR assays. At this stage, preference was given to Taqman assays, as these 
are a preferable option for mUltiplexing. 
7.1.1 AIM 
;rhe aim of this study was to evaluate the feasibility of using DBS for the 
detection of life-threatening causes of fever in children. The methodology 
could be used by organisations and countries to implement a surveillance 
methodology. 
7.1.2 OBJECTIVES 
1. The possibility of a DBS based surveillance system for fever related 
illnesses in children was assessed by the following sub-objectives; . 
a. To develop a method for detection of up to six pathogens on DBS 
b. To combine the detection methods into one streamlined process 
c. To perform an initial validation of the method with spiked and 
clinical samples 
d. To perform pilot studies in rural health care facilities 
148 
~: ).' 
. ~:. 
( .. 
,. 
.. ' 
~ 
Z1.3 OUTLINE 
To establish the possibility of a surveillance system as described above, 
the study took place at three locations: the development, experiments, and 
testing were performed in Leiden Cytology and Pathology Laboratory, in 
The Netherlands, and two field centres, one in Laos which provided already 
collected samples, and one field centre in Peru where the surveillance 
method was implemented. 
Most attention was. paid to the feasibility of the implementation of the 
method, collection of samples, extraction of nucleic acids, and detection of 
pathogens. Due to the technical nature of this laboratory based project, as-
pects as finances and public health impacts were not measured due to time 
and financial constraints. 
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7.2 MATERIAL AND METHODS 
Z2.1 PATHOGEN SELECTION 
The study focused on acute fever affecting children under ten years old. 
Pathogens were selected based on consultations of medical textbooks and 
journals, and on discussions held with various researchers and experienced 
clinicians who were active in one of o.ur research locations. Feasibility with 
regard to the technical aspects of detecting the pathogens was also been 
taken into consideration. A final selection was made that fitted both the 
clinical criteria and technical feasibility. 
As pathogens have different transmission routes and abilities to spread 
through the human body during infection, the ability to detect the pathogen 
by PCR heavily depends on pathogenic characteristics. Careful attention was 
therefore given to the selection of potentially suitable pathogens. 
The criteria to select the pathogens were developed after discussions with 
researchers and experts at the London School of Hygiene and Tropical Medi-
cine. A pathogen was considered eligible if the following criteria were met: 
• Pathogen should cause fever in children 
Pathogen should be clinically important e.g. life threatening 
• Pathogen should be detectable in blood 
• Pathogen should be detectable by PCR 
• Pathogens should be detectable during acute fever stage 
• Pathogen should be potentially detectable in a drop of blood 
Based on the list above, a large selection of pathogens could be included. 
To limit the selection, pathogens were reviewed based on prevalence at our 
research sites. The geographical distribution of pathogens was to some ex-
tent affecting the selection criteria as positive materials had to be obtain-
able within our collaborative network. The following pathogens were more 
....:> 
closely reviewed: , 
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Table 7.1: Details of selected pathogens 
Pathogen 
PLasmodium 
Dengue types 1-4 
Rickettsia 
typhi, Orienta 
tsustsugamushi 
Leptospira 
pathogenic species 
Chikungunya 
Bartonella 
bacilliformis 
Type 
protozoa 
virus 
bacteria 
bacteria 
virus 
bacteria 
Disease 
malaria 
dengue 
murine and scrub 
typhus 
Vector/transmission route 
Mosquito 
Mosquito 
Fleas - murine typhus 
Mites- scrub typhus 
leptospirosis/ Weil's Water, food - urine/semen, 
disease . animals 
chikungunya Mosquito 
bartonellosis/ oroya Sand flies 
fever/ Carrion's 
disease 
Although responsible for large epidemics, chikungunya virus is not usually 
life threatening to children. However, it would be potentially interesting to 
develop a suitable surveillance method, considering the recent outbreaks in 
Europe and South- East Asia (358). 
Z2.2 LITERATURE REVIEW 
A literature review was performed to assess the range and performance of 
peR based diagnostic methods on blood samples for pathogens related to 
acute fever with no localizing signs. The literature review was used to study 
pathogen load in blood, peR performance and to select preferred peR assays 
for our study. Pubmed was searched for suitable peR assays. The search 
strategy is given in Annex 10.7.1. 
Z2.3 ANALYSIS OF peR ASSAYS 
After the selection of potential methods from the literature, this study 
analysed the peR assays to determine the theoretical capabilities of the 
assay before trying different assays in the laboratory. 
Basic local alignment search tool (BLAST) was used as first analysis step 
(www.ncbLnlm.nih.gov/BLAST/). By entering the nucleotides of the primers 
or probe, BLAST reveals which organism genomes match the nucleotides. 
After BLAST, primer details were analysed by looking into homo I hetero-
, 
dimer capabilities of the primers. For this, we used an engine called; ITO 
primer (359). 
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The final analysis step was primer and probe alignment (Bio Edit sequence 
alignment editor software). The alignment results and the type of assay 
made up the final calL Once the assays were selected, laboratory tests were 
initiated. This process is described in Annex 10.7.2. 
To determine the best PCR assay for a pathogen, a selection of pathogen 
isolates of high concentration were ust;d for the initial comparison of assays. 
All preliminary experiments were performed on a Roche LightCycler 1.5 PCR 
machine (Roche Diagnostics, Basel, Switzerland). Melting curve analysis and 
4% agarose gel electrophoresis (E-gel, Agarose gel, Invitrogen, UK) were 
used to determine specificity and primer-dimer susceptibility. Additionally, 
the performances of other primers targeting the same pathogen were com-
pared by melt curve and DNA product analysis. After the probe was ordered, 
the laboratory steps as indicated above were repeated to visualise the bind-
ing of the probe and to determine whether the melt curve had the expected 
temperature. 
Z2.4 ANALYSIS OF peR ASSAYS IN THE LABORATORY 
Strains were obtained to aid the PCR assay development and"to compare 
the performance of assays against each other. Strains were provided by the 
Royal tropical institute (KIT) Amsterdam, The Netherlands, LSHTM, Institute of 
Animal Hygiene and Veterinary Public Health, Germany, School of Veterinary 
Science, Leahurst Campus, University of Liverpool, United Kingdom and 
Mahosot Hospital, Vientiane, Lao People Democratic Republic (Laos) (Table 
7.2). 
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Table 7.2: List of species and strains used during this project 
Strain 
Plasmodium vivax 
Plasmodium falciparum 
Plasmodium ovale 
Plasmodium ovale-mutant 
Plasmodium malariae 
Bartonella bacilliformis 
B.bacilliformis NCTC12135 
B.bacilliformis 
B.bacilliformis 
B. bacilliform is 
Orientia tsutsugamushi 
Rickettsia typhi 
Leptospira interrogans 
Leptospira santarosai 
Leptospira weilli 
Leptospira kirschneri 
Leptospira meyeri 
Chikungunya 
Dengue 1 cDNA 
Dengue 2 cDNA 
Dengue 3 cDNA 
Dengue 4 cDNA 
Origin 
LSHTM 
LSHTM 
LSHTM 
LSHTM 
LSHTM 
University of Liverpool 
Health Protection Agency, UK 
University of Liverpool 
University of Liverpool 
University of Liverpool 
Mahosot Hospital, Laqs 
Mahosot Hospital, Laos 
KIT Amsterdam 
KIT Amsterdam 
KIT Amsterdam 
KIT Amsterdam 
KIT Amsterdam 
Animal hygiene and Vet. Germany 
KIT Amsterdam 
KIT Amsterdam 
KIT Amsterdam 
KIT Amsterdam 
The PCR assays were optimised by trying different primer and probe 
concentrations. Once the optimal concentrations were identified, pathogen 
concentration ranges were used to review the performance of the assay. If 
necessary, another substitute PCR was chosen at this stage. 
Plasmid inserts were developed and ordered for the various pathogens in 
order to determine limits of detection, PCR performance, efficiency calcula-
tions, positive control and functions as positive DNA sequence for spiking 
blood samples. Plasmids were made and ordered by Genscript, USA. All se-
quences were inserted into pUC57 with EcoRV and protective bases were 
added to both ends. The following plasmids were based on the alignments 
obtained in the previous step. The plasmid sequences that were used can be 
found in Annex 10.7.3. 
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The following plasmids were developed: 
Dengue types 1,2,3, and 4 
Leptospira interrogans, L.weilli, L.santarosai, L. kirschneri, and L. meyeri 
PLasmodium vivax, P. maLariae, P. ovaLe, P. JaLciparum 
Rickettsia typhi 
Orientia tsutsugamushi 
B.bacillijormis, mutant 1,2, and 1 +2 combination 
Chikungunya 
The plasmids were eluted in Trisl0 EDTA buffer and concentration series 
were made with Nucleic Acid buffer till 10-2 concentrations per ~l. The 
concentrations of the plasmids were converted to number of copies by using 
Avogadro's number (6.022~·( 1023 ) employing this calculation: 
Copies = X ng/~l ~.( Avogadro's number / (length of basepairs ~.( 1.109 ~'(mole 
bp). 
PCR mastermix buffers were tested and compared to each other by running 
the same samples twice. We have tested the Quantitect SYBR green buf-
fer (Qiagen, Hilden, Germany), Fast start universal SYBR green (Roche, Basel, 
Switzerland), Lightcycler 480 mix (Roche, Basel, Switzerland), multiplex PCR 
kit (Qiagen, Hilden, Germany) and the quantitect virus kit (Qiagen, Hilden, 
Germany). 
All tests were performed at 50~l reaction volume instead of the more com-
mon 20 or 25~l reaction volume on the LightCycler 480 (Roche) (LC480). 
This was done to increase the detection limit and the potential for detecting 
the pathogens. 
PCR efficiency is an overall indicator of the PCR run conditions by combin-
ing the quality of the mastermix, primer and probe conditions, and sample 
quality. A PC,~ effiCiency is expressed on a scale from 0 to 2, of which a 2 
indicates a perfect PCR amplification efficiency (by every cycle the DNA is 
copied 2 times) and a P-CR efficiency of 0 indicates the PCR did not do any-
thing (by every cycle the DNA is copied 0 times). To summarise, we applied 
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the rule of thumb to all PCR assays that when a PCR obtains an efficiency of 
2, with a 10% lower value acceptance, we would not further optimise the 
assay. 
Z2.5 DBS VALIDATION 
Samples were spiked with blood, spotted onto filter paper with various 
concentrations of plasmids to determine the performance of the PCR in 
combination with DBS samples. Different spiking methods were applied 
to determine which would produce the least variability in the results. The 
three methods evaluated were (1) add plasmids and dilute blood, (2) add 
diluted plasmids to whole blood, and (3) add plasmids first, allow the cards 
to dry and then add whole blood to the filter paper. Different DBS extraction 
methods were compared within our laboratory. Different punching methods 
were applied among which scissors, hand punch and automated punch 
machine. Cleaning of the manual punches were done by dipping the punch 
into "RNAse away" solutions that contain nuclease 'enzymes that degrade 
DNA and RNA, followed by dipping into 96% alcohol and dried by punching 
through clean sheets of filter paper. 
Every laboratory experiment was performed with a positive and negative 
control and performed in duplicate or quadruplicate. 
Z2.6 SEQUENCING 
To assess the specificity of the PCR assay, B.bacilliformis positives where 
sequenced. As our PCR amplifies a small segment (105bp), primers developed 
by Garcia-Esteban et al. were used for sequencing (360). PCR results were 
purified by enzymatic treatment of Exonuclease 1 (exol) and Alkaline 
Phosphatase (AP) both produced by ABI (ABI research, New York, USA). 5/Jl 
PCR product and 5/Jl mix (3.35/Jl H20, o.5/Jl lOx AP dilution buffer, 0.15/Jl 
Exol and l/Jl~AP) were incubated for 60 minutes (min) at 37°C, 15 min at 
720C. Cycle sequencing reaction was performed according to manufacturer's 
instructions (Abi BigDye V3.1, 10/Jl reactions). The 96 well plates were 
cleaned by ethanol precipitation and a mixture (3/Jl 3M NaOAc, 62.5/Jl 
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absolute ethanol and 24.5~l H20) was added to 10~l sample. Plates were 
stored on ice for 20 mins, centrifuged at 3000g for 30 min and supernatant 
was discarded. 150~l of 70% ethanol was added and centrifuged at 3000g 
for 10 min. Supernatant was discarded and plates were left in the dark for 
25 min. 10~l Hi-Di formamide was added to each sample and plates were 
loaded into the ABI sequencer (ABI 3730) (Applied Biosystems, Carlsbad, 
USA). Sequence data was analysed in Geneious basic v.5.6.4, (Geneious, 
Biomatters, Auckland, New Zealand). 
Z2.7 EXTRACTION STUDY 
The generous donation of FTAelute filter paper from GE healthcare for this 
project gave us the opportunity to work with these cards. The Lao study 
site was collecting DBS from patients with suspected typhus on FTAelute 
filter paper cards si.nce 2010. As 100% cellulose filter papers (Whatman 
903 or PerkinElmer 226) are commonly used in the detection of infectious 
diseases, an extraction study was performed to review which filter paper 
and extraction method would be preferable. 
Three different types of cards and four extraction methods were compared. 
The M48 biorobot (MagAttract DNA kit Qiagen, Hilden, Germany), the blood 
DNA minikit spin columns (Qiagen, Hilden, Germany), Chelex (Sigma Aldrich, 
St Louis, USA), and the specific H20 extraction for FTAelute cards (Whatman 
GE healthcare, USA). Additionally to the FTAelute cards, the 903 filter paper 
cards (Whatman GE healthcare, USA) were used as well as the PerkinElmer 
cards 226 (PerkinElmer, Waltham, USA). An overview can be seen in Table 
7.3. 
Table 7.3: Provides an overview of extraction methods and filter paper cards 
used for the extraction study. 
. Extraction methods 
M48 Blood DNA 
Filter ~a~er cards biorobot minikit Chelex H2 o 
Whatman 903 x x x 
PerkinElmer 226 x x x 
Whatman FTAelute x 
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Filter cards 903 and 226 were spotted with 20iJl buffer containing vari-
ous concentrations of plasmids. Cards were dried and 50iJl of fresh EDTA 
whole blood was added. Unfortunately, the same protocol led to incorrect 
extraction for the FTAelute filter paper samples. As the FTAelute filter pa-
per itself contains impregnated lysis buffer, it became active when spotting 
the plasmids and was already dissolved when adding whole blood, leading 
to reduced lysis activity when whole "blood was spotted. This affected the 
extraction, as the eluate contained hemoglobin, which is a PCR inhibitor. 
Filter paper where therefore spiked with 40iJl whole blood containing the 
same amount of plasmids, per spot. The concentration of plasmids was kept 
the same for all types of filter papers. To make the study comparable, 6mm 
punch and final elution of 100iJl was used for each extraction method. PCR 
input volume was the same for all types of filter paper and types of extrac-
tion platforms. The concentration that was added to the filter papers ranged 
from 4.5 c/iJl of extracted sample to 450,000 c/iJl. The measure of "cl iJl 
extracted sample" allows easy comparison between methods. 
Z2.B CLINICAL VALIDATION 
The initial protocol was to establish a sample collection method in South-East 
Asia and allow paired testing on human sera or blood cultures to function 
as a reference standard for our surveillance detection methodology. Due to 
our South-East Asian collaborators' interests in this project and possibility 
of collaboration, we were able to obtain samples that were already collected 
during 2008-2010 and were collected from very well-defined clinically 
diagnosed patients. Obtaining ethical approval (in Ministry of Health, Laos 
and Oxford University, UK), setting up the study and enrolling patients had 
already been done by the collaborator. The reference PCR assays that were 
performed on the samples origin~ting from Laos where based on assays 
published in peer-reviewed journals; malaria PCR performed on whole 
blood (184),~ dengue PCR performed on serum (361), R.typhi (362) and 
a.tsutsugamushi where performed on buffy coat blood (363) and Leptospira 
PCR was performed on whole blood samples (364). 
" 
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Additionally, samples from the malaria reference center of the United King-
dom, located at the London School of Hygiene and Tropical Medicine, were 
used and analyzed. 
Variability caused by using DBS and laboratory methods was addressed in 
detail throughout the study during the evaluation and selection of assays 
and comparison of ext'raction method~. 
Z2.9 QUALITY ASSURANCE 
For QA and control measures, human housekeeping genes for both DNA 
and RNA were used. l3-actin for DNA control and GAPDH for RNA control 
were used. Additionally a quality check for DBS was developed based on the 
WHO guidelines (128). The DBS samples from Laos and Peru were visually 
checked and quality of cards was recorded per spot. Five criteria were used 
to categorise the quality of the spots (Annex 10.6). The humidity and overall 
quality of the card were recorded as welL Data was entered into a specially 
designed Epi-info file (CDC, Atlanta), to allow an easy linkage between PCR 
results and DBS quality. The record files developed for the studies performed 
in this thesis, have been posted online (354). 
A DNA control was needed to support the evaluation of DBS samples. A hu-
man housekeeping gene was selected (l3-actin) from the literature and the 
assay was performed on the LC480 (365). A sample needs to be positive for 
l3-actin and have a lower cycle point (cp) value than 35. This cp value was 
chosen as a minimum due to the unlikelihood of finding pathogenic DNA in 
samples where there is almost no human DNA. A low level of human DNA 
indicates that the run or extraction has failed, or that not enough blood was 
spotted on the card. 
To control the input volume of RNA, an assay targeting the human house-
keeping gene encoding GAPDH was used (366). We applied the same rule 
.~ 
of thumb as for the DNA human control that samples should have a lower 
cp value of 35. Well-pr~pared samples were used to determine the normal 
concentration of GAPDH to 'assure that a cp of 35 is acceptable. 
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7.2.10 IMPLEMENTATION OF THE SURVEILLANCE METHOD IN PERU 
The surveillance methodology was introduced in health clinics located in 
rural sites in Caraz, Ancash in Peru within the context of child health care 
services offered to patients with fever. All children with fever and under the 
age of 10 were eligible to participate in this study. Written consent of the 
parents or guardians was obtained before blood samples were collected. 
While patients at the study sites in Caraz were enrolled in 2010, an additional 
two healthcare clinics in Quillo and Yautan were included in 2011. Ethical 
approval was obtained from the ethical committees at the London School of 
Hygiene and Tropical Medicine and Universidad Peruana Cayetano Heredia. 
7.2.11 BARTONELLA 
This study was a unique opportunityto investigate detection of B.bacilliformis 
using DBS. B.bacilliformis is a bacterium that causes severe febrile episodes 
with often fatal outcomes. The bacterium enters the red blood cells and is 
capable of infecting up to 80-90% of all red blood cells, therefore causing 
acute anemia (43). If the infection becomes chronic it causes severe skin 
eruptions but the mortality rate decreases. It has been noted that the 
bacteria cause an epidemic every 5-7 years in young children in Caraz region, 
Peru (N.5olorzano, personal communication). To increase the possibility of 
detecting B.bacilliformis, we looked into all options to ensure our timing and 
methodology would be correct. In order to increase the likelihood of finding 
an epidemic, we initiated the following; 
• Contacted the local and national surveillance authorities 
• Determined best study sites to collect samples 
• Located where earlier outbreaks have been found and analyzed 
• Chose sites, based on past experience and outbreaks were first 
reported 
• Chose ~lhe appropriate time of the year (rainy season) 
• Took into account the likelihood of a 5 or 7 year interval between 
outbreaks. 
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Z2.12 STUDY PROCEDURES IN PERU 
At the beginning of the study, training was given to medical staff on how 
to obtain and store DBS samples correctly. The CDC guidelines regarding 
spotting, storing and mailing of DBS were used throughout the training 
(367). Stickers with specimen codes were placed on the DBS and on the 
patient's form before DBS were spotted with whole blood. DBS were spotted 
by holding finger or heel-prick blood against the filter paper. If venepuncture 
was necessary for other diagnostic tests, no finger pricks were performed but 
a small volume of venous blood was obtained to spot the DBS by pipette. 
Finger or heel prick were avoided whenever possible to reduce potential 
inconvenience for the child. 
DBS racks were provided for overnight drying and in the morning the DBS 
samples were placed with two desiccants in a zip lock bag. The date, pa-
tient's number, and. diagnostic test results for serology, blood culture or 
other diagnostic results were recorded on a standard form, using patient 
stickers to link the form with the DBS samples. This form was also used to 
record patient's admission date, symptoms, onset of symptoms and dura-
tion, to' record variables that can influence the performance of. the surveil-
lance methodology. Additionally, the peR results and clinical findings were 
combined to enable a better view of the patients' health and interpretation 
of diagnostic results. ALL the forms and training documents were translated 
into national languages. A visit to the health facility was made to thank par-
ticipants, obtain feedback on any problems and feasibility of implementing 
DBS as a continuous surveillance method, were discussed. The samples were 
transported to Leiden Cytology and Pathology Laboratory, The Netherlands. 
7.2.13 STATISTICAL METHODS 
The variability of cp values obtained by comparing the different extraction 
methods in combination with different filter paper types were summarised 
,.» 
with box plots to ~isplay the median, 75 th and 25 th percentile and outliers of 
cp values. 
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To review the likelihood of being B.bacilliformis positive based on self- re-
ported symptoms, the symptoms were tested with Fischer ChP test between 
the positive and negative B.bacilliformis group. Symptoms with p-value <0.20 
were included for the binomial logistical regression modeL High correlation 
between the symptoms was anticipated due to the close nature of various 
febrile illnesses and clinical presentation, which limited further evaluations. 
Akaike information criterions were used to select the variables in the mul-
tivariate analysis; general malaise, vomiting and diarrhoea were excluded 
from further analysis as they are not needed according to the Akaike in-
formation criterions). The binomial logistical regression model was used to 
identify symptoms that give patients a high probability (odds) of having a 
B.bacilliformis infection. Statistical software Stata 12 was used for the box-
plots and statistical analysis. 
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7.3 RESULTS 
Z3.1 LITERATURE REVIEW 
Searches were performed to identify suitable peR tests for every pathogen 
except Malaria. The search strategy is given in Annex 10.7.1 
, 
Figure 7.1: Flow chart of literature study, divided by pathogen. Numbers 
represent excluded or included number of studies 
,------------------------- --------
Pubmed search 
Dengue: 307 
Rickettsia: 208 
leptospira: 162 
Chikungunya: 213 
Bartonella: 242 
Duplicate remova I 
Dengue: 72 
Rickettsia: 40 
leptospira:_32 
Chlkungunya: 32 
Bartonella: 81 
Not matching study critera based on abstract 
Dengue: 171 
Rickettsia: 141 
leptospira: 112 
Chikungunya: 154 
Bartonella: 143 
..--··~~f~";~~t av;ll~bl;~---l ---------- - ------ -- -- ------- _._---- ._--- -----_.- ._------------- -----. 
Dengue: 16 . 
Rickettsia : 12 ~I _ .......... 
Not matching study critera based on full text 
Dengue: 20 ~ 
leptospira: 7 
Chikungunya: 0 
Bartonella: 5 
Included studies 
Dengue: 28 
Rickettsia: 12 
leptospira: 11 
chlkungunya: 21 
Bartonella: 11 
Rickettsia :3 
leptospira: 0 
Chikungunya: 3 
Bartonella: 1 
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7.3.1.1 MaLaria 
No literature searches for malaria peR assays were conducted due to the vast 
experience with malaria peR at the schooL The primers advised by malaria 
experts of LSHTM were used. 
7.3.1.2 Dengue 
The performance of a peR assays greatly depends on the sample type and 
the timing of sample collection in relation to the patient's illness. Typically 
applied sample types for dengue detection include plasma (368), serum 
(369) and whole blood (370) or DBS samples (96). The sooner the sample 
was taken after the onset of symptoms appears to be of great importance 
for dengue detection (371). When a sample has been collected within 5 
days after the onset of symptoms, plasma or serum samples gave good peR 
results (371). Surprisingly, it appears that whole blood and DBS samples are 
more sensitive than plasma when collected after 5 days of fever (5, 95, 96, 
370). A reason for this could be that dengue targets white blood cells, but no 
definite answer has been given. 
The sensitivity of the peR assays varied greatly between reference methods 
used. One assay obtained a sensitivity of 30.7% compared to an IgM assay 
(372), while most peR assays performed on plasma samples detected 64% 
to 100% of dengue virus -positive samples (5,95,361,368,369,371-386). 
Most assays made use of anti-dengue IgM as reference (377, 387), serology 
(388, 389), or the assay developed by Lanciotti (390-393). Although no of-
ficial statements could be found, the nested peR developed by Lanciotti et 
oL. seems to be generally accepted as the gold standard. Specificity was in 
general high, ranging from 92% (394) to 100% (389). When the peR assay 
consisted of multiple primers, the sensitivity varied by dengue strain from 
64% for dengue 4 to 100% for dengue 1 (386). 
In general, the detection limits of most peR assays were excellent, ranging 
. ..;:, 
from 40 copies p~,r ml to 100 copies per ml of whole blood (395). A few 
studies looked into quantitation of viral loads, which were reported to be up 
to 106 or 107 c/ JJl (383, 396'). 
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7.3.1.3 Rickettsia 
Rickettsia are commonly divided amongst three groups; Spotted fever group 
(SFG), typhus (TG) and scrub typhus group (STG). SFG and TG are caused by 
various Rickettsia species, while STG is caused by Rickettsia tsutsugamushi 
which recently has been renamed to Orientia tsutsugamushi. One PCR primer 
pair that can detect both O. tsutsugamushi and Rickettsia spp have not 
been described. The PCRs that detect'all Rickettsia species, instead of only 
specific species, also detect species that are not harmful to humans and 
could potentially bias the results found when analysing clinical samples. 
The aim is to detect TG and STG, while SFG is of less importance for the 
development of the surveillance method in Laos, as recommended by 
experts who participated in the pathogen selection process. In Laos, TG (as 
R. typhi) and STG are the most important rickettsial pathogens (397). 
The various targets and PCRs developed for Rickettsia species indicate com-
plexity in detecting the pathogen in blood related products. The sensitivity 
obtained by studies varied from 14% to 100% (398~403). The sample sizes 
of most studies are relatively low (average of 80 samples). The bacterial load 
detected in buffy coats or in serum where low (100-1000 c/ml) (404). A study 
detected the highest bacterial load in serum between 9-12 days (103 till 107 
c/ml) (405). As for dengue, the sooner the samples are collected after the 
onset of fever, the higher the sensitivity. One paper suggested a completely 
different strategy of sample collection for O. tsutsugamushi. Within 5 days, 
the sensitivity was 0%, while between 9-12 days, the sensitivity went up 
to 100% (405). It will be extremely difficult to obtain high sensitivities with 
DBS since timing seems to be of great importance to obtain samples with 
high bacterial loads. It is unclear how exactly the pathogen bacterial load 
varies over time and how quickly it raises or declines over time. It seems 
that different types of sample materials (buffy coat, serum) influence the 
performance of the PCR assays. As O. tsutsugamushi is present in peripheral 
blood mononuclear cells, most assays used buffy coat samples while some 
used serum or EDTA blood (362, 363, 402, 406, 407). 
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7.3.1.4 Leptospira 
The sample type varied between studies; serum (408-410), buffy coat (411, 
412), whole blood (413), or unstated were used (364, 414). The amplified 
region as well as the assay method varied amongst the articles reviewed. 
Some assays only detected pathogenic species (406, 408) while some 
detected all types of Leptospira (413). Leptospira species are classified as 
pathogenic, indeterminate and saprophytic based on their potential effect 
on humans. Due to the diverse clinical manifestations, leptospirosis is highly 
underreported and is a major neglected tropical disease (415). 
Although the specificity in general was 95-100% for all assays, the sensitiv-
ity varied from 29% up to 100% (15 samples) (408, 415). The contribution 
of sample selection and the reference methodology is believed to be essen-
tial for these varying results. It has been noted that within the first week of 
fever it is easier to detect Leptospira but sensitivity decreases when samples 
were collected after 4 days (411,415). 
The detection limits of the peR assays according to the authors were good, 
ranging from 2 c/~l to 10 c/ ~l which indicate the peR works optimal (364, 
408, 412, 416). One assay was capable to detect 10 leptospires/mL blood 
" 
which was based on spiked samples and by using alive leptospires, not tak-
ing dead ones into account (408). Based on the limited data available, the 
amount of leptospires in blood will be low but there is a potential for being 
detectable by DBS. 
7.3.1.5 Chikungunya 
Serum and plasma samples were used to evaluate the performance of the 
peR assays (368, 417-424). Some authors did not use a reference method 
for their developed peR but used well-characterised panels (425, 426). 
The sensitivity and specificity of the assays were, if reported, 100% (419, 
425, 427). The detection limits of the assays were very sensitive, around 5 
copies/ peR reaction (419, 422). The viral load in plasma appeared to be 
~ 
at its highest in t~e first 5 days of infection, as viral loads reached above 
1 billion copies per mL_of blood (425). Detection of chikungunya in acute 
febrile cases with smaller volume samples would be reasonably easy to be 
detected, according to the literature. 
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7.3.1.6 BartoneLLa 
There are over 20 species of Bartonella of which 11 are known to cause 
disease in humans and animals. B. henselae is known to cause cat-scratch 
disease and various strains cause culture-negative endocarditis or trench 
fever. B.bacilliformis is believed to be the most deadly Bartonella, with a fatal 
outcome up to 88% during the acute phase for untreated patients (428). 
Our primary focus is B. bacilliform is. 
The search for suitable real-time peR assays was complicated and only two 
assays were real time (429, 430). Most assays · target multiple Bartonella 
species (430-433) or specifically B.bacilliformis (429,434,435). No data on 
bacterial load from clinical samples could be found in any of the selected 
articles. 
Z3.2 THEORETICAL DETECTION CAPABILITIES 
To review the detection capabilities of the surveillance method, the 
theoretical detection capabilities were evaluated first. The detection of 
these pathogens depends on various factors which can be divided into three 
categories as depicted in Table 7.4. 
Table 7.4: Variables influencing the performance of the surveillance method 
Variables listed in three categories 
Pathogen characteristics DBS samples Laboratory methods 
Quantity of pathogen in Correct collection of blood DBS volume for assay 
blood during infection (punch size) 
Time pathogen is present Blood quantity collected DNA/RNA isolation 
in blood efficiency from DBS elute 
Clinical presentation Preservation of DNA/RNA Quality of DNA/RNA 
(fever) and active infection isolated from sample 
Infection differences Elution efficiency of DNA/ Removal of PCR inhibitors 
between children or adults RNA out of blood 
Presence in plasma, serum, In-correct storage effects 
or blood cell components on DNA/RNA 
Gram negative or positive 
bacteria 
Target sequence (e.g. 
plasmid DNA) 
Isolated sample volume 
used for PCR 
PCR sensitivity 
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As noted in Table 7.4, various factors influence the sensitivity of the surveil-
lance method developed in this proof-of- principle study. As this study aims 
to review the possibility of the method, potential limiting factors should 
be identified and addressed beforehand. As noted in the literature review, 
pathogen details and specific characteristics during infection cannot be 
found for many pathogens during infection or presence in blood. 
Although most of these factors are discussed in Chapter 2 of this thesis, 
some factors are discussed in more detail below. The quantity as well as the 
period during infection of which pathogenic material is present in the blood, 
varies greatly per pathogen. In enteric fever, a few (1-10) bacteria per mL of 
whole blood are present, while for HIV there can be > million copies per mL 
(436). The limited data that is available for the selected pathogens is pri-
marily based on clinical samples from adults. As infections in children often 
present differently than in adults, this limits the usefulness of this data. For 
example, malaria can be asymptomatic and potentially causes more severe 
infections in children. While malaria and Bartonella 'bacilliformis infect red 
blood cells, dengue infects white blood cells. This influences the composi-
tion and quantity of pathogen materials when extracting DNA ,?r RNA from 
DBS samples instead of serum samples. As whole blood is applied centrally 
to the DBS spot, an uneven distribution of plasma and whole blood com-
pounds can be expected on the filter paper (see Chapter 2 for more detail). 
Additionally, the laboratory steps and storage of samples influence the sen-
sitivity of the assays applied. More details regarding these variables and 
information of using DBS samples can be found in Chapter 2. 
To gauge the detection limits when using DBS, we looked at HIV as many 
studies have investigated quantifying HIV viral load. Based on these results, 
the limit of detection seems to range between 800-2,000 copies/ml (Chap-
ter 3). As a detection limit for each of the pathogens has not been estab-
lished for DBS samples, we used this limit as a guide. 
To determine if the detection limit of DBS samples would be sufficient to 
detect pathogens within the first few days of infection, published pathogen 
" 
loads in blood were reviewed (Table 7.5). 
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Table 7.5: Pathogen load in blood given by copies per mL (c/mL) 
Pathogen 
Malaria 
Leptospira 
Dengue 
Rickettsia typhi 
Orientia tsutsugamushi 
B.baci lUformis 
Chikungunya 
Pathogen load in acute cases 
>105 c/ml 
103 c/ml 
>105 c/ml I 4.6log c/ml 
unknown 
104 c/ml in buffy coat blood 
unknown 
104 c/ml to 109 c/ml 
Reference 
(437) 
(438) 
(439) (440) 
(399) (404) 
(425) 
Variability between pathogens and patients are important. Based on the 
limited data available, it is likely that we could detect malaria spp, dengue, 
B.bacilliformis and chikungunya in patients during-acute infection. For malaria, 
it is known that the infection can be detected successfully with DBS samples 
(441). This has also been demonstrated for dengue (5, 95, 370). Leptospira 
will be more difficult to detect as it will be likely that clinical cases could be 
below our detection limits and would be missed. No publication regarding 
the quantitation for B.bacilliformis in clinical samples could be found but 
based on results of blood smears and qualitative peR assays, it is believed 
that acute cases could be detected with DBS (43, 44; 429). 
The ne~essity for buffy coat blood samples for Rickettsia spp. and O. tsutsuga-
mushi indicates that detection with normal whole blood would be difficult, if 
not highly unlikely. Buffy coat blood contains leukocytes and platelets and is 
obtained by centrifugation. After centrifugation, buffy coat blood accounts 
for less than 1% of the whole blood sample. Even though the pathogen load 
in buffy coat blood can be high (around 10,000 copies/ml), extrapolated to 
a non-centrifuged whole blood sample, the bacterial load will be very low. 
Even though it is difficult to obtain a reasonable sensitivity for R. typhi and 
O. tsutsugamushi, it would be a valuable effort to determine the feasibility, 
particularly due to the limited pathogen load data available. 
The detection of dengue by DBS samples will potentially allow detection of 
acute disease, but will not be sensitive when sampled before or after acute 
infection. As .loted, the dengue viral load can quickly drop after a few days 
of infection (372). This stresses the importance of accurate case definition, 
to correctly determine the s~nsitivity of an assay. 
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Unfortunately, it is not within reach of this proof-of-concept study to evalu-
ate the pathogen levels in blood of febrile children. Additionally, assess-
ment of the complex relationship of clinical presentation and bacterial/viral 
load in blood is not within reach of this study. 
Z3.3 LABORATORY ASSAY COMPARISON 
After the literature was read and summarised, the data were reviewed to 
find the most suitable peR assays. The peR assays were compared and 
analysed using BLAST searches, primers or probe. characteristic analysis, and 
the alignment of primers as discussed in paragraph 7.2.4. Details are given 
in Annex 10.7.2. Based on these criteria, we discontinued underperforming 
assays for Leptospira, dengue and rickettsial pathogens (363, 364, 375, 381, 
395, 405, 442). For malaria and chikungunya, no additional primers were 
evaluated as the primers of Mangold et al. and Laurent et al. performance 
fulfilled the criteria set in chapter 7.2.4. For B.bacilliformis, primers were 
developed in this study (Annex 10.7.2). 
Below is given an overview of the assays that were finally selected after 
evaluating multiple peR assays in the laboratory. The peR settirl'gs that were 
used are also given (Table 7.6). 
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Table 7.6: Overview of assays used in this study, including PCR settings. 
Target Assa~ C~cle conditions For Rev Pr Vol method mix 
MaLaria 18sRNA MangoLd et al. 95°(-105, ' 500 500 20 L(1.5 FastSTART DNA SYBR Green 
500 ( -55, (Roche) 
72°( -205 +meltcurve 
This study 95°( -105, 50°C -105, 72°C 500 500 50 LC480 FastSTART DNA SYBR Green 
-155 +meltcurve (Roche) 
.- ---. ---
Leptospira secY Ahmed etal. 95°(-55, 400 400 25 Bio-Rad iQTM SYBR Green Supermix 
54°( -55, (bio-Rad) 
72°( -155 +meltcurve 
..... - - ."-- - =--_--&_-- ---
This study 95°C - 105, 54°C -105, 72°C 400 400 50 LC480 FastSTART DNA SYBR Green 
-155 +meltcurve (Roche) 
R.typhi ompB Henry et al. 94°( -55, 200 200 300 25 Smart-Cycler Separate consumabLes n J 
600 ( -305 (Invitr:ogen) OJ 
-0 
r-t 
This study 95°C -155, 60CoC -455 400 400 200 50 LC480 LC480 mastermix (j) 
-." 
(Roche) -..j 
O.tustsu-gamushi Paris et al. 95°(-155, 200 200 20 Rotor-gene Quantim'ix easy (Biotools) 
GroEl 54°( -155, 72°(-205 t.n c 
/, 
"'"' 
+ meltcurve < (j) 
This study 95°C -105, 54°C -155, 72°C 200 200 50 LC480 FastSTART DNA SYBR Green OJ 
-205 +meltcurve (Roche) :J n 
B.bacilliformis ITS Garcia Esteban et al. 94°( -305, 64.3°( -60s, 72°( 400 400 100 50 ecogen Not reported (j) 0 
region* -90s -h 
-h 
This study 95°( -155, 60°C -60s 500 500 250 50 LC480 Quantitect virus kit (qiagen) (j) 0' 
.... 
(j) 
n 
::lJ 
~ C l/) 
-.....J (j) 
0 l/) 
~ 
-.....,J 
~ 
Target Assay Cycle conditions For 
Chikungunya Laurent et af. 60°C -30min, 95°C -lOs, 450 
3'UTR 60CoC -305 
Dengue 3'NC 
This study 50°C -20min, 94°C -155, 60°C 400 
-455 
Leparc Goffard et al. 500 ( -15min, 95°C -155, 60°C 200 
-455 
Rev Pr Vol 
150 150 100 
400 200 50 
200 100 25 
This study 50°C -20min, 94°C -155, 60°C 200 200 ·100 50 
-455 
For= forwar'd primer in nM, Rev = reverse primer in nM, prob = probe in nM, vol= volume in ~l. Mg = Magnesium 
"'primers targeted the hypervariable intergenic transcribed spacer (ITS) located between 165 and 235 rRNA genes. 
method 
LC2.0 
LC480 
rotor-gene 
LC480 
mix 
Taqman RNA amplification kit 
(applied biosystem) 
Quantitect virus kit (qiagen) 
superscript 3 (Invitrogen) 
Quantitect virus kit (qiagen) 
n 
-:::J 
Q., 
"D 
~ 
(1) 
'" 
lJ) 
c 
, 
< 
ro 
ru 
:::; 
r') 
(1) 
0 
-.., 
--t'\ 
ru 
u 
::J 
ro 
r') 
OJ 
C 
V1 
It) 
V1 
For dengue, 5 different assays have been tried and all were unsuccessful in 
detecting all4 types of dengue. 2 assays could not detect all types, 2 assays 
could not detect low concentrations to an acceptable level and the last one 
required considerable amount of adjusting before it could be used (361, 
375,377, 395).ln order to do this, plasmids have been ordered and different 
mixes, primer and probe concentrations have been used. Surprisingly this 
did not alter the behaviour of the assay at low concentrations of dengue, in 
which the curves transformed into straight 35 degree lines instead of the 
traditional curves. In the end, samples were sent for dengue PCR tests to KIT 
Amsterdam. The dengue PCR that was used by KIT, was published by Ment-
ing et aL. in 2011 (443). Except for dengue, all other assays were performed 
at LCPL laboratory in Leiden, The Netherlands. 
Z3.4 DETERMINE BEST peR MIXES 
We have tested different PCR buffers as Quantitect SYBR green buffer 
(Qiagen, Hilden, Germany), and Fast start universal SYBR green (Roche, 
Basel, Switzerland), Lightcycler 480 mix (Roche, Basel, Switserland), Qiagen 
multip~ex PCR kit and the Qiagen quantitect virus kit. The most striking 
difference in mix was found with the Quantitect SYBR green mastermix and 
the Roche Fast start universal SYBR green mix. The result obtained with the 
Qiagen SYBR green mastermix mix and Roche Fast start universal SYBR green 
mix is given below, indicating a better performance of the Roche Fast start 
universal SYBR green mix. The evaluation was performed with Leptospira 
PCR and various Leptospira species. 
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Figure 7.2: The performance of two PCR master mixes, above is Qiagen SYBR 
green master mix, below is Roche SYBR green mix. X-as is cycle number and 
horizontal fluorescent level per Leptospira pathogen. 
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Both runs were performed on the same day, same peR machine and same 
sample material. The poor performance of the Qiagen Quantitect SYBR green 
mastermix has been discussed with technical representatives of Qiagen and 
runs were repeated several times. The Qiagen kits were refunded due to the 
lack of any suitable explanation by Qiagen technicians. 
The same comparison was done for the SYBR green mix. We compared the 
Roche SYBR green faststart mix, initially developed for the Lightcycler 1 and 
2 series, and the Lightcycler 480 SYBR green mastermix. 
Figure 7.3: Comparison of two Roche PCR SYBR green master mixes with 
the same sample input and same primer concentrations. PCR cycle numbers 
horizontally and fluorescence are given vertically with various malaria DNA 
concentrations. 
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The SYBR green faststart mastermix performed better than the Ughtcycler 
480 SYBR green mastermix as lower cp values were obtained (Figure 7.3). 
Additionally, at lower pathogen concentrations the SYBR green faststart 
mastermix (lighter lines) was better in detecting low DNA concentrations. 
This has been tested with one other assay and gave comparable results. We 
therefore decided to perform all SYBR green assays with the SYBR green 
faststart mastermix and optimise the PCR primers with this mastermix. 
To optimise the PCR reaction for Taqman assays, the Qiagen quantitect virus 
kit and the Roche LC480 mix for the Taqman based assays were evaluated 
(Figure 7.4). 
Figure 7.4: Shows the comparison of Roche (blue) and Qiagen (red) master mixes 
for Taqman assays. Cycle number (horizontally) and fluorescence (vertically) are 
given with various B.bacilliformis DNA concentrations as sample. 
14 pI IIcall.n c ....... 
,----------- - --------------, 
10 
The figure shows that there is practically no difference between the Roche 
(dark lines) and the Qiagen mix (darker lines). At the lower concentrations, 
the Qiagen mix was more sensitive and showed positive results while the 
Roche became negative. It showed that the Qiagen mix was more sensitive 
for low conc~ntrations which were confirmed by agarose gel. Comparable 
results were found for other assays. This is primarily due to the high con-
centrated mix (5X) in comparison to the -Roche kit (2X). Because of this high 
ff 
concentration, a smaller volume is required for the mastermix which makes 
it possible to increase the patient sample volume used for the PCR reaction. 
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This potentially produces a greater sensitivity. Even though this mastermix 
was initially developed as a Reverse transcriptase, we decided to use this as-
say also for DNA targets to standardise the procedures as much as possible. 
7.3.5 peR EFFICIENCY 
As the final primer and probe concentrations as well as the peR mastermixes 
were determined, experiments to determine the peR efficiencies where 
performed. peR efficiency is an overall indicator of the peR run conditions 
by combining the quality of the peR machine, the mastermix, primer and 
probe conditions, and sample quality. A peR efficiency is expressed on a 
scale from 0 to 2, of which a 2 indicates a perfect peR amplification efficiency 
(by every cycle the DNA is copied 2 times) and a peR efficiency of 0 indicates 
the peR did not do anything (by every cycle the DNA is copied 0 times). 
The peR efficiency .calculation is based on two separate runs, both with 
quadruplex samples of 8 different concentrations with a ten-fold dilution 
step of plasmids. 
Table 7.7: peR efficiencies of the assays with different targets are given. 
PCRs 
Plasmodium vivax 
Plasmodium falciparum 
Plasmodium ovale 
Plasmodium malariae 
Bartonella bacilliformis 
PCR efficiency 
1.98 
1.97 
1.95 
1.89 
1.97 
Orientia tsutsugamushi 1.95 
Rickettsia typhi 1.99 
Leptospira interrogans 1.99 
Leptospira santarosai 1.95 
Leptospira weill1 1.95 
Leptospira kirschneri 1.96 
Leptospira meyeri 1.98 
PCR efficiency is a valuable measure of performance of a PCR assay. A value of 2 is optimal 
performance. 
Different species and strains (see Table 7.1 for details) were tested per peR 
assay as varie bility in efficiency can occur. 
175 
Chapter 7 - Sur'veillapce of febrile causes 
7.3.6 peR ASSAY AND DBS VALIDATION 
Since the efficiencies of the PCRs were within the acceptable range 
established at the beginning of the study, the sensitivities of the assays 
were determined by using plasmids with known concentrations. Every 
plasmid concentration was run 8 times and at least in two runs, giving the 
performance in Table 7.8. 
Table 7.8: Total of positive outcomes of 8 samples tested with different 
concentrations 
peR # of samples detected ,with different plasmid 
concentrations ~er I;!l 
103 102 101 1 10-1 10-2 
Plasmodium vivax 8/8 8/8 8/8 8/8 5/8 2/8 
Plasmodium falciparum 8/8 8/8 8/8 8/8 4/8 1/8 
Plasmodium ovale 8/8 8/8 8/8 8/8 6/8 0/8 
Plasmodium malariae 8/8 8/8 8/8 7/8 5/8 2/8 
Bartonella bacHliformis 8/8 8/8 8/8 8/8 6/~ 4/8 
Orientia tsutsugamushi 8/8 8/8 8/8 8/8 2/8 0/8 
Rickettsia typhi 8/8 8/8 8/8 8/8 8/8 0/8 
Leptospira interrogans 8/8 8/8 8/8 8/8 8/8 3/8 
Leptospira santarosai 8/8 8/8 8/8 8/8 6/8 1/8 
Leptospira weHli 8/8 8/8 8/8 7/8 6/8 3/8 
Leptospira kirschneri 8/8 8/8 8/8 8/8 6/8 1/8 
Leptospira meyeri 8/8 8/8 8/8 8/8 8/8 ,· 2/8 
For the RNA assays, plasmids were ordered to validate and optimise the as-
says but were not used to determine the lower limit of detection of these 
assays, because this would exclude the efficiency of transforming RNA into 
DNA (reverse transcription) before the PCR reaction occurs. 
7.3.7 SPIKING BLOOD SPOTS 
The plasmids were eluted in a 1:100 elution with EDTA whole blood. 40~l 
was used to spot the cards and were dried overnight. The protocol of the 
filter paper manufacturer was slightly adjusted to improve the performance 
of extraction of FTAelute filter paper. A 6mm punch was used instead of 
3mm, 1ml was used to wash the punch, and an extra wash step was added 
and the total ~ lution volume was 100 ~l. Table 7.9 highlights the results of 
two PCR reactions performed in quadruplicate for each of the plasmids. 
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Table 7.9: Total of positive outcomes of 8 samples tested with different plasmid 
concentrations of dried whole blood 
peR 
Plasmodium vivax 
Plasmodium falciparum 
Plasmodium ovale 
Plasmodium malariae 
Bartonella bacilliformis 
# of samples detected with different plasmid 
concentrations per JJl of whole blood spotted 
on DBS (FTAelute) 
106 105 104 103 102 
8/8 8/8 8/8 8/8 8/8 
8/8 8/8 . 8/8 8/8 8/8 
8/8 . 8/8 8/8 8/8 8/8 
8/8 8/8 8/8 8/8 8/8 
8/8 8/8 8/8 8/8 8/8 
Orientia tsutsugamushi 8/8 8/8 8/8 8/8 8/8 
Rickettsia typhi 8/8 8/8 .8/8 8/8 8/8 
Leptospira interrogans 8/8 8/8 8/8 8/8 8/8 
Leptospira santarosai 8/8 8/8 8/8 8/8 8/8 
Leptospira weilli 8/8 8/8 8/8 8/8 8/8 
Leptospira Idrschneri 8/8 8/8 8/8 8/8 8/8 
Leptospira meyeri 8/8 8/8 8/8 8/8 8/8 
No plasmids series were spiked in DBS for the RNA targets (dengue and chikungunya). Plasmids are 
DNA structures and the results could therefore not be translated to RNA, as the amplification efficiency 
can be very different. 
Z3.B EXTRACTION STUDY 
Although we could not change filter paper because all our positive samples 
from Laos were already spotted on FTAelute, a comparison study was set-up 
with different kind of cards and extraction methods to obtain insight in how 
FTAelute compares to other filter papers. 
Because the detection limits of the different PCR assays did not show much 
variability (Table 7.8), we selected one assay (B. bacilliform is) and determined 
the extraction efficiency with only this assay instead of repeating this for the 
numerous pathogens. 
The mean cycle point (cp) given for every extraction method was used as a 
measure of extraction efficiency. A lower cp value means a higher concentra-
tion detected in the ·PCR. In theory, all extraction methods should provide 
the same cp value since all methods used the same samples. The M48 refers 
to the automated M48 BioRobot of Qiagen, the DNA blood minikit (Qiagen) 
is a spin colulnn based extraction (referred to as column) and the Chelex ex-
traction (Bio-Rad, Veenendaal, Netherlands) is a manual and more affordable 
option than the blood mini ,kit. H20 e><traction can only be performed with 
the FTAelute cards. 
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The concentrations of spiked samples are given as concentration per ~l e>{-
tract (4.5 copies/~l to 450,000 copies/~l). The concentration values above 
the tables would be obtained when the extraction obtains 100% extraction 
efficiency. 
Figure 7.5: The box plots show the performance of the different extraction 
methods given per concentration of DNA.per spot, with mean cp on Y-axis. 
The median, 75 percentile and 25 percentile of cp values are given in a box with the up-
per and lower whiskers representing the spread of the highest or lowest 25% of cp values. 
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Outliers are given as dots. The smaller the boxplot, the less variance in results, suggestive of 
very minor variability in results. Cp of 0 means no amplification was detected, suggesting an 
incorrect extraction. At 4.5 copies/~l, H20 and chelex extraction often failed, which causes 
the boxplots to be very wide. The three negative samples (2 at 45 copies/~l and 1 at 4500 
copies/~l), were potentially caused by extraction defaults. 
For Figure 7.5, the concentrations of spiked samples are given as concentration 
per ~l extract (4.5 copies/~l to 450.000 copies/~l) that would be obtained 
with 100% extraction efficiency. The M48, chelex, and column results were 
based on 903 and 226 filter paper . . 
The Chelex and H20 methods were not always successful in extracting the 
lowest concentration of 4.5 c/~l which caused the boxplot to be very wide. 
The small variation in r~sults found by the M48 and blood mini kit indicates 
a robust extraction performance throughout different plasmid concentra-
tions. The FTAelute cards showed increased variability when plasrT]id con-
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centrations were high. 
To evaluate if there was a difference between the two 100% cellulose filter 
paper cards, the 903 Whatman and 226 of PerkinElmer were evaluated (Fig-
ure 7.6). 
Figure 7.6: The extraction performance given per cycle point (Cp) per method 
and card type. 
226 = PerkinElmer 226 filter paper, 903= Whatman 903 filter paper. The median, 75 percen-
tile and 25 percentile of cp values are given in a box with the upper and lower whiskers rep-
resenting the spread of the highest or lowest 25% of cp values. Outliers are given as dots. 
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There seems to be no major difference between the 903 and 226 filter 
papers which could be expected since technically, there is no difference in 
the material of the cards. 
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Z3.9 CLINICAL SAMPLES 
A total of 122 FTAelute filter paper card samples were mailed from Laos to the 
laboratory in the Netherlands and were tested for all pathogens. Upon arrival 
of the samples, the quality of the DBS samples were checked '(procedure as 
given in chapter 5). In total, 64 samples (52%) were unfortunately invalid 
due to humidity (n=39, 61% ) or presence of serum rings (N=25, 39%). All 
samples were dried and extracted for a human DNA quality control peR test 
(p-actin). A total of 39 (32%) samples passed the criteria of 35 cpo Even 
though these samples were less affected by poor sample storage than the 
other samples, it is very likely that they are affected to some degree as 
well, as they were all stored and shipped in the same large plastic bags. Our 
partners in Laos were informed about the poor conditions of the samples. 
As the first batch of samples contained all the positive samples from 3 year 
sample collection, no further positive samples were available. 
Of the 39 samples, DBS results where compared to the reference test 
performed in Laos (Chapter 7.2.8). 7 out of 17 (41.2%) whole blood PCR 
positive Leptospira samples, lout of 16 (6.3%) buffy coat peR positive 
O.tsutsugamushi samples and lout of 5 (20%) buffy coat PCR positive 
R.typhi samples were detected. One sample was negative for all pathogens 
(Table 7.10). 
Although DBS samples are commonly used to diagnose malaria, we initi-
ated a small evaluation to see if our methodology would work with clini-
cal samples. A selection of malaria samples were obtained from the malaria 
reference laboratory based at the London School of Hygiene and Tropical 
Medicine. We used samples from Africa that were: PLasmodium ovaLe, P. jal-
ciparum, P. vi vax, P. ovale for evaluation of the performance of the meth-
odology. There was 100% concordance between DBS peR techniques and 
peR on whole blood. As the principal investigator was not blinded to these 
results, we could not include these samples to estimate the sensitivity. We 
~ 
obtained malaria positive DBS samples from Vietnam to provide an estimate 
of the sensitivity of the_methodology. Unfortunately, no chikungunya posi-
tive clinical samples could be obtained that were spotted onto filter paper 
from any of our contacts. 
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TabLe 7.10: Overview of the detection performance given per pathogen by our 
methodology 
Pathogen # detected TotaL Detection rate % 
Leptospira 7 17 41.2 
O.tsutsugamushi 1 16 6.3 
R.typhi 1 5 20.0 
Dengue 9 68 13.2 
Malaria 5 5 100 
Z3.10 IMPLEMENTATION OF THE SURVEILLANCE METHOD IN PERU 
The surveillance study was established in Ancash province, Peru to evaluate 
the performance of detecting a.bacillifarmis by DBS samples and secondly, 
to analyse the implementation of the surveillance method. 
A total of 196 cards were collected in Caraz, Ancash Peru between Novem-
ber 2010 and February 2011. In September 2011, an expedition was organ-
ised in a different district called Yuatan, Ancash province to search for signs 
of latent a.bacillifarmis. Based on the results of the expedition, we included 
2 clinics in Yuatan district, the main hospital in Yuatan and Quillo (Figure 
7.7). Clinics in Caraz area were given additional materials to collect samples 
should a a.bacillifarmis outbreak occur during the 2012 rainy season. How-
ever, there was no outbreak and no additional samples were collected in 
Caraz. In Yuatan district, 65 samples were collected in Yautan and Quillo 
health centres from December 2011 till July 2012. 
Figure 7.7: Map of Ancash province. Caraz, Quillo and Yautan are highlighted 
(source; Google maps) 
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7.3.11 QUALITY OF THE CARDS 
Upon arrival in The Netherlands, samples were checked for humidity and 
placed in new ziplock bags and stored at 4°C until further processed. Out of 
262 samples, 119 (49.3%) were invalid according to our quality assessment 
protocol, of which most incorrect samples were collected from Caraz and 
Yuracoto clinics. The poor quality of the cards was discussed and appeared 
to be caused by use of finger pricks with a small width and depth. These 
finger pricks were already used in the Peruvian clinics and were not supplied 
by this study. New lancets were purchased and transported to the clinics. 
When the new lancets were used, sample quality improved greatly as only 31 
(26%) incorrect DBS samples were collected instead of 88 (74% ) before the 
new lancets were used. The humidity of the cards was checked upon arrival 
at the laboratory which showed that 124 (63 .3%) DBS samples were dry 
and 72 required change of desiccants when they arrived in The Netherlands. 
Table 7.11 provides 'an overview of the samples collected in Peru. 
Table 7.11: Overview of samples obtained from Peruvian clinics 
Mato 
Caraz clinic & Yuracoto Yautan QuiUo ,. 
hos~ital outreach clinic hos~ital clinic Total 
Start 2010 2010 2010 2011 2011 
collection 
# samples 87 53 57 32 33 262 
Male 50 35 30 14 17 164 
(0/0) (57% ) (660;0) (53% ) (44% ) (52%) (63% ) 
Age 3.37 6.23 3.33 2.35 4.38 4.03 
(range) (0-10) (0-11) (0-10) (1-10) ( 1-8) (0-11) 
Average Temp 37.52 38.46 37.98 38.27 38.40 38.01 
(range) (36-39.5) (37-40) (36-39.8) (37-39.2) (37.5- (36-40) 
39.5) 
Average days 2.48 2.02 1.49 2.41 2.39 2.07 
of fever (1-8) (1-7) (1-4) (1-5) (1-5) ( 1-8) 
(range) 
Invalid 41 31 41 6 0 119 
samples (0;0) (47.10;0) (58.5% ) (71.9%) (18.8%) (0%) (49.3% ) 
Blood smear 0 0 0 1 1 0 
positive (00/0) (00;0) (0% ) (3 % ) (3 % ) (00/0) 
DBS-PCR 1 0 0 1 15 17 
positive (1 % ) (0 010) (0% ) (3 % ) (46% ) (60/0) 
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Z3.12 CLINICAL FINDINGS 
The febrile children participating in this study were young, with a mean age 
of 4 years (Table 7.11). The length of fever before samples are collected is 
an important variable that can affect the sensitivity of diagnostic assays as 
bacterial loads are likely to be lower during recovery. Additionally, days of 
fever are a suitable measure to review the social behaviour of visiting health 
centres and provide a measure of reviewing the accessibility of healthcare. 
The data indicates that most febrile children were brought to the health 
centres within 1-3 days of onset of fever (n=234, 890/0), indicating a positive 
trend towards early health seeking behaviour and accessibility of health 
centres. The temperature of children upon arrival at the clinics showed that 
93 children (350/0) had temperature below, and 169 (640/0) children had 
temperatures above 37.00 C. 
From each of the infants or children enrolled in the study, a DBS sample 
and blood smear was obtained. 2 blood smears were called positive while 
17 samples were positive with PCR on DBS samples. The two positive blood 
smear results were of children from Quillo region who suffered from anae-
mia (Hb <3 gm/dl) and had high densities of B.bacilliformis in ,their blood-
stream, according to the peR results (>100,000 copies/DBS spot). This was 
also visible, as DBS spots had serum rings and blood spot was light coloured. 
Almost 700/0 of the children sampled in 2010 had general malaise and cough-
ing as main symptoms and were diagnosed with upper respiratory tract in-
fections. In Figure 7.8, the symptoms of children who were B.bacilliformis 
PCR positive (n= 17) and children without B.bacilliformis infection detected 
(n=245) are plotted in percentages. 
,,':' 
183 
C/'1aptcr- 7 - Surveillance of febrile causes 
Figure 7.8: Symptoms of children in given as percentages. 
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Clinicians could record multiple symptoms per child. Neg=negative, pas = positive. 
To assess if diagnosis based on clinical symptoms would be feasible, we 
analysed separately the symptoms between B.bacillifarmis positive and 
negative patients, to select symptoms with a P <0.20 (Fischer chi2 test). 
A binomial logistic regression model was used to assess the association 
between symptoms and B.bacillifarmis infection. The symptoms that had a 
Fischer chi2 test of p <0.20 were included in the multivariate m9del. This 
selection process and Ale (Akaike information criteria) aids in minimal-
izing the variables in the model, excluded general malaise, vomiting and 
diarrhea. Even though the number of B.bacillifarmis positives are small, 
patients during the rainy season of 2011/2012 in Peru with pallor and 
muscle pain had a high probability (odds) of being B.bacillifarmis positive 
(binomial logistic regression, odds ratio (OR) 18.1,p= 0.007 (pallor) and OR 
4.5 p= O.Ol(muscle pain)). Even though this suggests that patients with 
these symptoms are more likely to be positive for B.bacillifarmis, it cannot 
be used for diagnosis of patients due to limited representativeness (i.e. 
one region) and small number of samples included in the study. 
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Z3.13 SEQUENCE RESULT 
To assess the specificity of the PCR assay, positive B.bacilliformis OBS samples 
were sequenced. In order to obtain a larger DNA fragment fOr sequencing, 
assay developed by Garcia Esteban et al. was used (360). Unfortunately, this 
assay is less sensitive and specific than the assay developed in this study. 
When reviewing the PCR product on agarose gel, multiple products could 
be seen, which did not occur for the PCR assay developed in this study. In 
June 2012, 10 samples were sequenced at the London School of Hygiene 
and Tropical Medicine. Two samples appeared to be false positive as they 
amplified human chromosome 17. Even though the PCR used for sequencing 
was not -developed to differentiate B.bacilliformis strains, the remaining 8 
samples were positive for B.bacilliformis, seven samples matched strain 
I<C583 and 1 matched ecol B.bacilliformis strain (Figure 7.9) (NCBI accession 
numbers: OQ179107 Bartonella bacilliformis strain ECOl and CP000524 
Bartonella bacilliformis I«583). 
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Figure 7.9: Sequence result of two samples matching two strains (1«583, Ecol) 
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7.4 DISCUSSION 
This proof of concept study was initiated to evaluate the possibility and 
suitability of a surveillance method by combining nucleic acid detection 
with DBS samples 
In this study, infectious diseases were detected by PCR and were developed 
and evaluated by using plasmids, whole genome of viruses, bacteria and 
parasite materials as well as clinical samples. Unfortunately, clinical samples 
were incorrectly stored which affected the detection of pathogens greatly. 
Based on the results obtained from spiked samples, results suggest that, 
when clinical samples are collected appropriately, it may be possible to ob-
tain reasonable sensitivities. As expected for R.typhi and O.tsutsugamushi, 
the detection rate was low but the detection of dengue was expected to be 
better than described in the literature (13% compared to 81.6% sensitivity) 
(95). The low detection rate of clinical dengue samples was primarily linked 
to effects of using a type of filter paper inappropriate for RNA viruses. The 
FTAelute filter paper that was used is not intended for RNA detection as the 
lysis buffer applied to these cards disintegrates RNA (personal communica-
tion GE Healthcare). Additionally, the extraction method seemed to be less 
suitable for low quantities of viral or bacterial DNA/RNA in clinical samples. 
The surveillance study was easily implemented at the health centres and 
sample quality was good when the correct finger prick lancets were used. 
The results indicate that DBS PCR method was more sensitive for detecting 
Bartonellosis than blood smears, as confirmed by sequencing. The only two 
samples classified as positive by blood smear reading were confirmed by 
peR. 
The Peruvian government has set-up a surveillance system for Bartonella 
bacilliformis in Ancash province. Blood smears of febrile patients thought to 
have Bartonellosis are collected in clinics and sent to the laboratory located 
at the local P,ospital where screening takes place. In case of an outbreak, 
reports are sent directly to the Ministry of Health. The sensitivity of blood 
smears are lower than those of the method developed in this study. Even 
though the surveillance method is used, clinical signs are more commonly 
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used as indicators for Bartonellosis cases than blood smears. Because of 
this, the blood smears have limited functionality (43). 
Z4.1 LIMITATIONS 
This proof of concept study was developed to highlight the possibilities and 
limitations of surveillance by using DBS. It was not intended to develop and 
validate all aspects of a surveillance method. 
The number of clinical samples was low and unfortunately, the samples from 
Laos were too wet to reliably be tested. This particularly raised the impor-
tance of developing adequate protocols to obtain good quality specimens. 
Correct storage information was shared and implemented in Laos. Addition-
ally, no positive samples for Chikungunya could be obtained which limited 
the evaluation. 
To sequence the B.bacilliformis positive Peruvian samples, a different assay, 
which was less sensitive and specific than the assay developed in this study, 
was used to obtain larger sequences. This complicates the interpretation of 
the two negative sequence results. The two false negative samples could be 
true positive samples but this was potentially not visible given the larger 
quantity of amplified human DNA. These two samples had, when visualized 
on agarose gel, many DNA products. Suggestively, by cutting out the band 
for sequencing, the human chromosome was extracted and not the thin-
ner B.bacilliformis band. In the future, it would be worthwhile to perform 
whole genome sequencing or develop an assay to genotype B.baciLliformis 
in greater detail. 
188 
Discussion 
Chapter 8 
8 Discussion 
8.1 MAIN FINDINGS 
The overall aim of the thesis was to assess whether DBS could improve 
patient management in remote settings. Here, the main findings are listed, 
followed by limitations of the study and recommendations for the future. 
8.1.1 DBS FOR DETECTION OF INFECTIOUS DISEASES 
This thesis highlighted the feasibility of DBS to be used for the detection of 
various infectious diseases, based on the available literature. From humans, 
almost all types of body fluids, from blood to saliva and faeces to breast 
milk, have been stored on filter paper. When using DBS it is inevitable that 
the processed sample volume is small compared to gold standard samples 
as long as there are sufficient levels of the target molecules are contained 
in a DBS, the use of DBS improves patient access to state of art technologies 
that they would otherwise be denied. 
DBS can be used to improve access to HIV VL measurements in remote set-
tings, even though the sensitivity can in some cases be 0.5 log lower than 
that for plasma samples. Depending on the threshold for switching to a sec-
ond line regimen, this loss of sensitivity may be tolerated if the use of DBS 
allows timelier switching to an appropriate and effective therapeutic regi-
men for HIV. The systematic reviews shows that key information was often 
not reported and there were frequent methodological variations such as 
in sample collection, storage, processing of filter paper and data analysis 
(chapter 3). 
Standardization of evaluation methods is essential to improve the use of 
DBS in public health. For reporting DBS evaluation studies, this thesis pro-
vided an updated STARD checklist with the inclusion of specific DBS related 
information fhat should be reported when publishing evaluation studies 
(Chapter 2). 
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8.1.2 DBS AS QA METHOD FOR POCT 
Syphilis serology using DBS as samples proved to be highly sensitive and 
specific compared to plasma samples. Although the method is robust 
and accurate, it relies on visual interpretation of agglutination, which is 
subjective. An increase in sensitivity was obtained when technicians were 
more experienced in interpreting DBS TPPA agglutinations, stressing the 
importance of training, particularly for subjective tests such as TPPA. 
The QA method was implemented to assess the quality of DBS samples and 
the quality of POCT testing over a period of ten months in Tanzania. The col-
lection of DBS by HCW in Tanzania was easily rolled out and the collection, 
storage and transportation proved to be good, giving high quality samples. 
The study showed that it is feasible to monitor test quality in field sites with 
DBS. Compared to the dried test method developed by the US CDC, DBS 
gave a more accurate picture of the quality of testing and was useful in iden-
tifying the need for training or refresher training. Like DTS, it is possible to 
carry out QA for both HIV and syphilis using a single DBS sample (Chapter 6). 
8.1.3 DBS FOR SURVEILLANCE FOR CAUSES OF FEVER 
Laboratory protocols were developed to enable the detection of seven 
pathogens from DBS. PCR assays were developed and evaluated by using 
plasmids, whole genome of viruses, bacteria and parasite materials, and 
clinical samples. Based on the results obtained from spiked samples, it was 
possible to obtain reasonable sensitivities for malaria, dengue, leptospira, 
and B.bacilliformis. R.typhi and O.tsutsugamushi are difficult to detect 
with DBS due to the very low number of pathogens in the blood stream. 
Unfortunately, many of the archived clinical samples were incorrectly stored 
which affected the detection of pathogens greatly. High quality clinical 
samples could only be obtained for B. bacilliform is. Using DBS with an in-
house B.baciljiformis PCR method resulted in a more sensitive method for the 
detection of B.bac;illiformis than the standard diagnostic test used in Peru. 
Positive results were confirmed by sequencing results. To our knowledge, 
this is the first validation of a B.bacilliformis PCR assay with DBS, and the 
assay showed excellent sensitivity and specificity. 
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8.2 THE ROLE OF DBS IN PATIENT MANAGEMENT IN THE 
FUTURE 
The applicability and potential benefit of using DBS in areas such as the 
detection of infectious diseases, surveillance and quality assurance has 
been highlighted in this thesis. However, with the development of novel 
pac diagnostic methods that can be used at remote areas in developing 
countries, the use of DBS may be no longer needed in the future. Our 
studies suggest that the use of DBS may remain useful to assure the quality 
and improve accessibility of diagnostic tests in remote settings. As long 
as diagnostic assays rely on high quality laboratory infrastructure and are 
technically demanding, the usefulness of DBS to improve accessibility of 
those tests for remote settings remains. It is highly unlikely that paCTs will 
replace syndromic management for all infectious diseases in the near future. 
DBS will remain useful for determining the changing aetiology of syndromes 
and for disease surveillance as long as collection of blood samples on filter 
paper remains easy and affordable. 
There is potential for filter paper to become more than just a sample col-
lection matrix. Filter paper is becoming a diagnostic test itself:, Microfluidic 
paper-based analytical devices have already been applied to HIV and syphi-
lis detection and showed comparable results to traditional laboratory based 
assays (444, 445). In a few years' time, it is expected that these filter paper 
based tests are ready for clinical use and when this happens, diagnostics 
will change dramatically. Microfluidic papers are an exciting development 
with great potential to improve patient management in both developing and 
developed countries. 
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8.3 RECOMMENDATIONS 
8.3.1 RECOMMENDATIONS FOR STANDARDISATION 
This thesis provided a general guideline for collecting, storing ~nd processing 
DBS samples in the laboratory, for NAAT or serological testing. These 
guidelines can be adjusted according to specific requirements depending 
on the disease syndrome or the diagnostic assays. Ideally, protocols should 
be developed in close collaboration with manufacturers, to assure high 
quality protocols are accessible for every laboratory using that platform. 
This will aid harmonisation of protocols and in obtaining consistency in test 
results between laboratories. Key concerns and the need for standardisation 
in terminology and methodology for DBS were addressed in this thesis, and 
will be published so that they are widely disseminated amongst those who 
work in global health. 
The quantification of RNA in DBS is technically challenging. HIV VL proto-
cols will be useful for other viruses as well, particularly when quantifica-
tion is necessary. The work of HIV VL on DBS samples in this thesis should 
ultimately aid in the development of standardised protocols for the use of 
DBS for other infectious diseases, particularly when low quantities of RNA or 
DNA need to be detected. 
8.3.2 RECOMMENDATIONS TO START USING DBS SAMPLES 
This work shows that DBS used with PCR is a feasible and highly sensitive 
alternative to the use of blood smears for the surveillance of B.bacilliformis. 
Epidemiological and cost-effectiveness studies are required before they 
can replace Giemsa stained blood smears. 
The significant variability of syphilis POCT results identified at the ten clinics 
highlight the necessity for a QA method to be implemented alongside POCTs. 
More attention should be given for the development and implementation of 
,.:. 
QA methods specifically designed for POCTs. While proficiency panels are 
regularly used as QA method for POCT, the work in this thesis showed that 
they are of limited use, com'pared to DBS QA, in detecting underperforming 
clinics that require remedial training. In this work, the QA method was devel-
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oped for POCT used in PMTCT services in Tanzania but could be extrapolated 
to other infectious diseases and settings. There is a considerable potential 
in collecting DBS to retest samples from remote clinics or for epidemiologi-
cal studies. 
When DBS samples are used instead of plasma, clinicians and laboratory 
technicians should be aware of potel)tial differences in results, particularly 
for HIV VL measurements when using the WHO recommended threshold of 
5,000 c/ml for changing to second line treatment. As DBS adds minor vari-
ability in HIV VL results, false positives or false negative outcomes are more 
likely to occur than with plasma samples. Although certain aspects of DBS 
HIV VL measurement require further investigation, the use of DBS remains 
the only viable means of improving access to HIV VL for monitoring HIV pa-
tients on treatment. 
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8.4 LIMITATIONS 
The limitations of each of the studies are discussed in the chapters 
individually. In retrospect, there are certain aspects that I have learned that 
would affect the design and execution of this type of study in the future. 
First, no data was obtained to monitor which HCWs collected the samples in 
the QA study. Monitoring which HCWs collected the samples can be useful 
to review the potential impact of training on the quality of the samples and 
the test results. Additionally, this data would have been useful to assess the 
attrition and rotation of HCWs. Within our research setting, where the study 
relied on the willingness of the HCWs to participate in this study, it was not 
feasible to track which HCWs provided the QA data. 
Second, the average time to get samples from the QA study sites in Tanzania 
to the laboratory in the Netherlands was 95 days, which exceeds the rec-
ommendations made in chapter 2. By increasing the number of shipments 
to The Netherlands, this could have been improved. Due to financial and 
staffing constraints to visit all ten clinics for sample collection (takes at least 
four days) and shipping the samples to the Netherlands, this was not fea-
sible in our study. The ideal scenario would be for the QA DBS samples to 
be processed in the Nationallnstititute for Medical Research in Mwanza on 
a monthly basis and the results reported to Geita district for any corrective 
action, if necessary. 
Third, the process of collecting and distributing data between the labora-
tory and clinics is an essential part of QA programs. Although an epi-info file 
and excel sheet were developed to potentially transform the QA data into 
useful figures for supervisors to monitor the performance and see trends 
in the quality of POCT, it was not within reach of the study to evaluate the 
process of collecting, distributing, and interpreting the QA data, due to time 
and staffing constraints . 
• -=> 
Fourth, for the su~veHlance study, certain choices were made that, in retro-
spect, potentially affected the outcome of the study (Chapter 7). Labora-
tory tests could have been performed at another laboratory with validated 
PCRs for most of the infectious diseases included in this study. Given that 
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this study was part of a PhD and logistically and financially dependent on 
the laboratory where testing took place, it was not feasible to make use of 
another laboratory. Unfortunately, due to financial and time constraints we 
could not take this study further and actively collect samples in more re-
search settings than in Peru. 
Fifth, there were two occasions relat~d to performing research abroad that 
influenced the study results. Even though these occasions where minor, the 
effects were substantial. The samples from Laos were ruined by a small mis-
take in not bringing samples from the freezer to room temperature before 
repackaging, causing condensate to be trapped inside. Study protocols and 
guidelines should have been distributed, even when collaborators have al-
ready collected the samples. The other occasion was in Peru, when samples 
were collected by HCW in Caraz. As they already obtained blood by finger 
prick, we did not distribute our finger prick lancets. Unfortunately, the finger 
prick lancets used in Caraz had a small needle that gave not enough blood 
for DBS, which caused the samples to be of poor quality. Before the study 
initiated, efforts could have been made to assess the quality of the lancets 
that were already used in Peru for spotting DBS samples. 
Sixth, since the positive B.bacilliformis cases were sampled in January 2012 
and confirmed to be positive in June by sequencing, we were not able to 
investigate this outbreak in greater detail. It is unfortunate that the positive 
cases were detected only in the extended study period as this limited the 
possibilities to obtain more funding to pursue our investigation. 
196 
8.5 FUTURE RESEARCH 
Before the QA method can be implemented on a larger scale, costing studies 
should be performed. The costs of QA, as well as the costs of training, lot 
testing, and the costs of the tests itself, should be included to calculate the 
program costs. A QA method for POCT is necessary and as shown in this study, 
proficiency panels alone are not enough to indicate clinics where remedial 
training is necessary. Because QA is not merely the collection and testing 
of DBS samples, but also the translation of QA data into useful monitoring 
data for supervisors, this thesis initiated the development of suitable tools 
for processing and managing data. It is recommended that this process is 
evaluated before DBS QA is implemented. 
For syphilis serology on DBS, the protocol developed in this study did not 
provide a solution for indeterminate TPPA test results. The thesis suggested, 
based on hands-on experience, that retesting in duplicate seemed suitable 
to establish a final reading. In the future, appropriate procedures for indeter-
minate results should be developed. 
A rigor,ous approach would be required to extend the development of a sur-
veillance method for febrile children. The main areas that would require at-
tention are: clinical case definition, selection of pathogens, details of patho-
gens in the blood stream during febrile periods, and harmonisation of the 
methodologies into a high throughput method. Selecting the pathogens for 
the surveillance method could be done by using, for example, the Plex-ID de-
veloped by Abbott diagnostics, USA. This PCR and mass- spectrometry com-
bination can differentiate undefined bacterial and viral infections by using 
broad spectrum PCR. This aids in prioritizing pathogens that are frequent, 
preventable and treatable. When a list of infections is made, it is worthwhile 
to determine the pathogen characteristics and quantity in blood during fe-
brile illness to support future development of diagnostics and surveillance 
methods. This information will aid in validating the method in greater de-
,..!) 
tail by using spiked samples that represent actual clinical situations. Clinical 
case definitions are indjspensable as the duration of infection and the mo-
ment of collecting a sample 'profoundly influences the bacteriallviralload in 
blood. As seen in Peru, many febrile infants did not have a high fev~r which 
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influences the chance of finding positive cases. The average number of days 
before seeking medical aid after the onset of fever was relatively low, but 
this varies per region and country. Efforts to develop protocols for multiplex 
reactions or techniques such as Luminex (Life Technologies, ,UI<) would be 
worthwhile to increase the number of pathogens being detected from OBS. 
A surveillance method based on serological markers could be worthwhile to 
assess. 
This thesis assessed the use of OBS for three aspects of patient management. 
It might be worthwhile to assess the potential of OBS for other aspects, as 
outbreak investigations, or drugs and vaccine research development. 
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8.6 CONCLUSION 
The goal of this research was to determine whether DBS can improve patient 
management in developing countries. The potential of a simple and reliable 
sample collection method such as filter paper was shown in this thesis. While 
DBS is not the best sampling method, it is the simplicity and robustness that 
makes it useful in remote settings. This thesis has shown the benefits and 
weaknesses of using DBS for the detection of infectious diseases in remote 
settings. More specifically, the utility of DBS in respect to three aspects of 
patient management have been discussed; first, to make laboratory based 
diagnostics more accessible for patients in remote settings, secondly, to 
assure the quality of diagnostics used at the point of care, and thirdly, for 
the surveillance of febrile illnesses in children. 
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10.1 ANNEXES TO CHAPTER 1 
No annexes for Chapter 1 
;4 
226 
10.2 ANNEXES TO CHAPTER 2 
10.2.1 REVIEW PROTOCOL 
Review of the clinical use of filter paper in infectious diseases 
Draft Protocol 
Review Team 
Pieter Smit, Ivo Elliott, David Mabey, Rosanna Peeling, Paul Newton 
Review Objectives 
Primary Objective 
To assess the use of dried blood spots (DBS) for the diagnosis or 
surveillance of infectious diseases. 
Secondary Objective 
To assess the general implications of using DBS compared with traditional 
sampling methods 
Tertiary Objective 
To assess the use of filter paper for diagnosis or surveillance for samples 
other than whole blood 
PICOS 
INCLUSION CRITERIA (PICOS) 
Population 
Studies evaluating the use of DBS as a replacement of a gold standard sample 
(plasma, serum, whole blood obtained by venous puncture, buffy coat blood, etc.) 
for any infectious disease diagnostic or surveillance assay. 
Interventions (index tests) 
Any commercially available technology for surveillance or for diagnosis of 
infectious diseases with DBS samples. 
Reference standard/comparators 
The same commercially available technology for the diagnosis or surveillance 
of infectious diseases with reference samples (plasma, serum, whole blood etc), 
when applicable. 
Outcomes 
Include studies evaluating DBS for quantitative as well as qualitative analysis of 
nucleic acid testing against plasma samples (DNA / RNA). 
Includedstudies evaluating DBS for Antibody Antigen detection as diagnostics, cut-
off determinJtion, and protocol development (in combination with commercially 
available assays) .. ~ 
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Study design 
Evaluation studies published in peer-reviewed literature. Conference abstracts 
and letters to the editor were excluded. 
Other 
English language only, 19BO-present. 
Identifying research evidence 
Sea rch strategy 
Databases: MEDLINE and EMBASE 
MEDLlNE: All aspects of clinical medicine, biomedicine, nursing, dentistry, 
allied health, health policy, genetics etc. Emphasis on English-language 
source, quite biased towards journals published in N. America. Includes 
journal articles from 1950s onwards and is updated daily. 
EMBASE: All aspects of clinical medicine, biomedicine, nursing, dentistry, 
allied health, health policy, genetics etc. Quite biased towards information 
in journals published in Europe. Particularly strong on pharmaceutical 
information. Includes journals from 1947 onwards and is updated weekly. 
Search Terms 
Search terms for MEDLINE and EMBASE: 
Ti,ab = keyword (title and abstract) 
Mp= keyword (free text) 
1. "dried blood".ti,ab 
2. "blood spor.':".ti,ab 
3. DBS.mp 
4. "filter paper".ti,ab, 
5. "Guthrie filter".ti,ab 
6. "filter cards".ti,ab 
7. "dried blood spot)"".ti,ab 
8. "FTA~"".ti,ab 
9. "Flinders Associates Technology" 
10. "Guthrie paper". Ti,ab 
11. "dried serum)"".ti,ab 
12. "serum spot"(II.ti,ab 
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13. "filter card~·:".ti,ab 
14. "filter disc':" .ti,ab 
15. "filter disk~':" .ti,ab 
16. "blotting paper".ti,ab 
17. "Guthrie card".ti,ab 
18."lsocode stix".ti,ab 
The following disorders and tests are commonly performed using DBS 
samples and were excluded: congenital hypothyroidism, phenylketonuria, 
cystic fibrosis, sickle cell disease, Tay-Sachs disease, haemoglobinopathies, 
galactosidase, spinal muscular atrophy, isovaleric acidaemia, maple syrup 
urine, cholesterol, triglycerides, HbAlc, human growth hormone, insulin, 
mercury. Other key words often associated with the search terms but not 
relevant to this review were also excluded: MRI, MR, CT, PET, N-glycan, 
Pharmacokinetic, Pharmacodynamic. 
Date 
1980 to present 
Language 
English 
Publication type/status 
Published works in peer reviewed journals 
Study selection 
Stage 1: Screening of titles/ abstracts against inclusion criteria. 
Titles and abstracts, where available, will be screened and either accepted, 
rejected as not relevant, or rejected due to failure to meet inclusion criteria 
(if so, the reason will be specified). 
Stage 2: Full papers obtained and assessed against inclusion criteria. 
Papers will be either accepted or rejected due to failure to meet inclusion 
criteria and the reason will be specified. 
Full pa~rers will be independently assessed by TWO members of the review 
team and results will be cross-checked and combined. 
229 
Inclusion Criteria 
Evaluation or comparison of performances of commercially available 
DNA/RNA assays with DBS and reference sampling methods 
• Evaluation or comparison of performances of commercially available 
Antibody/Antigen assays with DBS and reference sampling methods 
• Any human pathogen 
• Evaluations based on human clinical or reference materials 
Exclusion criteria 
Not an evaluation study or not having a correct reference sample or 
reference method 
In-house developed assays 
Full article not accessible 
Studies with other primary aims other than evaluation of DBS with 
reference samples (but keep these articles for objective 2) 
Studies related to drug resistance screening, genotyping, sequencing, 
other "non-diagnostics" evaluation studies 
Studies using filter paper for non-whole blood samples (urine, stool, 
cervical swabs, serum, plasma, saliva, cerebrospinal fluid, etc) (but 
include in objective 3). 
• Any non-infectious diseases included in neonatal screening 
programmes (e.g. Galactokinase deficiency, cystic fibrosis 
Data Extraction 
General Information 
Date of data extraction 
Identification features of the study: 
Record number 
Author 
Article title 
Citation 
Study Characteristics 
Aim/ objectives of the study 
Disease 
Filter pa7Jer type 
Participant/ Sample Characteristics 
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Characteristics of population from which 
samples were drawn: 
Age 
Sex 
Number of samples 
Sample countryl region of origin 
Sample type (finger prickl EDTA/ .. ) 
DBS storage: 
At research site 
At laboratory 
Type of reference sample 
DBS quality check performed? 
Technology 
Name and manufacturer of assays under 
evaluation 
Extraction method 
Extraction volume/adjustments 
Extraction kitl method used 
Detection method 
If quantitative; adjusted for DBS sample input? 
Outcome datal results 
Unit of assessmentl analysis 
Outcomes: 
NA: 
Mean pathogen load ± standard deviation 
Range of pathogen load 
Correlation (r) 
Bias (mean difference) 
Sensitivity, cut-off 
Specificity, cut-off 
0/0 CV index test, reference test 
Serology: 
Sensitivity, cut-off 
Specificity, cut-off 
Cut-off adjusted for DBS? 
Titre lower limit of detection 
For each pre-specified outcome: 
Reported (YIN) 
Definition used in study 
Additional outcomes reported 
Details of any additional relevant outcomes 
reported 
231 
t~n n eyc:s 
Objective 2: To fulfil the second objective of this systematic review, the 
following information will be collected from publications in combination 
with our experience: 
All articles excluded for objective 1 are reviewed that fulfil the criteria: 
Provide a better understanding of DBS samples regarding; card types, 
filter paper characteristics, collection, storage, extraction, environmental 
effects, stability, punch met~ods, cost compared to reference methods, 
transportation, policy & regulations, recommendations made by leading 
organisations (WHO, CDC), and other related topics that could improve 
understanding of filter paper] 
Data extracted: 
General Information 
Date of data extraction 
Identification features of the study: 
Record number 
Author 
Article title 
Citation 
Assay details 
Disease 
DBS Topic 
Results 
Key findings 
Objective 3: To fulfil the third objective of this systematic review, the 
following information will be collected from publications: 
All articles that are excluded for objective 1 and 2 can be included. 
Make use of alternative samples stored on filter paper such as; serum, 
plasma, stool, urine, CSF, etc 
.-\< 
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Data extracted: 
General Information 
Date of data extraction 
Identification features of the study: 
Record number 
Author 
Article title 
Citation 
Study details 
Disease 
Sample type 
DBS Topic 
Assay details 
Extraction method 
Detection method 
Results 
Sensitivity 
Specificity 
Key findings 
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10.2.2 FLOW CHART OF INCLUDED AND EXCLUDED STUDIES 
4011 Titles and abstracts 
reviewed for relevance 
J Excluded 3524: Not relevant to study question rl 
.I Excluded 92: not evaluating 
I filter paper 
I Excluded 60: conferen.:e 
rl abstracts 
, 
296 Full copies retrieved and 
assessed for eligibility 
Included 104 Publications 
I 
I 
Excluded 38: meeting 
summaries 
Excluded 60: No DBS 
evaluation 
Excluded 7: Not currently 
commercially available 
Excluded 34: in-house method 
Excluded 15: no diagnostic 
assays 
Excluded 31: no suitable "gold 
standard" used 
Excluded 16: not peer reviewed 
Excluded 26: non-human/ not 
whole blood evaluated 
I 
I 
I 
I 
Articles assessed for practical 
use of filter paper, samples 
other than blood and veterinary 
health 
Included 192 Publications 
Excluded 65: Not relevant to 
study questions 
Excluded 23: No suitable 'gold 
standard' used 
Excluded 16: not peer reviewed 
139 - filter paper practical aspects 
33 - non-whole blood samples 
20 - veterinary health 
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10.2.3 SUMMARY OF STUDIES EVALUATING DBS FOR HIV AND HTLV1 
Disease," ~ Number of 
Assay t~pe &. samples & filter 
country. ' . Author paper type 
HIV 1& 2 BoHLot et al. 359 sampLes 
serology (1997)(131) Whatman No.3 
Sierra Leone(131) 
India 
HIV 1 
serology 
BrazH(132) 
Rwanda 
Zimbabwe 
Lakshmi et al. 
(2007)(134) 
Castro et al. 
(2008)(132) 
ChaiLlet et al. 
(2009)(446) 
225 samples 
Whatman No. 3 
457 sampLes 
Whatman 903 
491 samples 
Whatman 903 
Mashange et al. 379 sampLes 
(2003)(135) Whatman No.35 
Sensitivity Specificity Notes 
Test % % 
Innotest (diagnostics 100 (HIV1) 100 
pasteur) 87.5 (HIV2) 
Murex Ag/Ab ELISA 100 (HIV1) 100 
(Murex Biotech) 
Q-Preven HIVl +2 100 
(Symbiosis 
Diagnostika) 
Uni-Form 2 (Abbott) 100 
& HIV-l.2.0 
(BioMerieux) 
GeL Particle 100 
AggLutination !OO 
HIV1&2 (Serodia) & 
Recombigen HIV1&2 
ELISA (Trinity 
Biotech) 
99.6 
99.1 
98.7 
99.6 
0/0 
DBS 2.3 times cheaper than venous 
bLood collection (BoHLot et al.) 
HIV 1&2. Also tested on 12,617 
patients for seroprevalence with overall 
sensitivity 99.6% and specificity 
99.9%, based on subset of samples 
evaLuated with PCR. (Lakshmi et al.) 
l> 
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Disease, Number of 
Assay type !t samples & filter Sensitivity Specificity Notes 
countr~ Author ~a~ert~~e Test % 0/0 0/0 
The Gambia Sarje-Njie et al. 200 samples ICE HIV1.0.2 NR NR PooUng of 5 DBS samples would not 
(2006)(136) Whatman BFC 1806 ELlSA,(Wellcozyme) lead to any missed positives. (Sarje-
HIV recombinant Njie et al.) 
(Murex), ICE HIV2 
ELISA GPA 
India Solomon et al. 89 samples HIVltt2 (Serodia), 100 100 00 decUned after 6 days storage at 
(2002)(137) Whatman 903 Pepti-LAV 1/2 (Sanofi) 36.8C tt 70% humidity. (Solomon et al.) 
, Micro-ELISA 
(Vironostika) 
HIV 1 Cachiafeiro et 617 samples Modified Up24 Ag 94.4 100 Storage of > 30 months, decreased 
serology (p24) al.(2009)(138) Whatman 903 (Perkin Elmer) sensitivity to 72.2% (39/54 samples) 
Dominican Rep, (Cachiafeiro et al.) 
USA, Vietnam, 
Malawi 
Tanzania I<nuchel et ai. 282 sampLes HIV p24 Ag (Perkin 84 100 Non subtype 0 sensitivity: 93% 
SwitzerLand (2007)(139) Whatman No.3 ELmer) ~ Non subtype C sensitivity: 94% 
(I<nucheL et al.) 
MaLawi Mwapasa et al. 222 samples ELISA Alliance HIVl 84 98 Study only included clear positive and 
(2010)(140) p24 without ELAST negatives. (Mwapasa et al.) 
(Perkin Elmer) 
» 
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Disease, Number of 
Assay type & samples & filter 
country ·· Author paper type 
South Africa Patton et ai. 141 samples 
South Africa 
HIV 1 
NAAT(DNA) 
ThaHand(143) 
Tanzania 
Tanzania 
South Africa 
South Africa 
South Africa 
(2006)(142) Whatman NO.1 
Patton et ai. 
(2008)(141) 
246 patients 
Whatman No.3 & 
nO.l 
Leelawiwat et ai. 162 samples 
(2009)(143) Whatman 903 
Lofgren et a.l 176 samples 
(2009)(144) Whatman 903 
Nsojo et al. 325 samples 
(2010)(145) Whatman 903 
Stevens et al. 206 samples 
(2008)(147) Whatman 903 
Patton et ai. 300 samples 
(2007)(146) Whatman NO.1 
Sherman et ai. 800 samples 
(2005)(130) Whatman 903 
Sensitivity Specificity Notes 
Test 
Ultrasensitive p24 
Ag ELISA (Perkin 
Elmer) 
Ultrasensitive p24 
Ag ELISA (Perkin 
Elmer) 
% 0/0 
98.8 100 
96.6 100 
(W. NO.1) 
9B.3 (W.903) 100 
Amplicor HIV-l DNA 100 100 
v. 1.5 PCR (Roche) 
-- -. 
Cobas AmpliPrep/ 97 100 
TaqMan DNA (Roche) 
AmpUcor HIV-l DNA 98.3 99.6 
vl.5 PCR (Roche) 
Amplico'r HIV-1DNA 9B.3 100 
vl.5 PCR (Roche) 
Amplicor HIV DNA 100 99.6 
v1.5 PCR (Roche) 
Amplicor HIV-l DNA 99 99.B 
vl.5 peR (Roche) 
0/0 
Only children included: 34 days - 12yrs 
old. After 6 weeks storage, sensitivity 
dropped to 88.9%. (Patton et al. 2006) 
Desiccant improved sensitivity for 
storage >6 weeks. (Patton et ai. 200B) 
Same results for manual and 
automated methods (Nsojo et al.) 
. On restesting false negatives, 
sensitivity increased to 100% (Patton 
et al.) 
J> 
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Disease, Number of 
Assay type & samples & filter 
country '" Author paper type 
HIVl NAAT (RNA) Leelawiwat et al. 162 samples 
Thailand (143) 
South Afrlca 
Senegal 
(2009)(143) Whatman 903 
Lilian et al. 
(2010)(150) 
Kebe et a1. 
(2011)(148) 
235 samples 
Whatman 903 
149 samples 
Whatman 903 
HIV 1 NAAT DNA & Huang et al. 45x6 sets 
RNA (2011)(153) Whatman 903 
USA(153) 
7 countries Kerr et al. (2009) 291 samples 
worldwide (149) Whatman 903 
Tanzania Lofgren et al. 176 samples 
(2009)(144) Whatman 903 
Sensitivity Specificity Notes 
Test 
manual NucliSENS 
(BioMerieux) 
% 
100 
NucUSens EasyQ 100 
peR v.? (BioMerieux) «3months 
old), 100 
(3-12 
months old) 
NucliSens 100 
EASYQ HIV 
v1.2(BioMerieux) 
RealTime HIV-1 NR 
quaUtative (Abbott") 
APTIMA HIV-1 RNA 99.2 
Qualitative Assay 
(Gen-Probe) 
RealTime HIV-1 100 
quantitative (Abbott) 
0/0 
100 
0/0 
HIV 1. VL also measured and was 0.4 
log lower in DBS. 
95.6 <3m DNA more stable than RNA. Stored at 
1003-12m -20 detection ok until 9 months storage 
except low VL whlch were stored at -70 
(Leelawiwa1 et al.) 
100 Age; 3 weeks -:- 24 months (Kebe et al.) 
100 LoD 95% Probit was 3085 IU/ml 
(Huang et al.) 
100 HIV 1. LoD 20-200 copies/ml, lower 
in DBS due to contribution of cellular 
RNA. 1 false pos was stored for 4years 
and had low initial VL (Kerr et al.) 
99 Results at a threshold of > 1000 copies/ 
ml (100% for sens & spec at >10,000) 
» 
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Disease, Number of 
Assay type & samp-les {to filter Sensitivity Specificity Notes , 
countr~ Author 2a2er t~2e Test % 0/0 0/0 
USA Nugent et al. spiked samples APTIMA HIV-l 100 NR For RNA vs DNA at >1000 copies/ml 
(2009)(151) only RNA Qualitative (86 Et 100% at >10,000) 
Whatman 903 Assay(Gen Probe) 
South Africa Stevens et al. 800 samples Cobas AmpliPrep/ 99.7 100 LaD: lx6mm punch = 10,217 copies/ 
(2008)(147) Whatman 903 TaqMan HIV-l Qual. ml. 1 spot (13mm) = 2384 copies/ml 
(Roche) 
South Africa Stevens et al. 494 samples APTIMA HIV-l RNA 100 99.7 
(2009)(152) Whatman 903 Qualitative Assay 
(Gen-Probe) 
HIV-1 Solomon et al. 89 samples Western Blot 92 100 
confirmation (2002)(137) Whatman 903 (Biorad) 
India 
~~~~~ 
HTLVl Parker et al. 26 samples Latex Agglutination 100 100 Based on a reference panel of samples 
Serology (1995)(157) Whatman 903 Test, Serodia HTLV1, from known positives. 
Japan, UK, South (Fujirebio) 
Africa 
----
HTLV 1 Noda et al. 53 samples In-house PCR 100 100 DNA remained detectable after 7 
NAAT (1993)(156) Whatman 903 weeks storage at room temperature. 
Japan 
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10.2.4 SUMMARY OF STUDIES EVALUATING DBS FOR HEPATITIS VIRUSES 
Disease, 
assay type, ,, Number of samples & 
Countr~ Author filter ~a~er t~~e Test Sensitivit~ % S~ecificit~% Notes 
HCV serology Croom et ai. 183 samples Monolisa anti- 100 100 Choke of elution buffer influences 00 
(2006)(103) Whatman 903 HCV PLUS Version value 
Australia (103) 2 EIA (Bio-Rad) 
UI< Judd et aI. 643 samples Ortho HCV 3.0 99.2 100 Adjusting cut-off can improve 
(2003)(158) Whatman 903 (Ortho) sensitivity 
France Tuaillon et al. 200 samples Ortho HCV 3.0 99 98 
(2010)(159) Whatman 903 (Ortho) 
HBV (HBsAg) Mendy et al. 209 samples Determine HBsAg 96 100 Also applied Alpha-foeto protein tests 
(2004)(160) W. BFC180 (Abbott) on DBS samples for hepatocellular 
Gambia(160) carcinoma 
~ -- - ~- ~-
Brazil Villar et al. 133 sampLes ETI-MAK4 97.6 96.7 
(2011)(447) Whatman 903 (OiaSorin) 
HBV (anti-HBc) Villar et al. 155 samples ETI-AB-COREI< 90.5 92.6 Storage at -20 gave lowest 00 
Brazil (2011)(447) Whatman 903 PLUS (DiaSorin) variation, suggesting best storage 
condition 
HBV (anti-HBs) VilLar et al. 134 sampLes ETI-AB-AUK-3 78 97.3 
BraziL (2011)(447) Whatman 903 (OiaSorin) 
HCV Solmone et al. 53 samples Versant HCV TMA 100 >95 » ":) 
NAAT (2002)(163) (Bayer) ":) tv CD ...... 
+=--
"..... 
ItaLy ro 0 lJ') 
N 
~ 
~ 
Disease, 
assay type, Number of samples & 
Country Author 'tilter paper type Test Sensitivity % Speci'ticity% 
France 'V' TuaHLon et al. 200 sampLes Cobas Taqman 97 NR 
(2010)(159) Whatman 903 HCV (Roche) 
HEV Merens et al. 89 samples In-house (Enouf 84 88 
NAAT ' (2009)(448) Whatman 06) 
Sudan Merens et al. 92 sampLes In-house (Enouf 93 96 
(2009)(448) Isocode stix 06) 
NR= not reported 
Notes 
HCV RNA is susceptible to 
degradation, store DBS at -200 C 
Multiple tests are necessary for HEV to 
obtain high sensitivity 
HEV viremia detectabLe for >39 days 
after onset of jaundice 
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10.2.5 SUMMARY OF STUDIES EVALUATING DBS FOR OTHER VIRUSES 
Disease, Number of 
assay type samples & filter Sensitivity Specificity 
Countr~ Author ~a~ert~~e Test 0/0 0/0 Notes 
CMV Dowd etal. (2011) 75 samples CMV IgG (Diamedix) 93 94 
serology (106) Whatman 903 
USA 
EBV Fachiroh et al. (2008) 140 samples In-house IgA ELISA 80 100 ~': performance on venous 
sero'logy (179) Whatman 903 (fachiroh 06) blood instead of capHlary 
Indonesia 96~': 93.6 ~: blood 
--- -..-.------. 
Fachiq)h et al. (2008) 140 samples In-house IgA ELISA 75 97 * performance on venous 
(179) W.No.3 (fachiroh 06) blood instead of capillary 
89* 97* blood 
HSV Hogrefe et al. (2002) 22 samples Herpeselect (Focus) NR NR 
erology (449) W. No.3 
USA 
Measles Riddell et al. (2002) 216 samples Enzygnost IgM (Oade- 90.2 98.8 
serology (450) Whatman 903 Behring) 
Australia (450) 
Australia Riddell et al. (2003) 98 samples Enzygnost IgG (Dade- 96.2 92 DBS OD values were adjusted 
(178) Whatman 903 BehriQg) (00 ~': 1.28) to correlate with 
matching serum samples 
Uganda Uzkanin et ai. (2011) 588 samples Enzygnost IgM (Oade- 98.7 88.9 2-5 weeks after rash, 
(177) Whatman 903 Behring) collected samples were 100% 
sensitive and specific » 
::::::J 
:::J 
N CD 
~ CD 
N . .J'I 
Disease, Number of 
assay type samples & filter Sensitivity Specificity 
Country Author paper type Test 0/0 0/0 Notes 
... ~t' 
Rubella Karapanagiotidis et al. 88 sampLes Enzygnost IgM (Dade- 96 100 DBS can be shipped 
serology (2005)(451) Whatman 903 Behring) internationally 
Australla (451) 
Peru HeLfand et al. (2001) 87 sampLes Captia IgM (Sanoft) NR NR 94% concordance (4 DBS 
(452) Whatman 903 and 3 serum indeterminate 
WampoLe IgG (ALere) NR NR resuLts) 
93'0/0 concordance (2 DBS 
and 4 serum indeterminate 
resuLts) 
Peru HeLfand et al. (2007) 273 sampLes Enzygnost IgM (Dade- 98 97 
(452) Whatman 903 Behring) 
Enzygnost IgG (Dade- 99 98 
Behring) 
UK HardeUd et al. (2008) 73 sampLes Enzygnost IgG (Dade- NR NR 
(453) Whatman 903 Behring) 
IgG ELISA (Diesse) 
'"f"'-_ 
CMV Binda et al. (2004) 195 sampLes (MV EarLy Ollgo Mix 100 100 Umit of detection: 4000 
NAAT (180) Whatman 903 (BioUne- AmpUmedicaL) copies/mL whoLe bLood » 
ItaLy ::::::i ::::::i 
N r;) 
.t::"-
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10.2.6 SUMMARY OF KEY STUDIES EVALUATING THE DIAGNOSIS OF 
INFECTIOUS DISEASES ON FILTER PAPER USING SAMPLES OTHER 
THAN WHOLE BLOOD. 
Sample Type Notes Reference 
Bone Marrow 
Visceral Leishmaniasis PCR positive in 34 of 35 dried bone Alam et al. (2009) 
(251) PCR marrow samples from patients 
clinically' suspected of having visceral 
leishmaniasis. 
Serum 
Hepatitis A IgM, IgG & 
PCR 
Hepatitis C PCR 
HIV ELISA 
Plasma 
HIV Quantitative PCR 
BU/fycoat 
HIV Proviral DNA PCR 
Hepatitis A IgM & IgG ELISA was Desbois et af. 
both 100% sensitive and specific (2009)(244) 
compared to serum. HIV ELISA was Abe et af. (1998) 
able to detect infections of less than 6 (246) 
months duration with a sensitivity of Barin et af. (2005) 
83%. (454) 
Hepatitis A PCR was 92.3% sensitive 
and 100% specific and Hepatitis C 
PCR 100% sensitivity and specific, 
though with a very small sample size. 
Both Hepatitis A and C showed a 10-
fold drop in viral load after 4 weeks 
storage at room temperature. 
Good correlation was observed in all" 
3 studies, between whole plasma and 
dried plasma spots and also between 
DBS and dried plasma. 
HIV RNA was more stable stored on 
paper at room temperature than as 
whole liquid plasma and was stable 
for more than 1 year. 
Ayele et af. (2007) 
(247) 
Cassol et af. 
( 1997)(248) 
Brambilla et al. 
(2003)(249) 
100% concordance of proviral DNA Rossi de Gasperis 
extracted from dried buffy coat spots et af. (2010)(250) 
with DNA extracted from whole blood. 
244 
Sample Type 
Skin lesion samples 
Cutaneous 
Notes 
Sensitivity ranged from 92.3 to 
Anne)'es 
Reference 
Leishmaniasis PCR on 100% and specificity up to 100% 
Fata et of. (2009) 
(253) 
dried skin exudates using PCR directly on a lesion sample 
as the reference sample. Filter 
paper comparable to PCR on tissue 
and superior to microscopy and 
culture. leishmania speciation also 
successfully performed. 
Boggild et of. 
(2010)(252) 
Kato et of. (2010) 
(455) 
Aye et of. (2011) 
(254) 
Leprosy PCR on skin slit 116 of 192 multibacillary leprosy 
smears patients positive on FTA Elute paper. 
Breast mille 
HIV Quantitative PCR 
Sputum 
HIV PCR 
Measles PCR 
HHV 6 & 7 PCR 
Tuberculosis PCR 
Malaria (P. falciparum) 
PCR 
Pneumocystis jirovecii 
PCR 
Equivalent to standard method of 
storage in 70% ethanol. 
No statistical difference between viral Ayele et of. (2007) 
load in dried breast milk and breast (247) 
milk in lysis buffer (gold standard). 
Low sensitivity for the detection of Kakizawa et of. 
HIV RNA in saliva compared with (1996)(456) 
whole blood. Chibo et of. 
Dried saliva less sensitive than (2005)(256) 
whole saliva & nose/throat swab for Guio et of. (2006) 
measles by PCR. 67% of serologically (457) 
confirmed cases positive by PCR. " Mharakhurwa et 
Sensitivity and specificity for HHV6 & of. (2006)(257) 
7 were comparable with whole saliva Zerr et of. (2000) 
samples. (458) 
M. tuberculosis PCR sensitivity Nuchprayoon et 
82%, specificity 96% - greater of. (2007)(258) 
than microscopy. DNA detected 
even after 6 months storage at 
room temperature. Thickest parts of 
purulent sputum must be applied to 
paper. 
Malaria DNA detectable in saliva and 
urine. Sensitivity poor when compared 
with microscopy. Refinements to 
methods required. 
Induced sputum and brochoalveolar 
lavage dried on paper had similar 
sensitivity and specificity of 67 & 90-
91 % - compared with direct PCR. 
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Sample Type 
Cervkal sample 
HPV peR 
Stool 
Vibrio cholera culture 
Enterocytozoon 
bieneusi PCR 
Adenovirus 40 & 41 
PCR 
Norovirus PCR 
Rotavirus PCR 
Urine 
CMV PCR 
Cerebrospi na l fluid 
Streptococcus 
pneumoniae Et 
Haemophilus 
influenzae PCR 
Neurocysticercosis 
ELISA 
Notes 
Two studies reported excellent 
concordance of 94-100% between 
Anne>(es 
Reference 
Gustavsson et al. 
(2009)(259) 
filter paper and cervical smear or I<ailash et al. 
cytobrush samples(259, 260). Banura (2002)(260) 
et al. found low agreement with a Banura et al. 
kappa of only 0.18. DNA is stable for 1 (2008)(261) 
year at r(jom temperature. 
No significant difference between 
filter paper and standard transport 
medium for culture of Vibrio cholera. 
Samples viable after 14 days storage 
when kept moist. . 
Viral enteric pathogens are all readily 
stored and identified by PCR from 
filter paper after up to 4 months. 
90% concordance with d.irect urine 
DNA extraction and PCR 
Page et al. (2011) 
(263) 
Carnevale et al. 
(2000)(459) 
Zlateva et al. 
(2005)(266) 
Wollants et al. 
(2004)(264) 
Rahman et al. 
(2004)(265) 
Nozawa et al. 
(2007)(267) 
Sensitivity and specificity for 
Streptococcus pneumoniae and 
Haemophilus injluenzae were 92 Et 
700/0, and 99 % 100% respectively. 
Peltola et al. 
" (2010)(262) 
There was good correlation in genome Fleury et al. 
counts between liquid and dried CSF. (2001)(227) 
High specificity of >90% but low 
sensitivities of 52-63°;0 depending on 
the type of paper used. 
246 
10.2.7 STARD CHECKLIST 
STARD CHECKLIST FOR REPORTING OF STUDIES OF DIAGNOSTIC ACCURACY 
ADJUSTED FOR DRIED BLOOD SPOT EVALUATION STUDIES 
Section and Topic 
TITLE/ABSTRACT / 
KEYWORDS 
INTRODUCTION 
METHODS 
Participants 
Test methods 
Statistical methods 
Item 
# 
2 
3 
4 
Amendments highlighted in blue, 
(version August 2012) 
Identify the article as a study of diagnostic accuracy (recommend MeSH heading 
'sensitivity and specificity'). 
Make usc of terminology: i.e. Dried Blood Spots, Dried Serum Spots, Dried Urine 
Spots, Dried Fluid Spots, etc. 
State the research questions or study aims, such as estimating diagnostic accuracy 
or comparing accuracy between sample types or across participant groups. 
The study population: The inclusion and exclusion criteria, setting and locations 
where data were collected. 
Participant recruitment: Was recruitment based on presenting symptoms, results 
from previous tests, or the fact that the participants had received the index tests or 
5 the reference standard? 
Participant sampling: Was the study population a consecutive series of participants 
defined by the selection criteria in item 3 and 4? If not, specify how participants 
6 were further sclected. 
Data collection: Was data collection planned before the index test and reference 
7 standard were performed (prospective study) or after (retrospective study)? 
Sample collection: State which filter paper was used, which and how fluids were 
8 obtained and spotted onto filter paper, and the drying period before storage 
9 
The reference standard and its collection, storage, and transportation details. If 
reference sample was not performed with the same tests or manner as the index 
sample, provide detailed rationale 
The index sample and its collection, storage, and transportation details. Provide 
10 detailed rationale for discordances in methods between index and reference test 
11 
Sample processing: state the time and storage conditions (humidity control and 
temperature) at the field, during transportation, and at the laboratory, preferably in 
a tabled manner. 
Punching method with reference to source or manufacturer, and cleaning proce-
12 dure, ifused. 
Technical specifications of material and methods involved including how and when 
measurements were taken, and/or cite references for index tests and reference 
13 standard. 
Definition of and rationale for the units, cut-otIs and/or categories of the results of 
14 the index sample and the reference standard. 
For quantitative or numerical test results, indicate the calculation methods and 
15 rationale of the index and reference standard 
The number, training and expertise of the persons executing and reading the index 
16 sample and the reference standard. 
Whether or not the readers of the index tests and reference standard were blind 
(masked) to the results of the other test and describe any other clinical information 
17 available to the readers. 
18 
19 
Methods for calculating or comparing measures of diagnostic accuracy and bias 
(e.g. Bland Altman), and the statistical methods used to quantify uncertainty (e.g. 
95% confidence intervals). 
Methods for calculating test reproducibility, lower limit of detection, if done. 
For quantitative test outcomes, the mean and range of results for index and refer-
20 ence test. 
On page 
# 
247 
RESULTS 
Participants 
Test results 
Estimates 
DISCUSSION 
21 
22 
When study was performed, including beginning and end dates of recruitment. 
Clinical and demographic characteristics of the study population (at least informa-
tion on age, gender, spectrum of presenting symptoms). 
The number of participants satisfying the criteria for inclusion who did or did not 
undergo the index tests and/or the reference standard; describe why participants 
23 failed to undergo either test (a flow diagram is strongly recommended). 
24 
Time-interval between the index tests and the reference standard, and any treat-
ment administered in between. 
Distribution of severity of disease (define criteria) in those with the target eondi-
25 tion; other diagnoses in participants without the target condition. 
A cross tabulation of the results of the index tests (including indeterminate and 
missing results) by the results of the reference standard; for continuous results, the 
26 distribution of the test results by the results of the reference standard. 
27 Any adverse events from performing the index tests or the reference standard. 
28 
Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% 
confidcnce intervals). 
For quantitative test outcomes, Estimates of diagnostic accuracy and measurcs 
of statistical uncertainty (e.g. 95% confidence intervals) by quantitative grouped 
29 ranges (e.g. 1,000-5,000 copies/mL). 
How indeterminate results, missing data and outliers of the index tests were 
30 handled. 
Estimates of variability of diagnostic accuracy between subgroups of participants, 
31 readers or centers, if done. 
32 Estimates of test reproducibility, ifdone. 
33 Discuss the clinical applicability of the study findings. 
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10.2.8 REFERENCES OF EXCLUDED IN-HOUSE ASSAYS 
"IV 
!:...n n c:"<c~s 
Comeau(460) De Crignis(283) luo(461)Mehta(462)Ou (463)Panteleeff(464) Nyambi(465)Jacob(466) 
Chohan(467) Walter(468) Zhang(469)Youmo(470, 471) Barin(454)Beck(472) Bellisario(473)Cas-
sol(474, 475) Lindhardt(476) Newell(477)Sriwanthana(478) 
HEPATITIS B & C 
Parker( 479) De Crignis(283) Gupta( 480) Lira( 481) 
CMV 
Soetens(482) Scanga(483) Vauloup-Fellous(484) Yamamoto(485)Atkinson(486) Barbi(487, 488) 
Boppana( 489) 
1\1EASLES 
Condorelli(490)De Swart(491) El Mubarak(492) 
RUBELLA 
Punnarugsa( 493) 
:~ 
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10.3 ANNEXES TO CHAPTER 3 
10.3.1 INCLUSION AND EXCLUSION ALGORITHM 
Search 15-2-2010 
265 Titles and abstracts 
reviewed for relevance 
-'" 
~ 
35 Full copies retrieved and 
assessed for eligibility 
---. 
~ 
, 
Included 11 Publications J 
Excluded 21S: Not relevant 
to study question 
I Excluded 15: Paediatric study 
Excluded 8: Not research 
articles 
Excluded 2: in-house 
methods or not commercially 
available 
Excluded 2: qualitative HIV 
RNA 
Excluded 3: Evaluation of 
DP5 
Excluded 8: Drug resistance/ 
DNA 
Excluded 1: no valid 
reference (DPS) 
Search 10-1-2012 
208 Titles and abstracts 
reviewed for relevance 
17 Full copies retrieved and 
assessed for eligibility 
Excluded: 191 Not relevant 
to study question 
11 Not research articles 
Excluded 2: in-house 
methods or not commercially 
available 
t------.tJ Excluded 2: infant diagnosis 
I Included 2 Publications I 
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10.3.2 SEARCH STRATEGY PROTOCOL 
Systematic review of HIV DBS: Search strategy protocol 
Databases 
MEDLlNE: All aspects of clinical medicine, biomedicine, nursing, dentistry, 
allied health, health policy, genetics etc. Emphasis on English-language 
source, quite biased towards journals published in N. America. Includes 
journal articles from 1950s onwards and is updated daily. 
EMBASE: All aspects of clinical medicine, biomedicine, nursing, dentistry, 
allied health, health policy, genetics etc. Quite biased towards information 
in journals published in Europe. Particularly strong on pharmaceutical 
information. Includes journals from 1947 onwards and is updated weekly. 
Search Terms 
Search Embase: 
("1998/01/01"[Publication Date] : "3000"[Publication Date]) AND 
((((dried[tw] OR dry[tw]) AND (spot[tw] OR spots[tw]) AND blood[tw]) OR 
dbs[tw] OR filter paper[tw] OR filter papers[tw] OR guthrie cardl'([tw] OR 
903 paper[tw]) AND (hiv~'([tw] OR human immunodeficiency virus~'([tw] OR 
human immune deficiency virus~'([tw] ) AND (DNA~'( OR RNA OR infant OR 
heonatl'() 
Search medline: 
• ((dried or dry) and blood and spot}'() 
• (dbs or "filter paper~'(" or "guthrie card}'(" or "903 paper") 
• (hiv~'( OR "human immunodeficiency virus~'(" OR "human immune 
deficiency virus-::" OR HIV-l) 
• (DNA[tw] OR RNA OR infant OR neonate OR neonatal OR infants~'r) 
• ("early infant diagnosis"OR EID) 
• limit to yr="1998 -Current" 
• 1 OR 2 AND 3 AND (4 OR 5) 
Date 
• 
1998 to pre~ent 
251 
Language 
English 
Publication type/status 
Published works in peer reviewed journals. 
Study selection 
Stage 1: Screening of titles/ abstracts against inclusion criteria. 
h Il n (: irs 
Titles and abstracts, where available, will be screened and either accepted, 
rejected as not relevant, or rejected due to failure to meet inclusion criteria 
(if so, the reason will be specified). 
Stage 2: Full papers obtained and assessed against inclusion criteria. 
Papers will be either accepted or rejected due to failure to meet inclusion 
criteria and the reason will be specified. 
Full papers will be independently assessed by TWO members of the review 
team and results will be cross-checked and combined. 
Inclusion Criteria 
Evaluation or comparison of performance of commercially available 
DNA/RNA assays with DBS and reference sampling methods 
• Evaluations based on human clinical or reference materials 
Exclusion criteria 
Not an evaluation study or not having a correct reference sample or 
reference method 
In-house developed assays or a no longer commercially available assay 
Studies with other primary aims other than evaluation of DBS for early 
infant diagnosis with reference samples ~': 
Studies related to drug resistance screening, genotyping, sequencing, 
other "non-diagnostics" evaluation studies 
Studies with a population that does not include newborns or infants 
Study written in a language which is not English 
252 
Data Extraction 
General Information 
Date of data extraction 
Identification features of the study: 
Record number 
Author 
Article title 
Citation 
Study Characteristics 
Aim/ objectives of the study 
Filter paper type 
Participant/ Sample Characteristics 
Characteristics of population from which 
samples were drawn: 
Age 
Sex 
Number of samples 
Sample country/ region of origin 
Sample type (finger prick/ EDTA/ .. ) 
DBS storage: 
At research site 
At laboratory 
Use of desiccants 
Type of reference sample 
DBS quality check performed? 
Technology 
Name and manufacturer of assays under 
evaluation 
Extraction method 
Extraction volume/adjustments 
Extraction kit/ method used 
Detection method 
If quantitative; adjusted for DBS sample input? 
Outcome datal results 
Unit of assessment/ analysis 
253 
Outcomes: 
NA: 
Mean pathogen load + standard deviation 
Range of pathogen load 
Correlation (r) 
Bias (mean difference) 
Sensitivity, cut-off 
Specificity, cut-off 
0/0 CV index test, reference test 
Serology: 
Sensitivity, cut-off 
Specificity, cut-off 
Cut-off adjusted for DBS? 
Titre lower limit of detection 
Variability, cut-off, replicates 
For each pre-specified outcome: 
Reported (YIN) 
Definition used in study 
Additional outcomes reported 
Details of any additional relevant outcomes 
reported 
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Quality Assessment 
Titlel abstract 
Introduction 
Methods 
Participantl Sample 
Characteristics 
Test methods 
Statistical methods 
Results 
Participants 
Test results 
Discussion 
Is the article easily identified as a study of test 
evaluation? 
Does it clearly state the research question and 
study aims? 
Do the authors clearly describe the study 
design? 
Are study inclusion and exclusion criteria 
provided? 
Were steps taken to introduce blinding 
and random allocation where possible and 
appropriate? 
Is the population from which the samples 
were drawn described? 
Is the country/ region of sample origin 
detailed? 
Were the samples collected prospectively? 
Do the authors describe how the samples 
were acquired, stored and prepared? 
Was the choice of anticoagulant appropriate 
for the technology? 
Were staff traineq, in the use of the technology 
prior to performing the index and reference 
tests? 
Was the reference standard explained in 
sufficient detail to be reproduced? 
Is the index test explained in sufficient detail 
to be reproduced? 
Did the authors report the number of 
technicians reading the index/ reference 
tests? 
Was a single sample divided and tested by 
each technology included in the study or were 
a different set of samples used for each test? 
Were the methods used reported in detail? 
Were the methods used appropriate? 
Were the demographic characteristics of the 
population described? 
Was the distribution/ range of viral load of the 
sampled population reported? 
How were the data presented? 
Was subgroup analysis performed for different 
HIV-l subtypes? 
Was the clinical relevance of the study 
findings discussed? 
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10.3.3 SUMMARY OF STUDIES THAT EVALUATED THE USE OF OBS FOR HIV VL AND flO 
sample # spots DBS elutiol1 Extraction 
Author origin 
HIV viral load 
ART +/- # sam2les S20t ~l used volume Elution 2rocess method Detection Platform 
Andreotti et al Malawi neg 102 75 1 2 ml Overnight, room NucliSens CaSAS TAQMAN RT 
T miniMAG analyzer 
---------
Arredondo et Spain 700/0 neg 154 50 2 2ml 120 min, room T M2000sp Abbott RealTIME HIV-l 
al 
Garndo et al Spain 103 50 1 2 ml 2 hours, gentle Manual NucUSens easyQ vl.l 
rotation NucUSens kit 
--- ---
Garrido et al Spain . 103 50 1 2 ml 2 hours, gentle M2000sp M2000rt 
rotation 
~..,....-.~ -
_ -r' ~- _____ 
-
Ikomey et al Cameroon 60 50 0.9ml RSC 10 min AmpUcor Monitor vl.5 
lysis 
Kane et al Senegal 33 50 2 2 ml 30 min, room T NucliSens NucliSens easyQ v1.2 
MiniMAG 
Leelawiwat Thailand pos 56 50 1 0.9ml 120 min, 25°C Manual AmpUcor Monitor vl.5 
et al NucliSens kit 
Lofgren et al Tanzania pos 137 50 2 1.7ml 2 hours, room T M2000sp M2000rt 
Marconi et al Italy 168 50 2 2 ml 2 hours, room T M2000Sp M2000rt 
Mbida et al Cameroon pos 41 50 2 1.7 ml 2 hours M2000Sp M2000rt 
Pirillo et al France 98 50 1 1.25 ml 30 min, Room T VERSANT Versant HIV-l kPCR 
preparation 
module 
v Deursen et al The pos 83 50 2 2 ml 30 min, NucliSens easy NucliSens easyQ v2.0 
» 
I Netherlands MAG :::J I_~~~._~-.-- _ .....---0 ___ "'-_-_.........,, _________ -_ ...... - ----" --> ...... _ ..... - --.- - - ----- -.- - ~ 
--
- - - _. - --- :::J 
N ~ Ln ro 
0\ VI 
~ 
U1 
"'-I 
sample 
Author origin 
Rottinghaus Nigeria 
, 
et al 
Vidya et 2l India 
Early infant diagnosis 
Anitha et al India 
Nsojo et al Tanzania 
Sherman et al South Africa 
Stevens et al South Africa 
Stevens et al South Africa 
ART +/- # sam~les S~ot l:!l 
neg 173 100 
---- -
100 50 
-- - -- - --- -- -- -
766 
325 20 
280 20 
- 800 70 
- 800 70 
# 'spots DBS elution 
used volume 
1 2 ml 
2 1.75 ml 
1 100 ul 
1 200ul 
1 200ul 
7~o: 200ul 
3.2mm 
1 1100ul 
Extraction 
Elution ~rocess method Detection Platform 
30 min, Room T NucliSens easy NucliSens easyQ vl.l 
MAG 
2 hours, 56°( M2000Sp M2000rt 
3 hours, 56°(, 10 (helex-l00 AmpUcor 1.5 
min 1000 ( resin 
15 min 60°C, Amplicor 1.5 
1000 ( 
15 min 60°(, AmpUcor 1.5 
1000 ( 
15 min 60°C, AmpUcor 1.5 
1000 ( 
10 min, 56°C ' Cobas Taqman 
AmpUprep 
l> 
::J 
::J 
ro 
....... 
ro 
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10.4 ANNE)(ES TO CHAPTER 4 
10.4.1 MANUSCRIPT 
j~nn('/ c's 
The accuracy and utility of syphilis point of care tests and 
laboratory assays in Tanzania 
Pieter W. SmiP·2*, David Mabey2, John Changalucha 3, Julius Mngara3, Benjamin 
Clark2.3, Aura Andreasen2.4, Jim. Todd2.3, Mark Urassa3, Basia Zaba2, Rosanna 
W Peeling2 
1 Leiden Cytology and Pathology Laboratory, Leiden, Netherlands 
2 London School of Hygiene & Tropical Medicine, London, UK 
3 National institute for Medical Research, NIMR Mwanza, Tanzania 
4 Mwanza intervention Trials Unit, Mwanza, Tanzania 
Abstract 
The availability of rapid and sensitive methods to diagnose syphilis facilitates 
screening of pregnant women, which is one of the most cost-effective health 
interventions available. We have evaluated four methods in Tanzania: the 
Treponema Pallidum Particle Agglutination assay (TPPA), the Treponema 
Pallidum Haemagglutination Assay (TPHA), an Enzyme Immuno Assay (EIA), 
and a point of care test (POCT) The POCT was performed in the clinic on 
whole blood, while the laboratory assays were performe~d on plasma at the 
laboratory 
In total, 2459 samples were tested and gave a TPPA seropositivity of 17.3%. 
With TPPA as reference assay, the sensitivity and specificity of TPHA was 
87.9% and 97.4%, of EIA was 95.3% and 97.8% , and of the POCT was 
59.6% and 99.4% respectively. The sensitivity of the POCT to detect active 
syphilis cases (TPPA positive and Rapid Plasma Reagin titre 2! 1/8) was 82%. 
The low sensitivity of the POC test is critical and should be further assessed 
under routine clinical use in African developing countries. Even though the 
sensitivity of the POCT is low, 'the sensitivity of detecting active syphilis cas-
es and large increase in accessibility of diagnostic tests makes the POCT the 
preferred choice for remote clinics in Tanzania. 
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Introduction 
The prevalence of syphilis is high among pregnant women attending 
antenatal clinics in sub-Saharan Africa [1]. During pregnancy, syphilis can 
have devastating effects on the developing foetus and is a major cause of 
stillbirths and neonatal deaths in Africa [2-4]. Screening and treatment of 
pregnant women with a single dose of benzathine penicillin before the 
third trimester could prevent up to 500,000 stillbirths and neonatal deaths 
annually, in Africa alone [5]. 
Serological assays are important for the diagnosis of syphilis. Laboratory 
based assays such as the Treponema Pallidum Particle Agglutination (TPPA), 
Treponema Pallidum Haemagglutination (TPHA), and Rapid plasma Reagin 
(RPR) are widely used. As the agglutination is interpreted by a technician, 
the test result is subjective. By the introduction of Enzyme Immunoassays 
(EIA) with a plate reader, test results could be read objectively and large 
quantities of samples could be processed. EIAs are suggested to be more 
robust and more sensitive than TPPA, but are also more expensive [6, 7]. 
These laboratory based assays are not available in rural health facilities in 
Africa. POCTs are easy to perform, require only a finger prick drop of blood, 
and do not require refrigeration; they could enable same day testing and 
treatment for syphilis at any health facility 
Comparative evaluations of these TPPA, TPHA, EIA and POCT assays have 
not been previously performed in Sub Saharan Africa [8]. Considering the 
major burden of syphilis in Sub Saharan Africa, this study was performed in 
Tanzania to evaluate the POCT against 3 laboratory assays. Besides the per-
formance of a test, kit costs, necessary equipment, cold chain requirements, 
and complexity of executing tests are essential for evidence based decision 
making and were included in the discussion. This study is performed to aid 
decision makers in developin"g countries to select a suitable screening test 
for syphilis . 
.. 
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Methods 
Samples and Field Procedures 
The Kisesa open cohort is a well established ongoing community-based 
study in Northern Tanzania [9]. The cohort study uses ,regular demographic 
surveillance with serological surveys, providing data on HIV incidence and 
prevalence [10]. Subjects that accepted Voluntary Counselling and Testing 
(VCT) were tested for HIV and syphilis using POCT. All subjects with a positive 
syphilis result were given free medical treatment according to Tanzanian 
government guidelines, and all those positive for HIV were referred to the 
Tanzanian care and treatment centre. The study was approved by the Medical 
Research Coordinating Committee of the National Institute for Medical 
Research in Tanzania and the Ethical Committee of the London School of 
Hygiene and Tropical Medicine. 
Whole blood was collected into heparinised tubes from consenting sub-
jects, by the VCT nurse, and transported to the National institute for Medical 
research (NIMR) laboratory in Mwanza. Within 24 hours the blood was cen-
trifuged and stored at -200C. Samples were collected from April 2010 until 
September 2010 and were tested until March 2011. Samples were bar-cod-
. . 
ed to ensure anonymous testing. Double data entry was used to enter the 
results. Results were entered automatically (EIA) or manually into the Labo-
ratory Information Management System (LlMS). 
Poi nt-of-ca re test 
The SO bioline syphilis 3.0 POC tests (Standard Diagnostics, Kyong gi-do, 
Korea) were performed by trained and experienced clinicians, with whole 
blood samples collected by venous puncture. A timer assured 15 minutes 
waiting time were applied before reading the test results. The manufacturer's 
procedures were followed. 
TPPA &TPHA 
(t 
A total of 2459 plasma aliquots were raised to room temperature and tested 
by use of TPPA (FuJirebio, Tokio, Japan) and TPHA (newlab21, UK). Both tests 
were performed according to the manufacturer's instructions. TPPA and 
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TPHA results were read by two trained and experienced technicians. The 
reading of the TPPA and TPHA occurred while masked to results of other 
tests. Discordant results between the two technicians were discussed and 
one outcome was agreed by consensus. Results were deemed indeterminate 
for biologically reactive samples or when a conclusive outcome could not be 
obtained due to difficulty in interpretation or lack of technician agreement. 
Enzyme Immuno Assay 
The Syphilis Enzyme Immuno Assay (EIA)(Lab21 healthcare, Kentford, UK) was 
performed on 1272 samples (50%). The EIAwas included halfway during 
the course of the study. The EIA was carried out according to manufacturer's 
instructions and read by Optical Density (00) 450/620nm by automated 
reader (DTX 800, Beckman Coulter, USA) which calculated the cut-off limit 
according to the instruction manual. The results were then entered directly 
into the Laboratory Information Management System (LlMS). 
The sensitivity, specificity, positive predictive value (PPV) and negative pre-
dictive value (NPV) were calculated according to standard calculations. The 
agreement between various methods was tabulated. Mi~rosoft Excel (Mic-
rosoft Corp., USA), the statistical package Stata 11 (Stata corp Lp,Texas, USA) 
were used for analysis of the results. 
Results 
In total, 2459 samples were tested with TPPA and TPHA, 2099 (85.3%) POCT 
were performed and 1273 (51.7%) were tested using the EIA. The syphilis 
seroprevalence was according to TPPA 17.1% , for TPHA 17.1%, for EIA 
19.3% and 10.7% according to POCT. 
The comparison between TPPA, TPHA and EIA is shown in table la-e. There 
was a 95.80/0 agreement between TPPA and TPHA and a 97.3% agreement 
between TPPA and EIA. The sensitivity and specificity of TPPA, TPHA and EIA 
are summarised in Table 2. Figure 1 shows the distribution of all positive 
samples iden'tified by one or more of the laboratory assays. 
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Table 1. Summary of samples tested with TPPA, TPHA, SO bioline 3.0, and EIA. 
TPPA EtA 
+ totaL + totaL 
TPHA + 364 52 416 TPHA + 205 25 230 
50 1959 2009 37 996 1033 
total 414 2011 2425 ~-: total 242 1021 1263~-: 
la. TPHA against TPPA lb. TPHA against EIA 
>'< 33 indeterminate, 1 not tested for TPHA >-< 10 indeterminate excluded 
TPPA EtA 
+ TotaL + TotaL 
. 
EtA + 222 23 245 poe + 114 6 120 
11 1016 1027 85 836 921 
Total 233 1039 1272 ~-: Total 199 842 1041 
le. EIA against TPPA ld. paCT against EIA 
>'< 1 not tested for TPPA 
TPPA 
+ Total 
poe + 214 11 225 
145 1729 1874 
Total . 359 1740 2099 
le. paCT against TPPA 
All discordant and indeterminate result obtained by any of the three laboratory 
. ~ 
methods were retested by TPPA, TPHA and EIA. When retesting all discordant 
results, 24 out of 50 TPPA positive discordant samples became negative, and 
11 out of 105 TPPA negative discordant samples became positive. For TPHA, 
41 initially positive samples became negative when retested and 11 initially 
negative discordant results became positive. Although EIA was performed 
on fewer samples than TPPA and TPHA, only five samples changed outcome 
when retested (5 initially positive samples became negative out of 41 
discordant results). 
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Figurel. Distribution of positive samples among the three assays. Numbers represents 
positive samples detected by three assays (number is given in 3 circles), or by two assays 
(overlapped by two circles) or by one assay (given as number below the assay name). 
TPPA 
Sensitivity Specificity PPV NPV I< 
(95% CI) (95% CI) 
TPHA 87.9°1<> 97.4% 87.5% 97.5°1<> 85.2°1<> 
(84.4 -90.7°1<» (96.6-98.0%) 
EIA 95.3% 97.8% 90.6% 98.9% 91.2% 
(91.8-97.3%) ( 96.7 -9 8. 5 % ) 
POCT 59.60% 99.40% 90.6% 98.9°;6 91.2% 
(54.5-64.60/0) (98.9-99.7 01<» 
Table 2. The TPHA and EIA performance are given against the TPPA as reference method. 
PPV= positive predictive value, NPV= negative predictive value, 1(= kappa correlation value, 
95% (I = 95% confidence interval. 
Point- of- care test 
The performance of the POCT with TPPA as reference is shown in table 
ld. To evaluate the sensitivity of detecting active syphilis cases, RPR was 
performed (Table 3). Of the 146 false negatives with TPPA as reference, 115 
(79%) were RPR negative and 31 samples were positive. Based on the RPR 
interpretation of the 145 false negatives, nine active syphilis cases were 
missed when using POCT instead of TPPA. Based on 2099 samples, 50 had 
an active syphilis infection (positive TPPA and RPR titre ~ 1/8) of which 41 
were detected by POCT, giving a sensitivity of 82% (69.2% -90.2%). 
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Anne)(es 
TPPA POCT RPR Samples 
< 1/8 ~ 1/8 Neg 
+ + 71 41 102 214 
+ 22 9 115 146 
+ 3 0 8 11 
44 9 1675 1728 
Total 140 59 1900 2099 
Table 3 The TPPA and POCT performance are given with RPR results divided into titres lower 
« 1/8) or higher than 1/8 (;~ 1/8), += positive, - = negative, Neg=negative 
Costs 
The kit cost (excluding labour) in Tanzania of one TPHA reaction is $0.18 -
$0.32 1 one EIA reaction is $0.42- $0.93 and one TPPA reaction costs $0.46. 
The costs vary depending on the size of the purchased kits. This simple 
calculation does not include the number of negative and positive controls 
necessary per run l which is higher for the EIA. The cost of the POC test was 
$ 1.10 per test in Tanzania. 
Discussion 
To our knowledgel this is the first study compa'ring TPPAI TPHAI POCT and EIA 
performed in an African setting. The TPPAI TPHA and EIA were comparable in 
performancel with TPHA yielding the lowest performance (88.4% sensitivity). 
It is important to note that this study was performed in Tanzania and on Tan-
zanian samplesl which potentially influence the results. African samples can 
contain high immunoglobulin levels due to other infections which potential-
ly cause false positive test results [11 1 12]. 
Although tests were performed and stored according to manufacturerls rec-
ommendationsl potential environmental effects by transporting and using 
the kits under tropical conditions could not be completely ruled out. There-
fore l performing tests in an African country relies more heavily on the ro-
bustness of the tests than i~ developed countries. This could potentially 
influence the test results. 
Based Or.1 the results found in this studYI it seems that both the EIA and TPPA 
perform well and are suitable to be ,used for syphilis screening in developing 
, 
countries. The TPHA is tess suitable due to limited reproducibility of results l 
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lower sensitivity compared to TPPA or the EIA, and more equivocal results. 
The reproducibility of the TPHA was limited due to the high number of sam-
ples that changed outcomes when retested, which could be an indication of 
difficulties in test interpretation or reduced reliability with low titre samples. 
There were very few discordant EIA results between the first test results 
and when retesting discordant results. Thesamples that were discordant had 
very low 00 measures, just above the cut-off. Therefore, EIA seems to be a 
more stable and reliable test, but it is debatable if the benefit outweighs 
the costs compared to TPPA. EIA's require a plate washer and a reader for 
objective interpretation of the results. Additionally, EIA's laboratory proce-
dures require more steps and more controls per run than TPPA, which could 
make TPPA a preferable option for handling smaller sample volumes. When 
a laboratory is experienced in interpreting agglutination results, it may be 
preferable to continue the use of TPPA instead of switching for the more 
objective and more expensive EIA. 
The performance of the POCT (59.6% sensitivity and 99.4% specificity) was 
below the manufacturer's claim (99.3% sensitivity and 99.9% specificity). 
~his is consistent with another multi-country comparispn study conduct-
ed in Africa which found a performance below the manufacturer's claims, 
although the sensitivity of POCT was higher than in this study (85.7%)[4]. 
This finding is concordant with other studies that found a reduced sensitiv-
ity when the POCT is performed on whole blood [13, 14]. Additionally, this 
study compared the POCT in a field setting while laboratory tests were per-
formed on plasma. 
For routine screening in developed countries, treponemal and non-trepone-
mal tests are combined to differentiate past and current syphilis infection. 
The positive samples that were missed by POCT were mostly RPR negative 
(77%) and only 9 out of 50 active syphilis cases were missed. This finding 
suggests that POCT is less sensitive than laboratory tests but still capable 
of detecting most active syphilis cases. Even though the sensitivity is low, 
POCT provides additional benefit~ compared to laboratory based assays. 
POCT require no refrigeration, provide fast results, and are easy to operate, 
enabling health care workers without access to laboratories to offer a same 
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day testing and treatment service [15]. The alternative test that was used at 
some rural clinics in Tanzania was RPR. If a health centre has a freezer and 
plate rotator, RPR can be performed, although the results obtained in rural 
clinics in Africa have not been encouraging [13]. 
The acceptability of losing sensitivity while gaining accessibility of diagnos-
tic tests is often misjudged. To emphasise the importance of accessibility 
of diagnostic tests, a study was conducted that evaluated the implementa-
tion of POCT in antenatal care clinics in Tanzania (Mabey, Plos one, in press). 
The use of POCT instead of RPR tests led to a 4 times increase of pregnant 
women being tested (3.561 with RPR versus 14.562 with POCT in 3 months). 
Because of this, 8.4 times more positive cases were detected with POCT. Al-
though the sensitivity of POCT is low, the increased accessibility of syphilis 
diagnostics increased the number of women screened and adverse births ef-
fects prevented. An improved POCT would be preferable but at the moment, 
these POCT are an acceptable solution for remote clinics in Tanzania. 
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10.5 ANNE}(ES TO CHAPTER 5 
No Annexes to Chapter 5. 
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10.6 ANNEXES TO CHAPTER 6 
10.6.1 PROTOCOLS DEVELOPED 
Quality assurance protocol for dried blood spots 
Standard operating procedure 3.0 
Subtitle: Laboratory protocol for TPPA testing using Serodia Fujirebio test kit 
ProtocollD: 3.0 
Date: March 2012 
Created by: Pieter Smit, Thomas van der Vlis 
Email address:Pieter.smit@lshmt.ac.uk 
Purpose of protocol: 
Serodia TPPA test kit from Fujirebio inc. for qualitative detection of Trepone-
ma Pallidum antibodies is used for the detection of syphilis on DBS samples. 
This protocol describes in detail the testing procedures when using DBS 
samples. The procedure is divided into two stages. The first stage explains 
the creation of a masterplate which needs to be incubated overnight. The 
second stage describes the TPPA test kit protocol using the masterplate as 
sample material. Test result interpretation is qualitative and described at the 
end of this SOP. 
TPPA testing should be performed after DBS card quality evaluation (proto-
collD 2.0). Printed 96 wells templates are needed to record test results. If 
bar-coded stickers on the DBS cards are used the printed template might be 
exchanged for an excel using a bar-code scanner device. The template to be 
printed can be found at the global health diagnostic website. 
* HEALTH AND SAFETY INFORMATION CAUTION: 
You are worl<ing with potentially infective materials. Read the manufac-
tures manual for safety regulation. 
Procedure (1): 
Materials needed: 
• Specimen DBS cards + empty DBS 
• Punch machine or punchers 
• Disposable gloves 
• Disposable tips 
• Pipette's (multi-pipette) 
• PBS quffer (96 1'c lOOul = 9,6ml for 1 plate)~'( 
• 96 fla"t we lls plate + cove r 
• Printed 96well~ template 
• Plate shaker 
* see page 4 (bottom) for detailed PBS-buffer requirements. 
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Operations: 
• Collect (sample) OBS cards 
• Set up 96 wells plate (number the plate for reference) 
• Leave well Ai empty for positive control 
• Punch blank card at Bl for blank control 
• Punch samples into the well's starting at Cl (followed by 01 etc) 
• For each punch, write down card-number on printed template 
• For each punch, write down what punch (number) you used in the small 
square (optional) 
• Add 100IJl of PBS buffer to each well (using multi-pipette) 
• Tap the plate from the side (3x), the spots will turn 
• Shake plate for -30sec on a shaker 
• Cover wells and place in a refrigerator (4 degrees Celsius) overnight to 
elute 
This is your master plate. 
Do not store the plate longer than 2 days (at 4 degrees Celsius) 
I. 
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Procedure (2): 
Serodia TPPA test (following within 2 days after creating master plate). 
Materials needed: 
• (Multichannel) Pipette's 
• Timer 
• Gloves 
Disposable tips 
• U-shaped 96 wells plate (2x.per one fully filled masterplate) 
1.5ml vial 
• Pen 
Pre-test 
• Prepare reagents 30min in advance. 
• Bring TPPA test kit at room temperature. 
• . Bring the Master plate at room temperature. 
• Every test requires 2 wells, so for a full master plate, 2 u-shaped 96wells 
plate are needed. 
Operations 
• Number the U-shaped 96 wells plate 1 and 2 if applicable and mark the 
plate's with numbers as on the masterplate. U-shaped 96 wells = U96W 
• Pipette 25IJl of sample diluents into the whole first column (Al-H 1) 
Repeat this step for column 3; 5; 7; 9 and 11 (A3-H3; A5-H5; A7-H7 etc) 
and go on, on the 2nd U96W plate if necessary. 
Elute 251.Jl of positive control (from kit) and 190IJl sample diluents into a 
vial and mix thoroughly, with pipette. 
• Pipette 25IJl of the positive control mix into well Ai of the U96W plate 
Read the following 4 steps first before proceeding 
• Pipette 25IJl of each well from the first column of the master plate into 
the first column of the U96W plate 
• Mix specimen solution with sample diluent in U96W plate with pipette, 
thoroughly. 
• Without changing tips, pipette 25IJl of the diluted specimen solution into 
the column next to it (first column Ai-Hi a A2-H2) 
• Repeat for the other columns of the master plate. Column two of master 
plate must be pipetted into column 3 of the U96W plate, column 3 of the 
master plate into column 5 of the U96W plate etc. (column 7 of the mas-
ter plate must be pipetted into column 1 of the second U96 W plate.) 
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- ) 
• Pipette 2SI.1t unsensitized particles with dropper or multi-pipette in every 
even column (A2-H2; A4-H4 .. etc) 
Pipette 2SI.1t sensitized particles in each well of every first (odd) column 
(Al-H 1; A3-H3; A5-H5 etc) 
• Cover the U96W plate's and shake the plate's with shaker for about 20sec 
• Incubate at room temperature for at least 2 hours. 
• I(eep the plate free from vibrations 
)'(if you are using the multichannel pipette instead of the provided droppers 
to add the unsensitized and sensitized particles, make sure that you place the 
pipette tips high on the wells to minimize contamination (see figure below). 
This is only of relevance when you are not changing tips. 
Test interpretation: 
• After incubation period, make a photo of the plate's 
• Write down the results on the printed template (P = positive N = negative 
I = Indetermined) 
• Every odd column of the U96W plate corresponds with consecutive col-
umns on the printed template 
• Fill in results Column 1 of 1st U96W on column 1 of the printed template 
• Fill in results Column 3 of 1st U96W on column 2 of the printed template 
Fill in results Column 5 of 1st U96W on column 3 of the printed template 
Fill in results Column 7 of 1st U96W on column 4 of the printed template 
Fill in results Column 9 of 1st U96W on column 5 of the printed template 
Fill in results Column 11 of 1st U96W on column 6 of the printed tem-
plate 
• Fill in results Column 1 of 2nd U96W on column 7 of the printed template 
Fill in results Column 3 of 2nd U96W on column 8 of the printed template 
Fill in results Column 5 of 2nd U96W on column 9 of the printed template 
• Fill in results Column 7 of 2nd U96W on column 10 of the printed tem-
plate 
• Fill in results Column 9 of 2nd U96W on column 11 of the printed tem-
plate 
Fill in results Column 11 of 2nd U96W on column 12 of the printed tem-
plate 
Particles are concentrated in the shape of a button at the center of the 
well with a smooth (sharp) round outer margin. Read: (-) Non-reactive 
Partic:.les are concentrated in the shape of a compact ring with a very 
small 'hole' in the middle and a smooth (sharp) round outer margin. 
Read: (-) Non-reactive 
Particles are concentrated in the shape of a compact ring with a 'hole' the 
middle and a smooth round outer margin. Read: (+/-) Inconclusive 
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Defined large ring with a rough multiform outer margin and peripheral 
agglutination. Read: (+) Reactive. 
• Agglutinated particles spread out covering the bottom of the Well uni-
formly. Edges sometimes folded. Read: (++) Reactive. 
Interpretation criteria: 
Check if all unsensitized particles are negative 
Positive: specimen is (-) with unsensitized particles, but (+) with sensitized 
particles 
Negative: (-) or (+) with unsensitized particles, if sensitized particles is (-) 
If unsensitized and sensitized are both positive, the sample must be re-
tested. 
Test validity 
The test is valid when the positive control is reactive. 
Limitations of procedure 
• Alterations in the physical appearance of the test kit materials may indi-
cate instability or deterioration 
• All highly sensitive assays have the potential for non-specific reactions 
• Adaptations have been made to the manufacturers' protocol. 
• This protocol is established and validated within our laboratory setting. A 
test validation within your laboratory setting is highly recommended. 
PBS-buffer 
Needed: PBS buffer with 0.05% tween20 
Example: 
BOml PBS 
40ul tween 
Use 'positive displacement' pipette tips to add the tween20 to the PBS. 
This is a very thick soap, and normal tips will not work. 
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Quality assurance protocol for dried blood spots 
Standard operating procedure 2.0 
Subtitle: Laboratory protocol for the quality evaluation of dried blood spot samples. 
ProtocollD: 2.0 
Date: March 2012 
Created by: Pieter Smit, Thomas van der Vlis 
Email address:Pieter.smit@lshmt.ac.uk 
Purpose of protocol: 
Dried Blood Spots (DBS) samples are used in various settings and used 
for different purposes throughout the world. As originally intended for 
neonatal screening, DBS are currently used for surveillance, diagnostics, 
quality control or infection monitoring. 
The quality of a clinical sample is essential for good quality diagnostic 
testing, irrespective of which tests are applied. Based on a study for 
the development of a quality assurance method for rapid diagnostic 
tests, a protocol was developed to review the quality of DBS. As DBS are 
susceptible for environmental influences, test. results could be influenced 
by the quality of the spot. 
In this protocol, the quality criteria for DBS samples are incorporated into 
the laboratory process. The protocol makes use of the fo(m to write down 
the quality of the DBS samples. This form is called: DBS quality assessment 
template.docx and can be found at the global health diagnostic website as 
well. 
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* HEALTH AND SAFETY INFORMATION CAUTION: 
You are worldng with potentially infective materials. Read the manufac-
tures manual for safety regulation. 
Procedure: 
Materials needed: 
Desiccants (preferably color changing) 
Zipper lock bags (Large & small) 
Notation stickers (optional) 
QA forms 
Disposable gloves 
substance mask (optional) 
Operations: 
One form can contain 30 entries (1 form double sided printing). 
Note date and sample location on the form. 
Note if there were desiccants in the bags and if new ones were necessary on the form. 
Assess (see below for details) the individual DBS cards and fill in the form. 
When the form is completed, place the cards in a 'small' zipper-lock bag with enough 
new desiccants (about 1-3 desiccants). 
Note the "bag-number" (starting from 1) on the form and on the bag (use notation stick-
ers). 
Press as much air out of the bags as possible and seal bag. 
Place 5 smaller zipper-lock bags in one large one and note bag-numbers. 
For long term storage (over 2 weeks), store at minus 4 degrees Celsius. For short term 
storage you may place the bags in a refrigerator (4-6 degrees Celsius) 
Assessment of DBS cards: 
Punch 1-5: 
Fill in code 1 through 9 for every spot. The most left spot represents spot 1. The codes 
representations are given below in the visual examples. As most examples are easily recog-
nized, 2 codes are highlighted below: 
Code 3: Contamination (mold) can occur. Discoloration and other forms of contamination 
should also be marked with code 3 
Code 5: Layered spots occur more commonly. Layered spots will be fairly easy to recognize 
because of darker blood spots above lighter ones. Spots with different colors and scratches 
can also be marked with code 5 
(general) card impression: 
Assess the card itself. Is it severely damaged or very dirty on the in- and/or outside? Does it 
look like the sample has been very wet? If this is so, a negative assessment should be given. 
The 'card impression' does not judge individual spots, only the card itself. 
I~ 
Humidity:" . 
Humidity can have serious influences on test results so registration is important. Assess the 
color of the desiccants'on a~rival. If they are green the cards get code 2 (if the cards are dry). 
If the card appears to be wet, mark with code 4. If it looks like the card has been (very) wet 
in the past, mark with code 5 (e.g. wrinkled and frayed) 
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Tampered sticker: 
If stickers are used on the cards for registration, it can be useful to look if the stickers have 
been tampered with since this could lead to errors in correct registration. If stickers have 
been removed and re-pasted this can often be seen quite easily. Use code 2 if the sticker 
has been tampered with and code 3 if you are not sure. 
Usable?: 
Depending on the set requirements, the DBS cards can in theory always be used if they 
contain enough blood. Sometimes, however, it might be necessary to discard a DBS (e.g. high 
level of contamination with mold). 
Note: 
Space to record extra information. Sometimes the codes on the form will not be sufficient 
to describe a DBS card properly. This area can be used to supplement extra information (e.g. 
bugs on the cards). 
DBS assessment results 
When a DBS card contains good quality spots, the test procedure can be initiated. If the card 
contains none acceptable spots, this sample should be recorded as "not usable". If this is 
the case, it is recommendable to exclude the sample for further analysis. 
Recording of the results 
We recommend entering the quality assessment data into a database. To be able to relate 
the quality of the DBS samples with test outcome, the data should be linked with test re-
sults. It greatly depends on the setting which databases are available or which can be used. 
If no databases are suitable, Epi-info could be a suitable alternative. Please find more details 
about Epi- info here: (http://wwwn.cdc.gov/epiinfo/) 
Legend as on QA form; 
Sticker# = card/stickernumber 
Punl-5 = spot number from left to right 
Values 1-7 in consecutive order (see below for invalid samples): 
1. good spot 
2. insufficient quantity 
3. diluted/discolored or contaminated 
4. exhibits serum rings 
5. clotted or layered 
6. no spotting 
7. Un-determined 
- (1= (general) card impression 
Values 1-3 in consecutive order: 
1. Good 
2. Bad 
3. Doubtful 
9. Un-determined 
- Hum = Humidity 
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Values 1-5 in consecutive order: 
1. dry with yellow desiccants": 
2. dry with green desiccants 
3. Moist 
4. (very) wet 
5. signs of past humidity 
9. Un-determined 
'~If no color changing desiccants were used and the card is dry use code 1. 
- Tamp. Stick = Tampered sticker (has the sticker been tampered with?) 
Values 1-3 
1. No, It looks good. 
2. Yes, it looks like it has been removed and re-pasted. 
3. Doubtful uncertain whether sticker has been replaced. 
9. Un-determined. 
Anne)(es 
BAG-NUMBER: After entering sample data on the form, write down the given bag-number. 
Invalid Samples 
1 . 1 ) Insufficient Quantrty 
2. 2) Appears Scratched or 
abraded 
3 . 3) Not dried prior to mailing 
4. 4) Supersaturated 
5. 5) D iluted discolored, or 
contaminated 
6 . 
6) Exh ibits serum rings 
7 . 7) Clotted or layered 
8 . 8) No blood 
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10.7 ANNEXES TO CHAPTER 7 
10.Zl SEARCH STRATEGY 
The following search parameters were used: 
Databases Pubmed 
Date 1995 to present 
Language English 
Publication type Peer reviewed journals 
Search terms 
Searches will be in combination with the following: 
1. PCR, polymerase chain reaction 
2. Blood OR serum OR plasma 
3. 1 of the pathogens 
Leptospirosis 
Leptospirosis, leptospira, Weil's disease, Weil's syndrome, canicola 
fever, canefield fever, nanukayami fever, 7-day fever, Rat Catcher's 
Yellows, Fort Bragg fever, Pretibial fever 
Dengue 
Dengue, DENV, flavivirus, flaviviridae 
Japanese encephalitis 
Japanese encephalitis, West Nile virus, WNV, JE, flavivirus, flaviviridae 
Rickettsia 
Rickettsia, tsutsugamushi, Rickettsia typhi, murine typhus, scrub 
typhus, 
Bartonella 
Bartonella, carrion, bartonella bacilliformis, oroya 
Chikungunya 
Chikungunya, chickungunya, chik, flavivirus 
No searches were conducted for m~laria as various experts at LSHTM were 
able to provide established PCR methods and protocols. 
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Inclusion criteria 
The following inclusion criteria were used: 
PCR based methodology 
• Primers and probe sequences available (not patented) 
Human clinical blood, serum or plasma samples are used ( not culture 
extractions) 
• Sensitivity and specificity determined with a reference method 
Exclusion criteria 
The following exclusion criteria were used: 
. Studies that rely on sequencing or microarray 
"case studies" or "case reports" 
Animal focused studies 
• Not using clinical samples 
• Studies that do not determine PCR performance 
Data extraction 
Table 10.1: List of data extracted from the literature study 
General information 
Author 
Article title 
Country of origin 
Study Characteristics 
Aim/ objectives of the study 
Study inclusion and exclusion criteria 
Blinding of technicians 
Participant! Sample Characteristics 
Participants: 
Age 
Sex 
Fever length and status 
Additional characteristics (HIV status, co-infections) 
Number of samples 
country 
How were the samples acquired? 
Sample type 
Sample storage 
Method of sample preparation 
Technology 
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Sample volume processed 
Nucleic Acid Extraction method 
PCR: 
multiplex 
Platform 
PCR method (SYBR green, Taqman, etc) 
Primers and probe are given 
Cycle conditions 
Detection method (agarose gel, probes, melting 
curve,etc) 
Subspecies differentiation 
Reference method 
Pathogen 
Pathogenic subtypes detected 
Target region 
Outcome (qualitative) 
Artificial specimen (plasmids, pos. controls, etc) 
Sensitivity 
Specificity 
LDL 
Clinical specimen 
Sensitivity 
Specificity 
LDL 
Correlation with reference method 
Personal judgement on methodology/performance 
Comments 
10.Z2 peR ASSAY SELECTION 
MaLaria 
!·nrie/c:, 
There were no searches conducted for malaria due to the vast experience 
with malaria peR at the school. We therefore decided it was not useful to 
conduct searches but use the advised primers by malaria experts of LSHTM. 
The suggested assay showed good performance with DBS samples and 
showed excellent sensitivity(441). 
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Dengue 
The Dengue primers target a non-coding region. Both ends of the open 
reading frame are flanked by an un-translated region (UTR). The genome 
organization is 5_-UTR-C-prM(M)-E-NS 1-NS2A-NS2 B-NS3-NS4A-NS4B-NS5-
3_-UTR, and this order is the same for other flavivirus (395). All assays target 
the 3' UTR region and are shown below: 
Table 10.2: Table 10.2 Overview of dengue assays 
Amplification Assay 
region Assa~ t~~e t~~e Develo~er co~ied method 
3' UTR, monoplex SYBR Chutinimitkul(377), 
Non coding green Shu(494) 
region bronzoni Dos Santos(369) 
Taqman Conceicao(495), 
WU(496), 
gurukumar(372) 
multiplex Taqman Ito(387), Chien(376), Munoz 
/(ong(395),lrie ]ordan(385), 
warrilow(386) 
Callahan(375) Naze(368) 
Drosten(381) Poersch(393) 
Nested Yamada(497) Ito(387) 
Lanciotti Saxena(391), 
matheus(95), 
Prado(96), 
Gomes(382), 
/(lungthon{370), 
/(umaria{389), 
Raengasku lrach 
(498) 
Seah(499) Singh(388) 
SYBR Yong(500) 
green 
X~~ mono/ taqman Sadon(390), Bai(371), 
duplo/ 4plex ]ohnson(392) 
Harris /(umaria(389) 
Wang(396) 
Although the Lanciotti primers are often used by others, the methodology is 
a nested PCR that amplifies a large region (> 500bp). It is therefore not useful 
to use for our surveillance methodology. It is extremely difficult to make a 
1000/0 evidence based choice at this stage, but we have assessed three PCR 
methods using the following primers: 
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Table 10.3: Primer and probe sequences per selected assays 
Paper Target Forward Reverse Probe 
Gurukumar 3'UTR GARAGACCAGAGATC ACCATTCCATTTTCTG AGCATCATTCCA 
GGCAC 
CAGCATCATTCC 
AGGCACAG 
Drosten 
Chien 
CTGCTGTCT GCGTT 
3'NCR GGATAGACCAGAGATC CATTC CATTTTCTGG 
CTGCTGT CGTTC plus CAATCC 
ATCTTGCG GCGCTC 
Ns3 TTGAGTAAACYRTGC GGGTCTCCTCTAAC C 
TGCCTGTAGCTC TCTAGTCCT 
The BLAST results indicate that none of the primers provide a perfect match, 
although BLAST shows only a selection of the matches. We therefore aligned 
all three PCR's to see how they match a selection of strains. 
Alignment 
The Chien reverse primer showed a few mismatches on the aligned sequences. 
The reverse primer of Drosten could not be aligned since it attaches at the 
end of the sequences. Since the last few basepairs (bp) of sequences are 
not really trustworthy, we cannot say how this primer would behave. The 
Gurukumar primers and probes had a good alignment on the strains and 
showed no mismatches. The alignment with strain 3 could not be used to 
test the performance of the reverse primer with the current alignments that 
were used. A new alignment to see if it works for strain 3 is required. The 
amplified product with Gurukumar primers is 68bp. While the Chien primers 
gave 121 bp product. The special MGB probe of Gurukumar seems to fit the 
DNA sequence of dengue well. 
Table 10.4: Prlmer-dimer details of dengue assays 
article primer Self dimer F Self dimer R Heterodimer 
Gurukumar F:58.8C, -4.62 kcall -5.02 kcall -8.2 kcallmole F+R 
R:55.4°C mole mole -6.62 kcallmole R + P 
-6.69 kcal/mole F+P 
Chien F:60.4C, -6.34 kcall -4.41 kcall -4.41 kcallmole 
R:58.5°C mole mole 
The primers of G,.urukumar seemed to be one of the better options out of 
the various primer sets analysed. It appears that the primers are more likely 
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to heterodimer than the Chien primers. At this moment it is not Possible to 
determine the effects of primer-dimer in the PCR reaction since it also great-
ly depends on the magnesium levels, PCR mix, and cycle conditions. The 
primers developed by Gurukumar showed 100% specificity when tested on 
10 samples with various infections (malaria, JEV, West nile virus, rickettsia) 
according to the author. This specificity determination can be seen as a pre-
liminary evaluation. The Chien. primers were validated with yellow fever, JE, 
St. Louis encephaplitis, west Nile viruses and were optimised by using 109 
Dengue strains. 
Kong primers where also chosen because the WHO Dengue workgroup lab-
oratories uses these primers relatively often. 
Ricl<ettsia 
Since O.tsutsugamushiwas initially in genus Rickettsia, Orientia and Rickettsia 
terminology are both used. We therefore combined the search for Rickettsia 
typhi and Orienta tsutsugamushi. Most assays targeted the same DNA region 
but varied on a more specific level as given in the table below. 
Table 10.5: Overview of Rickettsia assays 
Amplification 
region Assay type Developer 
GltA Sybr green Roux(432) 
16s-RNA Taqman Sonthayanon 
(404) 
OmpB standard Roux(432) 
Sybr green Blair(501), Parola 
Henry(362) 
Mol. beacon 
17-kOa Nested Leitner(403) 
Taqman Jiang(363) 
47-kOa Taqman Jiang(363) 
56-kOa Taqman I<ramme(405) 
copied method target 
Paris(401), Rickettsia spp 
Sousa(407) 
tsutsugamushi 
Souse(407) 
Rickettsia spp 
Henry(362) Rickettsia spp 
Paris(401), Paris tsutsugamushi 
(399) 
tsutsugamushi 
Nested Horinouchi (502) Paris(399) tsutsugamushi 
Nested Furuya l<im(503), tsutsugamushi 
saisonkorh 
(402) 
SY~R green Bakshi(406) tsutsugamushi 
GroEl SYBR gr€en Paris(399) tsutsugamushi 
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The assays reviewed were based on different assay types as SYBR g 
reen and 
Taqman. The different approaches to develop a suitable PCR ass I 
ay rna <e 
comparison more complicated. Based on the literature review we s l 
' e ected 
some assays for further BLAST analysis. When looking at a. tsutsugamushi, 
the Kramme primers were highly successful in amplifying the target. It is 
however, unclear why the second probe has been developed. According to 
the author, it would be requi~ed to detect all the various strains but the 
second probe is less well suited than the first probe. 
The disadvantage of the Jiang primer is that they are degenerative, a specific 
type of real time PCR assay. This type of assay has special features in how 
the PCR results should be interpreted with borderline cases. 
Table 10.6: Primer-dimer details of Rickettsia assays 
Article 
Jiang 
Kramme 
Primer Self dimer F Self dimer R Heterodimer 
F:56, R:53.3 DC -17.98 kcal/mole -8.16 kcallmole F&R;-6.91, 
F:50.8, R:52.2 DC -11.42 kcallmole -3.91 kcal/mole F&R:-4.95, R&P;-
2.94, F&p;-5.85 
Theoretically, the high selfdimereffectofboth forward primers is unexpected. 
The specificity of the primers developed by Jiang has b~een validated with 
26 a.tsutsugamushi strains, 17 Rickettsia strains and 18 other bacterial DNA 
samples. No further details are given considering which pathogens have 
been analysed for the Kramme assay, other than "an extensive panel has 
been used". 
The Oxford collaborating hospital has done extensive work in developing 
PCRs for Rickettsia spp. Since they participate in this project, we will include 
the assay developed by D. Paris MD as well. 
Leptospira 
For leptospira, the few articles that were selected made a comparison on PCR 
primer level relatively easy. There were 4 amplification regions used as can 
be seen in the table below. Most authors developed an assay themselves. 
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Table 10.7: Overview of Leptospira assays 
Amplification 
region 
LipL32 
16s/23sRNA 
SecY 
pLlPs60 
Assay type 
LUX 
SYBR green 
Taqman 
Nested PCR 
Taqman 
SYBR green . 
2x mono 
Developer 
Roczek(442) 
Levett(414) 
Stoddard(40B) 
Djadidad(409 ), 
l(ositanont(411) 
Smythe(364) 
Ahmed(415) 
Gravekamp(504) 
Copied method 
Slack(413) 
Fonseca(412, 416), 
Ooteman(410) 
The pLlPs60 has been found to provide less efficient PCR's and less repro-
ducible than other primers analyzed in this review. Based on the data e)(tract-
ed and preference of methodology, we decided to focus on three methods: 
Table 10.8: Details of Leptospira assays 
Paper Target 
smythe 16srDNA 
Roczek Lip32 
Ahmed secY 
Forward Reverse Probe 
cccgcgtccgatt ag tccattgtggccgRalgacac ctcaccaaggcgacga 
tcggtagc 
TAATCG CTGAAA AGCAGACCAACAGAT 
TGGG GCAACG 
GCGATTCAGT TT GAGTTAGAGCTCAAAT Sybr green 
AATCCTGC CTA 
The three assays were used for BLAST analysis. All three assays performed 
good according to BLAST searches. Based on these results, alignments were 
made with available sequences online. Because the Smythe probe detects 
other bacteria according to BLAST searches, we have decided not to include 
these primers for further analysis. It would be highly unlikely that Zebrafish 
would become an issue when using the Ahmed primers. Additionally, the 
Ahmed primers are developed by Royal Tropical Institute (KIT) Amsterdam. 
Since we will use the samples provided by KIT we will include their primers 
in the analysis. 
Alignment results 
The Rockzek primers attach well on the various Leptospira species and strains 
in our alignnlent evaluation. The amplified length is long; 247bp. The melt 
temperature of Rockzek primers are relatively high (70.S 0 C) but since melt 
curve and cycle detection can be used with a assay type called Light-upon-
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extensions (LUX), it should not cause any problem. LipL32 nucleotide BLAST 
resulted in only Leptospira related bacterial results. Intraspecific attachment 
was not tested. The amplified length is 204bp. The melt temperature is 72 0 (, 
which is even higher than for Roczek. 
Table 10.9: Primer-dimer details of selected Leptospira assays 
Article 
Roczek 
Ahmed 
Primer Self dimer F Self dimer R Heterodimer 
F:54.8C, R:58.1°C -3.61kcal.mole -7.05 kcal/mole -5.02 kcal/mole 
F:51.8C,R:47.8°C -4:99 kcallmole -9.49 kcallmole -4.99 kcallmole 
It seems that both assays are quite good and could be used for our assay. 
The final choice depends on the methodological preference. The Roczek 
primers have not been analysed for specificity, other than BLAST results. 
The specificity of Ahmed primers has been validated with over 46 different 
pathogens by the authors and showed good results. Both primer sets have 
been ordered and tried in the laboratory. 
Chil<ungunya 
For chikungunya, the various peR assays were analysed and categorised. All 
assays targeted the same DNA region El . 
Table 10.10: Overview of PCR assays reviewed 
Amplification 
region Assay type 
E1 SYBR green 
Taqman 
standard 
Developer 
Santhosh(424) 
Ho(419) 
Panning(421) 
Laurent(425) 
Edwards (418) 
Dash (379) 
Copied method 
Panning(420, 422), 
Staikowsky(358), 
Naze (368) 
Hasebe (505) Rohani (506) 
LAMP Parida (426, 507) 
Most primers developed are using plasma/serum. Surprisingly, one group 
has developed 3 different peR's (SYBR green, Taqman and LAMP assay) with 
different primers. Basically, all articles are from groups based in India, France 
or Gerrr.any. 
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All primers target the same region which allows primers to be easily anal-
ysed by alignment. First a selected group of primers were selected based on 
performance and quality of research performed. 
Table 10.11: Sequence data of selected assays 
Pa~er Target Forward Reverse Probe 
Panning 1 El TGATCCCGACTC GGCAAACGCAG TCCGACATCATC 
AACCATCCT TGGTACTTCCT CTCCTTGCTGGC 
Panning 2 lOS CCGACTCAACC CGGCAGACGCA TCCGACATCATC 
ATCCTGGAT GTGGTACTTCCT CTCCTTGCTGGC 
He El ggcagtggtcccag gctgtct agatccac 
ataattcaag cccata catg 
Laurent El AAGCTCCGCGTC CCAAATTGTCC CCAATGTCTTCAG 
CTTTACCAAG TGGTCTTCCT CCTGGACACCTTT 
Dash El ACGCAGTTGA CTGAAGACATTG 
GCGAAGCAC GCCCCAC 
All assays selected above were analysed with BLAST which gave a perfect 
match for all primers and probes reviewed. While the Panning primers scored 
very well, Dash primers seemed to work just as well. Dash primers have the 
huge advantages that they can be combined with general dengue primers. 
According to Ho et al. the primers have a few weaknesses regarding strains 
in Africa. Laurent primers gave good results as well but needed adjustment 
since this assay is a molecular beacon type which works as Taqman assay but 
is less suitable to optimize. The Laurent primers are used by the collaborating 
partners of our Laos collaborators and gave good results. The Laurent primers 
were adjusted to Taqman format and tried in the laboratory. 
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Bartonella bacilli/armis 
For Bartonella bacillijormis, the assays targeted 5 different regions whkh 
made comparisons more complicated. Additionally, the concern that primers 
could bind and amplify other regions appeared to be a true issue. 
Table 10.12: Overview of reviewed assays 
Amplification region Assay type 
ribC standard 
16s-23sRNA standard 
groEl 
ftsZ 
16s 
Taqman 
standard 
standard 
Developer 
Bereswill (435) 
Jensen 
(434)Roux (432) 
Maggi (431) 
Garcia-esteban (360) 
Norman '(508) (excluded) 
Birtles 
(509) Houpikian (510) 
Callison (429) 
zeaiter (430) 
Relman (511) 
Copied method 
zeaiter (433) 
Patented! 
Koehler (512) 
The primers developed by these authors all amplify a larger region than 
would be preferred when using Taqman. T~e aim of these primers is to 
amplify all Bartonella species and to allow differentiation, except the groEL 
primers. The groEL primers are specifically developed for B.bacillijormis . 
. Maggi et al showed that the primers developed by Jensen, Houpikain, Birtles 
and Roux all amplify the bacteria mesorhizibium species, whkh appears to 
be relatively common in water. 
Table 10.13: Sequences of selected PCR assays 
Paper Target Forward Reverse Probe 
Maggi ITS AGATGATGATCCCAA TGTICTYACAACAAT 
GCCTTCTGG GATGATG 
Callison groEL CTTA AGCG CTGAGGTTTGGATCT CTGTTGAAGCGGTTG 
CGGAATTGATGC TCTTCGC TTGCAGATCTTTTC 
When comparing the two assays with BLAST, differences in primer binding 
capabilities are reviewed. The interpretation of Callison's primers is difficult. 
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It seems that the primers primarHy ampllfy the bacHllformis species and not 
any other Bartonella bacilliformis strains. Depending on the BLAST database, 
it could be that there are not many groEL sequences widely avaHable as 
16s-23sRNA region. The primer and probe seems to weakly bond to other 
pathogens and even human DNA but this could be too weak to cause any 
problem. 
The Maggi primers seem to work very well to identify many Bartonella spe-
cies. This method is intended to be performed with agarose gel for the dif-
ferentiation and identification of the Bartonella species. It has been com-
mented that the adjusted primers developed by Maggi do not allow a good 
differentiation of B.henselae since the ampllcon size only differs 6-8bp with 
some other strains. For our project, this is not a major problem. The ampllfied 
product is also very long for the Maggi primers, which ampllfies over 4S0bp. 
This ampllcon size is ideal for gel based detection but is not preferable with 
DNA isolate9 from DBS since the chance of fragmentation is larger than us-
ing serum. 
Table 10.14: Primer-dimer details of selected Bartonella PCR assays 
Article 
Maggi 
Callison 
Primer Self dimer F Self dimer R Heterodimer 
F:58,7,R: 50.1 °C -5.02 kcal/mole -5.24 kcal/mole -3.36 kcal/mole 
F:54.9, R:55.8 °C -10.36 kcal/mole -4.62 kcal/mole -6,75,-6,75,-6,75 
kcallmole 
Both primer sets have acceptable self and heterodimer features. Both 
primer assays have not been thoroughly valldated for the specificity. The 
Maggi primers are adjusted existing primers that have been tested for other 
bacteria. There is llttle known about the Call1son primers. 
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Development of Bartonella bacilliformis peR 
After the extensive literature study was performed for Bartonella bacilliform is, 
no valuable Real-Time PCR assay could be found. An assay developed for 
reverse line blotting showed heterogenous Bartonella primers suitable for 
all Bartonella species. Based on these and the specific probe for Bartonella 
bacilliform is, we optimised and converted this PCR based reverse line 
blotting assay into a Taqman based Real Time PCR assay(360). The figure 
below shows the place of the initial primers (Bartl16-23F and Bart/16-23R), 
the developed probe (red) and the new reverse primer BACI R. 
Figure 10.1: Shows the DNA sequence of Bartonella bacilliformls and the locatlon 
of Garda-Esteban prlmers (Bartl16-23F, Bartl16-23R and S-BACI) and new prlmers 
and probes (BACI Rand BACI-probe) 
These primers were chosen based on BLAST searches and alignment of 8 
bacilliformis strains. After the primers and probe were ordered and used 
successfully, we found another strain of B.bacilliformis that had 1 mismatch 
at two places with the reverse primer. To see what the effect would be, we 
ordered 3 more plasmids containing 1 of the two possible mismatch places 
and one containing both mismatches. Although it appeared that the PCR 
efficiency was slightly negatively influenced, the effect was too little to 
consider redeveloping the reverse primer. Below are given the primer details. 
Table 10.15: PCR sequences of selected Bartonella assays 
Paper 
Smit 
Garcla 
Target Forward 
16-235 TTGATAAGCGTGA 
GGTCGGAGG 
16-23s GCCYCCTTGCGGTTA 
GCACAGCA . 
Reverse Probe 
GCAACCACACATAGT ATgTCTgCCTAgAAAT 
AAGCCTAA CAATCATAggCC 
CCTTCAGTTMGGCTG CTCGCCCTTAGTTGC 
GATC CAGCATT 
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Table 10.16: Primer- dimer details of selected Bartonella assays 
Article Primer Self dimer f Self dimer r Heterodimer 
Smit F:5B.7, R: 55.0 °C -3.61 kcallmole -3.4 kcallmole -4.61, -6.95, 
-B.77 kcallmole 
Garcia F:54.0, R:65.4 °C -5 .67 kcallmole -5 .09 kcal/mole -B .B1,-6.75, 
-9.67 kcal/mole 
The newly developed assay s~ows good primer qualities, the primer melting 
temperatures are closer together and self or heterodimer binding capabilities 
have a lower kcallmole values, indicating that primer-dimers are less likely 
than with the Garcia assay. 
10.Z3 PLASMID SEQUENCES 
Plasmids that were developed and ordered for each of the assays are given 
below. 
Gene name:" Bart bacilliformis, Length: 221 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
GCGTGAGGTCGGAGGTICAAGTCCTCCCAGGCCCACCATTTATCCAGGCCT ATGATI-
GATTTCTAGGCAGACATTTATTCCAGGCTTATCTTATAGTTTTAGGCTTACTATGTGTG-
GTTGCGTTTTTATCTTTTAACTGCCATGTTGTTTGGTTAAAGAGGGGCCGTAGCTCAG 
CTGGGAGAGCACCTGCTTTGCAAGCAGGG 
Gene name: Leptospira interrogans, Length: 215 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
CAGCGATTCAGTTTAATCCTGCAGAATTGGCTGAGAATTTGAAAAAATACGGTGG 
GTTCATTCCAGGAATTCGTCCGGGTTCTCACACAAAAGAATACATTGAAAAAGTGTTA 
AATAGAATCACTCTTCCCGGAGCTATGTTTCTTGCAGGTTTGGCATTAGCACCTTATAT 
TATTATAAAATTCTTAGATTTGAGCTCTAACTCCGGCGGTGGA 
Gene name: Plasmodium vivax, Length: 211 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
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CCGATAACGAACGAGATCTTAACCTG CTAATTAGCG GCAAATACGATATATTCT TACGT 
GGGACTGAATTCGGTTGATTTGCTTACTTTGAAGAAAATATTGGGAAACGTAACAGTT 
TCCCTTTCCCTTTTCTACTTAGTTCGCTTTTCATACTGTTTCTTTTTCGCGTAAGAATGTA 
TTTGCTTGATGTAAAGCTTCTTAGAGGAACGAT 
Gene name: Plasmodium falciparum, Length: 260 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
GTCTGGTTAATTCCGATAACGAACGAGATCTTAACCTGCTAATTAGCGGTAAGTACA 
CTATATTTTTATTTGAAATTGAATATAGGTAATTATACATGTTTATTCAGTGTTCAAATTA 
G G ATATTTTTTTATTAAAATATTCTTTTC C CTG TTCTA CTATAATAATTTG TTTTTTTTTAC 
TCT ATTTCTCTCTTCTTTT AA G AAT G T A CTT G TTTG ATT AAAT AAA G CTT CTTA GAG G AA 
CAGTGTGTATCTAACACAAG 
Gene name: Plasmodium ovale, Length: 234 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
CTGGTTAATTCCGATAACGAACGAGATCTTAACCTGCTAATTAGCGGCGAATACGTTAT 
ATTCCTACTTGAAATTGAATATAGCTGAATTTGCTTATTTTGAAGAATATATTAGGATGC 
ATTATAGTGTCCTTTTCCCTTTTCTACTTA ATTCGCTATTCATGCTGTTTCTTTTTTGTGTA 
G AATG TATTC G TTTG ATTG TAAA G C TTC TTA GAG G AA C G ATG TG TG TC T AA C 
, . 
Gene name: Plasmodium malariae, Length: 249 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
CTGGTTAATTCCGATAACGAACGAGATCTTAACCTGCTAATTAGCGGTAAATACACTAT 
ATTCTTAAGTGAAATTAGAATATAGATAAATTGTGCTAATTTTGATTAAAATATTAGAATG 
TTTTTTTTAATAAAAAC GTTCTTTTCC CTTTTTTTCTTAATTATG CATATTTATTCTTTTTCT 
TTTTTCGCATAAGAATGTATTTGCTTAATTGTAAAGCTTCTTAGAGGAACGATGTGTGTC 
TAACAC 
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Gene name: Orienta tsutsugamushi, Length: 189 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
ACAGTACTTTGCAACGAATCGTGAAAAGATGATTACTGAATTTGAAAATCCTTATATTTT 
GCTATTGGATCAGAAGGTATCTACAGTGCAGCCACTGGTTCCTGTGCTTGAAGCTG 
TTGCTCACACTGGCAAGCCATTAGTATTGATTGCTGATGATGTAGACGGAGAAGCTCT 
TACTGCATTGATATT 
Gene name: Rickettsia typhl, Length: 167 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoHed), 
Sequence: 
AAGTCTTACCATAACAGGTCATGGTATTACTGCTCAACAAGCTGCTACTACAAAAAG 
TG CTCAAAATGTTGTTTCAAAAGTTAATGCTGGTGCTG CTATTAACG ATAATG A TCTTA 
GCGGTGTAGGATCAATAGACTTTACTGCTGCGCCTTCTGTATTAGAATTTA 
Gene name: Bartonella BacHliformis mismatch combi G-T537, T552 dele-
tion, Length: 220 bp, Vector name: pUC57, . 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
GAGCGCGCGCTTGATAAGCGTGAGGTCGGAGGTTCAAGTCCTCCCAGGCCCACCA 
TTTATTCCAGGCCTATGATTGATTTCTAGGCAGACATTTATTCCAGGCTTATCTTATAGT 
TTTAGGTTTACTATGTGTGGTGCGTTTTTATCTTTTAACTGCCATGTTGTTTGGTTAAAG 
AGGGGCCGTAGCTCAGCTGGGAGAGCACCTGCTTTGCAAGCAGGG 
Bartonella BacHliformis mismatch combi G-T537, T552 deletion-
Mutagenesis: 
Variant name: Bartonella Bacilliformis mismatch 1 T552 deletion, Vector: 
pUC57, 
Quality grade: Research Grade (Predominantly supercoHed), 
Variant sequence: 
GAGCGCGCGCTTGATAAGCGTGAGGTCGGAGGTTCAAGTCCTCCCAGGCCCACCA 
TTTATTCCAGGCCTATGATTGATTTCTAGGCAGACATTTATTCCAGGCTTATCTTATAGT 
TTTAGGCTTACTATGTGTGGTGCGTTTTTATCTTTTAACTGCCATGTTGTTTGGTTAAA 
GAGGGGCCGTAGCTCAGCTGGGAGA GCACCTGCTTTGCAAGCAGGG 
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Bartonella Bacllliformis mismatch combi G-T537, T552 deletion-
Mutagenesis: 
Variant name: Bartonella Bacllliformis mimatch2 G-T537, 
Quality grade: Research Grade (Predominantly supercoiled), 
Variant sequence: 
Anne)(es 
GAGCGCGCGCTTGATAAGCGTGAGGTCGGAGGTTCAAGTCCTCCCAGGCCCACCA 
TTTATTCCAGGCCTATGATTGATTTCTAGGCAGACATTTATTCCAGGCTTATCTTATAGTT 
TTAGGTTTACTATGTGTGGTTGCGTTTTTATCTTTTAACTGCCATGTTGTTTGGTTAAAG 
AGGGGCCGTAGCTCAGCTGGGAGA GCACCTGCTTTGCAAGCAGGG 
Gene name: dengue 1 Lp- Goffart, Length: 135 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
AGGACTAGAGGTTAGAGGAGACCCCCCGCATAACAATAAACAGCATATTGACGCTG 
GGAGAGACCAGAGATCCTGCTGTCTCTACAGCATCATTCCAGGCACAGAACGCCAG 
AAAATG GAATG GTG CAGTTGAAT 
Gene name: dengue 2 Lp- Goffart, Length: 138 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercolled), 
. Sequence: 
GTCTCACTGGAAGGACTAGAGGTTAGAGGAGACCCCCCCAAAACAAAAAACAGCA 
TATTGACGCTGGGAAAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCAC 
AGAACGCCAGAAAATGGAATGGTGCT 
Gene name: dengue 3 Lp- Goffart, Length: 127 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
CCTCCTTGCAAAGGACTAGAGGTTAGAGGAGACCCCCCGCAAATAAAAACAGCATA 
TTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCACA 
G AACGCCAGAAAATG 
Gene name: dengue 4 Lp- Goffart, Length: 127 bp, Vector name: pUC57, 
Cloning strategy: pUC57, 
Quality grade: Research Grade (Predominantly supercoiled), 
Sequence: 
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CTTCTGGTGGAAGGACTAGAGGTTAGAGGAGACCCCCCCAACACAAAAACAGCATA 
TTGACGCTGGGAAAGACCAGAGATCCTGCTGTCTCTGCAACATCAATCCAGGCACA 
GAGCGCCGCGAGATG 
Gene name: Leptospira Meyeri, Length: 233 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoHed), 
Sequence: 
ACTTTTATACAGCGATTCAGTTTAATCCTGCAGAATTGGCTGAGAATTTGAAAAAATAC 
GGTGGATTCATTCCAGGAATTCGTCCGGGTTCTCACACAAAAGAATACATTGAAAAA 
GTGTTAAATAGAATCACTCTTCCCGGAGCTATGTTTCTTGCAGGTTTGGCATTAGCAC 
CTTATATTATTATAAAATTCTTAGATTTGAGCTCTAACTCCGGCGGTGGATCTTTGGTT 
Gene name: Leptospira santorosai, Length: 233 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoHed), 
Sequence: 
ACTTTTACACTGCGATTCAGTTCAACCCTGCGGAGTTGTCCGAAAATCTGAAGAAATA 
CGGCGGGTTCATTCCAGGCATTCGTCCCGGTTCTCACACAAAAGAATACATCGAAAA 
GGTGTTAAACAGAATCACACTTCCCGGCGCGATGTTCCTCGCGGGATTGGCTCTGG 
CTCCTTACATCATCATCAAATTCTTAGATTTGAGCTCCAACTCCGGAGGCGGATCTTTG 
. GTT 
Gene name: Leptospira Weilli, Length: 225 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoHed), 
Sequence: 
ACTTTTATACCGCGATTCAGTTTAACCCTTCGGAGTTGGCTGAAAATITGAAGAAATAC 
GGCGGGTTCATTCCGGGAATTCGTCCAGGTTCTCACACGAAAGAATACATCGAAAAA 
GTGTTAAACAGAATCACTCTTCCGGGTGCGATGTTTCTCGCTGGATTGGCATTAGCA 
CCTTATATTATTATAAAATTCTTAGATTTGAGCTCCAACTCCGGCGGCGGAT . 
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Gene name: Leptospira Kirschneri, Length: 225 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoHed), 
Sequence: 
ATTTTTATACTGCGATTCAGTTTAACCCTGCGGAGTTGGCTGAGAATCTGAAAAAATA 
CGGCGGATTTATCCCAGGAATTCGCCCCGGTTCTCATACAAAAGAATACATCGAAAA 
AGTGTTAAATAGAATCACCCTTCCTGGAGCCATGTTTCTTGCCG GTTTG GCATT AGCA 
CCTTATATTATTATAAAATTCTTAGATTTGAGCTCCAACTCCGGAGGTGGGT 
Gene name: Chikungunya, Length: 230 bp, Vector name: pUC57, 
Quality grade: Research Grade (Predominantly supercoHed), 
Sequence: 
CATCTGCATCAGCTAAGCTCCGCGTCCTTTACCAAGGAAATAACATCACTGTAACTGC 
CTATGCAAACGGCGACCATGCCGTCACAGTTAAGGACGCCAAATTCATTGTGGGGC 
CAATGTCTTCAGCCTGGACACCTTTCGACAACAAAATTGTGGTGTACAAAGGTGAC 
GTCTATAACATGGACTACCCGCCCTTTGGCGCAGGAAGACCAGGACAATTTGGCGA 
TATC 
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